


**CUMULATIVE
SUPPLEMENT 5
May 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 5

May 2012

CONTENTS

| | <i>PAGE</i> |
|--|-------------|
| 1.0 INTRODUCTION | iii |
| 1.1 How to use the Cumulative Supplement | iii |
| 1.2 Cumulative Supplement Content..... | iv |
| 1.3 Applicant Name Changes..... | v |
| 1.4 Levothyroxine Sodium..... | v |
| 1.5 Availability of the Edition | vi |
| 1.6 Report of Counts for the Prescription Drug Product List | vii |
| 1.7 Cumulative Supplement Legend | viii |
| | |
| DRUG PRODUCT LISTS | |
| Prescription Drug Product List | 1-1 |
| OTC Drug Product List | 2-1 |
| Drug Products with Approval under Section 505 of the Act | |
| Administered by the Center for Biologics Evaluation and Research List..... | 3-1 |
| Orphan Product Designations and Approvals List | 4-1 |
| Drug Products Which Must Demonstrate in vivo Bioavailability | |
| Only if Product Fails to Achieve Adequate Dissolution | 5-1 |
| | |
| PATENT AND EXCLUSIVITY INFORMATION ADDENDUM | |
| A. Patent and Exclusivity Lists | A-1 |
| B. Patent and Exclusivity Terms | B-1 |

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 5
May 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

| <u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u> | <u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u> |
|--|--|
| ALCON UNIVERSAL LTD (ALCON UNIVERSAL) | ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD) |
| OVATION PHARMACEUTICALS INC (OVATION PHARMS) | OAK PHARMACEUTICALS INC (OAK PHARMS) |

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

| Trade Name | Applicant | Potency | TE Code | Appl No | Product No |
|----------------------|-------------|---------|---------|---------|------------|
| UNITHROID | STEVENS J | 0.025MG | AB1 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB1 | 76187 | 001 |
| LEVOXYL | KING PHARMS | 0.025MG | AB1 | 21301 | 001 |
| SYNTHROID | ABBOTT | 0.025MG | AB1 | 21402 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB1 | 21342 | 001 |
| | | | | | |
| SYNTHROID | ABBOTT | 0.025MG | AB2 | 21402 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB2 | 76187 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB2 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB2 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MERCK KGAA | 0.025MG | AB2 | 76752 | 001 |
| | | | | | |
| LEVOXYL | KUNG PHARMS | 0.025MG | AB3 | 21301 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB3 | 21342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB3 | 21210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB3 | 76187 | 001 |
| LEVOTHYROXINE SODIUM | MERCK KGAA | 0.025MG | AB3 | 76752 | 001 |
| | | | | | |
| LEVOTHEROID | LLOYD | 0.025MG | AB4 | 21116 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB4 | 76187 | 001 |
| | | | | | |

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

| <u>CATEGORIES COUNTED</u> | <u>DEC 2011</u> | <u>MAR 2012</u> | <u>JUN 2012</u> | <u>SEPT 2012</u> | <u>DEC 2012</u> |
|---------------------------------|------------------|------------------|-----------------|------------------|-----------------|
| DRUG PRODUCTS LISTED | 14480 | 14711 | | | |
| SINGLE SOURCE | 2451 (16.9%) | 2446 (16.6%) | | | |
| MULTISOURCE | 11953 (82.5%) | 12187 (82.8%) | | | |
| THERAPEUTICALLY EQUIVALENT | 11792 (81.4%) | 12037 (81.8%) | | | |
| NOT THERAPEUTICALLY EQUIVALENT | 161 (1.1%) | 150 (1.0%) | | | |
| EXCEPTIONS ¹ | 76 (0.5%) | 78 (0.5%) | | | |
| NEW MOLECULAR ENTITIES APPROVED | 6 | 8 | | | |
| NUMBER OF APPLICANTS | 810 | 826 | | | |

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|------|---|
| NEWA | New drug product approval usually in the supplement month. |
| CAHN | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |

| | |
|------|---|
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| AB | EMCURE PHARMS LTD | 25MG | A202271 001 | Feb 07, 2012 | Jan | NEWA |
| AB | | 50MG | A202271 002 | Feb 07, 2012 | Jan | NEWA |
| AB | | 100MG | A202271 003 | Feb 07, 2012 | Jan | NEWA |

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

| | | | | | | |
|----|---------------|--------------------|-------------|--|-----|------|
| AA | + PHARM ASSOC | 120MG/5ML;12MG/5ML | A087508 001 | | Jan | CRLD |
|----|---------------|--------------------|-------------|--|-----|------|

SUSPENSION; ORAL

CAPITAL AND CODEINE

+ VALEANT

120MG/5ML;12MG/5ML

| | | | |
|-------------|--|-----|------|
| A086024 001 | | Jan | CTEC |
|-------------|--|-----|------|

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | |
|----|------------|-----------------------|-------------|--------------|-----|------|
| AA | VISTAPHARM | 325MG/15ML;7.5MG/15ML | A200343 001 | Jan 25, 2012 | Jan | NEWA |
|----|------------|-----------------------|-------------|--------------|-----|------|

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | |
|----|---------------------|-------------|-------------|--------------|-----|------|
| AA | AUROLIFE PHARMA LLC | 325MG;5MG | A201013 001 | Apr 11, 2012 | Mar | NEWA |
| AA | | 325MG;7.5MG | A201013 002 | Apr 11, 2012 | Mar | NEWA |
| AA | | 325MG;10MG | A201013 003 | Apr 11, 2012 | Mar | NEWA |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

| | | | | | | |
|----|----------------|-------------|-------------|--------------|-----|------|
| AA | ACTAVIS TOTOWA | 325MG;7.5MG | A040800 001 | Apr 03, 2012 | Mar | NEWA |
| AA | | 325MG;10MG | A040800 002 | Apr 03, 2012 | Mar | NEWA |

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

| | | | | | | |
|----|-------------|--------------|-------------|--------------|-----|------|
| AB | ALVOGEN INC | 325MG;37.5MG | A202076 001 | Mar 30, 2012 | Mar | NEWA |
|----|-------------|--------------|-------------|--------------|-----|------|

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

| | | | | | | |
|----|----------------|--------------------|-------------|--------------|-----|------|
| AP | SAGENT STRIDES | EQ 500MG BASE/VIAL | A200880 001 | May 09, 2012 | Apr | NEWA |
| AP | + X GEN PHARMS | EQ 500MG BASE/VIAL | A040784 001 | Dec 10, 2008 | Apr | CRLD |
| | DIAMOX | | | | | |
| | @ TEVA WOMENS | EQ 500MG BASE/VIAL | N009388 001 | Dec 05, 1990 | Apr | DISC |

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

| | | | | | | |
|-----|-----------------------|-------|-------------|--------------|-----|------|
| >D> | @ BELCHER PHARMS | 200MG | A074889 001 | Oct 31, 1997 | May | CAHN |
| >A> | @ HERITAGE PHARMS INC | 200MG | A074889 001 | Oct 31, 1997 | May | CAHN |

TABLET; ORAL

ACYCLOVIR

| | | | | | | |
|-----|------------------|-------|-------------|--------------|-----|------|
| >D> | @ BELCHER PHARMS | 400MG | A074891 001 | Oct 31, 1997 | May | CAHN |
| >D> | @ | 800MG | A074891 002 | Oct 31, 1997 | May | CAHN |

TABLET; ORAL

ACYCLOVIR

| | | | | | | |
|-----|-----------------------|-------|-------------|--------------|-----|------|
| >A> | @ HERITAGE PHARMS INC | 400MG | A074891 001 | Oct 31, 1997 | May | CAHN |
| >A> | @ | 800MG | A074891 002 | Oct 31, 1997 | May | CAHN |

ADAPALENE

CREAM; TOPICAL

ADAPALENE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.1% | A090824 001 | Jun 30, 2010 | Jan | CAHN |
|----|----------------|------|-------------|--------------|-----|------|

LOTION; TOPICAL

DIFFERIN

| | | | | | | |
|---|------------------|------|-------------|--------------|-----|------|
| + | GALDERMA LABS LP | 0.1% | N022502 001 | Mar 17, 2010 | Apr | CAHN |
|---|------------------|------|-------------|--------------|-----|------|

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

| | | | | | | |
|---|-----------------|--------|-------------|--------------|-----|------|
| @ | TEVA PARENTERAL | 3MG/ML | A078676 001 | Jul 31, 2008 | Mar | DISC |
|---|-----------------|--------|-------------|--------------|-----|------|

| | | | | | | |
|---|--|--------|-------------|--------------|-----|------|
| @ | | 3MG/ML | A076564 001 | Jun 16, 2004 | Jan | DISC |
|---|--|--------|-------------|--------------|-----|------|

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

| | | | | | | |
|---|------------|-----------------------|-------------|--------------|-----|------|
| @ | SANDOZ INC | EQ 0.083% BASE;0.017% | A076867 001 | Dec 21, 2006 | Apr | DISC |
|---|------------|-----------------------|-------------|--------------|-----|------|

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

| | | | | | | |
|----|----------------|-------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.05% | A076973 001 | Jul 12, 2005 | Jan | CAHN |
|----|----------------|-------|-------------|--------------|-----|------|

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

| | | | | | | |
|----|----------------|-------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.05% | A076884 001 | Jul 18, 2005 | Jan | CAHN |
|----|----------------|-------|-------------|--------------|-----|------|

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

| | | | | | | |
|---|----------------|--------------|-------------|--------------|-----|------|
| + | MISSION PHARMA | EQ 70MG BASE | N202344 001 | Mar 12, 2012 | Mar | NEWA |
|---|----------------|--------------|-------------|--------------|-----|------|

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | INVAGEN PHARMS | 10MG | A090284 001 | Jan 17, 2012 | Jan | NEWA |
|----|----------------|------|-------------|--------------|-----|------|

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

| | | | | | | |
|---|---------|-------------|-------------|--------------|-----|------|
| @ | GENZYME | 80 UNITS/ML | N020057 003 | Apr 05, 1991 | Mar | DISC |
|---|---------|-------------|-------------|--------------|-----|------|

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

| | | | | | | |
|---|------------|-------|-------------|--------------|-----|------|
| @ | SANDOZ INC | 0.5MG | A077777 001 | Jun 30, 2006 | Mar | DISC |
|---|------------|-------|-------------|--------------|-----|------|

| | | | | | | |
|---|--|-----|-------------|--------------|-----|------|
| @ | | 1MG | A077777 002 | Jun 30, 2006 | Mar | DISC |
|---|--|-----|-------------|--------------|-----|------|

| | | | | | | |
|---|--|-----|-------------|--------------|-----|------|
| @ | | 2MG | A077777 003 | Jun 30, 2006 | Mar | DISC |
|---|--|-----|-------------|--------------|-----|------|

| | | | | | | |
|---|--|-----|-------------|--------------|-----|------|
| @ | | 3MG | A077777 004 | Jun 30, 2006 | Mar | DISC |
|---|--|-----|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

| | | | | | | |
|----|---------|--------|-------------|--------------|-----|------|
| AB | UCB INC | 0.25MG | N021726 001 | Jan 19, 2005 | Jan | CAHN |
| AB | | 0.5MG | N021726 002 | Jan 19, 2005 | Jan | CAHN |
| AB | + | 1MG | N021726 003 | Jan 19, 2005 | Jan | CAHN |
| AB | | 2MG | N021726 004 | Jan 19, 2005 | Jan | CAHN |

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

| | | | | | | |
|---|---------------|------|-------------|--------------|-----|------|
| + | CUBIST PHARMS | 12MG | N021775 001 | May 20, 2008 | Feb | CAHN |
|---|---------------|------|-------------|--------------|-----|------|

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

| | | | | | | | |
|----|---|----------------|------|-------------|--------------|-----|------|
| AB | + | FOUGERA PHARMS | 0.1% | A076065 001 | May 15, 2003 | Jan | CAHN |
|----|---|----------------|------|-------------|--------------|-----|------|

LOTION; TOPICAL

AMCINONIDE

| | | | | | | |
|---|----------------|------|-------------|--------------|-----|------|
| + | FOUGERA PHARMS | 0.1% | A076329 001 | Nov 06, 2002 | Jan | CAHN |
|---|----------------|------|-------------|--------------|-----|------|

OINTMENT; TOPICAL

AMCINONIDE

| | | | | | | | |
|----|---|----------------|------|-------------|--------------|-----|------|
| AB | + | FOUGERA PHARMS | 0.1% | A076096 001 | Nov 19, 2002 | Jan | CAHN |
|----|---|----------------|------|-------------|--------------|-----|------|

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

| | | | | | | |
|--|--|-------------------|-------------|--------------|-----|------|
| | | 15%(150GM/1000ML) | A091112 001 | Apr 13, 2012 | Mar | NEWA |
| | | 15%(300GM/2000ML) | A091112 002 | Apr 13, 2012 | Mar | NEWA |

NOVAMINE 15%

@ HOSPIRA INC

| | | | | | | |
|--|--|------------------|-------------|--------------|-----|------|
| | | 15% (75GM/500ML) | N017957 004 | Nov 28, 1986 | Mar | CPOT |
|--|--|------------------|-------------|--------------|-----|------|

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

| | | | | | | |
|--|--|----------|-------------|--|-----|------|
| | | 250MG/ML | N015229 002 | | Mar | CAHN |
|--|--|----------|-------------|--|-----|------|

SYRUP; ORAL

AMICAR

| | | | | | | | |
|----|---|---------------|------------|-------------|--|-----|------|
| AA | + | CLOVER PHARMS | 1.25GM/5ML | N015230 002 | | Mar | CAHN |
|----|---|---------------|------------|-------------|--|-----|------|

TABLET; ORAL

AMICAR

| | | | | | | | |
|----|---|---------------|-------|-------------|--------------|-----|------|
| AB | | CLOVER PHARMS | 500MG | N015197 001 | | Mar | CAHN |
| | + | | 1GM | N015197 002 | Jun 24, 2004 | Mar | CAHN |

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ TEVA PARENTERAL

| | | | | | | |
|--|--|---------|-------------|--------------|-----|------|
| | | 50MG/ML | A076163 001 | Sep 05, 2003 | Jan | DISC |
|--|--|---------|-------------|--------------|-----|------|

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

| | | | | | | | |
|-----|----|----------------|-------|-------------|--------------|-----|------|
| >D> | AB | AUROSAL PHARMS | 200MG | A077069 001 | Apr 08, 2005 | May | CAHN |
| >D> | AB | | 400MG | A077069 002 | Apr 08, 2005 | May | CAHN |
| >A> | AB | MURTY PHARMS | 200MG | A077069 001 | Apr 08, 2005 | May | CAHN |
| >A> | AB | | 400MG | A077069 002 | Apr 08, 2005 | May | CAHN |

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | |
|----|--------|-------|-------------|--------------|-----|------|
| AB | CARACO | 10MG | A040816 002 | Jun 27, 2008 | Apr | NEWA |
| AB | | 50MG | A040816 003 | Jun 27, 2008 | Apr | NEWA |
| AB | | 75MG | A040816 004 | Jun 27, 2008 | Apr | NEWA |
| AB | | 100MG | A040816 005 | Jun 27, 2008 | Apr | NEWA |
| AB | | 150MG | A040816 006 | Jun 27, 2008 | Apr | NEWA |

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | |
|---|----------------------|--------------------|-------------|--------------|-----|------|
| | MYLAN PHARMS INC | EQ 12.5MG BASE;5MG | A071297 002 | Dec 10, 1986 | Feb | CTEC |
| + | | EQ 25MG BASE;10MG | A071297 001 | Dec 10, 1986 | Feb | CRLD |
| | LIMBITROL | | | | | |
| | @ VALEANT PHARM INTL | EQ 12.5MG BASE;5MG | N016949 001 | | Feb | DISC |
| | LIMBITROL DS | | | | | |
| | @ VALEANT PHARM INTL | EQ 25MG BASE;10MG | N016949 002 | | Feb | DISC |

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

| | | | | | | |
|----|---------------------|--------------|-------------|--------------|-----|------|
| AB | MACLEODS PHARMS LTD | EQ 5MG BASE | A201380 001 | Apr 13, 2012 | Mar | NEWA |
| AB | | EQ 10MG BASE | A201380 002 | Apr 13, 2012 | Mar | NEWA |

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

| | | | | | | |
|--|--------------------|-------|-------------|--------------|-----|------|
| | @ RANBAXY LABS LTD | 600MG | A065159 001 | Dec 04, 2003 | Apr | DISC |
|--|--------------------|-------|-------------|--------------|-----|------|

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | |
|----|----------------------|---------------------|-------------|--------------|-----|------|
| AB | AUROBINDO PHARMA LTD | 250MG;EQ 125MG BASE | A091569 001 | Jan 20, 2012 | Jan | NEWA |
| AB | | 500MG;EQ 125MG BASE | A091569 002 | Jan 20, 2012 | Jan | NEWA |
| AB | | 875MG;EQ 125MG BASE | A091568 001 | Jan 20, 2012 | Jan | NEWA |

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

| | | | | | | | |
|-----|---|----------------|------------|-------------|--------------|-----|------|
| >D> | + | ALDOPHARMA USA | 50MG/VIAL | N050729 001 | Nov 22, 1996 | May | CAHN |
| >D> | + | | 100MG/VIAL | N050729 002 | Nov 22, 1996 | May | CAHN |
| >A> | + | ALKOPHARMA USA | 50MG/VIAL | N050729 001 | Nov 22, 1996 | May | CAHN |
| >A> | + | | 100MG/VIAL | N050729 002 | Nov 22, 1996 | May | CAHN |

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

| | | | | | | |
|----|--------------------------|---------------|-------------|--------------|-----|------|
| AB | SHIRE LLC | EQ 0.5MG BASE | N020333 001 | Mar 14, 1997 | Jan | CAHN |
| | ANAGRELIDE HYDROCHLORIDE | | | | | |
| | @ SANDOZ INC | EQ 0.5MG BASE | A076683 001 | Apr 18, 2005 | Mar | DISC |
| | @ | EQ 1MG BASE | A076683 002 | Apr 18, 2005 | Mar | DISC |

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

| | | | | | | | |
|-----|------------|----------------|-------------|--------------|--------------|------|------|
| AB | APOTEX INC | 1MG | A200654 001 | May 11, 2012 | Apr | NEWA | |
| >A> | AB | IMPAX LABS INC | 1MG | A091242 001 | May 31, 2012 | May | NEWA |

>D> APROTININ

>D> INJECTABLE; INJECTION

>D> TRASYLOL

| | | | | | | | |
|-----|---|----------------|--------------|-------------|--------------|-----|------|
| >D> | + | BAYER HLTHCARE | 10,000KIU/ML | N020304 001 | Dec 29, 1993 | May | DISC |
| >A> | | @ | 10,000KIU/ML | N020304 001 | Dec 29, 1993 | May | DISC |

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

| | | | | | | | |
|----|---|--------|------------------------|-------------|--------------|-----|------|
| AP | + | PFIZER | 250MG/2.5ML (100MG/ML) | N020883 001 | Jun 30, 2000 | Jan | CTNA |
|----|---|--------|------------------------|-------------|--------------|-----|------|

ARGATROBAN

| | | | | | | | |
|----|--|--------------------|------------------------|-------------|--------------|-----|------|
| AP | | HIKMA PHARM CO LTD | 250MG/2.5ML (100MG/ML) | N203049 001 | Jan 05, 2012 | Jan | NEWA |
|----|--|--------------------|------------------------|-------------|--------------|-----|------|

ARMODAFINIL

TABLET; ORAL

>A> ARMODAFINIL

| | | | | | | | |
|-----|----|------------------|-------|-------------|--------------|-----|------|
| >A> | AB | MYLAN PHARMS INC | 50MG | A200043 001 | Jun 01, 2012 | May | NEWA |
| >A> | AB | | 150MG | A200043 002 | Jun 01, 2012 | May | NEWA |
| >A> | AB | | 250MG | A200043 003 | Jun 01, 2012 | May | NEWA |

NUVIGIL

| | | | | | | | |
|-----|----|----------|-------|-------------|--------------|-----|------|
| >D> | | CEPHALON | 50MG | N021875 001 | Jun 15, 2007 | May | CFTG |
| >A> | AB | | 50MG | N021875 001 | Jun 15, 2007 | May | CFTG |
| >D> | | | 150MG | N021875 003 | Jun 15, 2007 | May | CFTG |
| >A> | AB | | 150MG | N021875 003 | Jun 15, 2007 | May | CFTG |
| >D> | + | | 250MG | N021875 004 | Jun 15, 2007 | May | CFTG |
| >A> | AB | + | 250MG | N021875 004 | Jun 15, 2007 | May | CFTG |

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

| | | | | | | | |
|----|--|----------------|---|-------------|--------------|-----|------|
| AA | | NOVEL LABS INC | 4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM | A090145 001 | Jan 25, 2012 | Jan | NEWA |
|----|--|----------------|---|-------------|--------------|-----|------|

MOVIPREP

| | | | | | | | |
|----|---|--------------|---|-------------|--------------|-----|------|
| AA | + | SALIX PHARMS | 4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM | N021881 001 | Aug 02, 2006 | Jan | CFTG |
|----|---|--------------|---|-------------|--------------|-----|------|

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

| | | | | | | | |
|----|--|-------------|-------------|-------------|--------------|-----|------|
| AB | | PROSAM LABS | 325MG;200MG | A040252 001 | Dec 10, 1997 | Feb | CAHN |
|----|--|-------------|-------------|-------------|--------------|-----|------|

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

| | | | | | | | |
|----|--|-------------|------------------|-------------|--------------|-----|------|
| AB | | PROSAM LABS | 325MG;200MG;16MG | A040283 001 | Dec 29, 1998 | Feb | CAHN |
|----|--|-------------|------------------|-------------|--------------|-----|------|

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

| | | | | | | | |
|-----|----|------------------|--------------|-------------|--------------|-----|------|
| >A> | AB | APOTEX INC | EQ 10MG BASE | A090548 001 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 20MG BASE | A090548 002 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A090548 003 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 80MG BASE | A090548 004 | May 29, 2012 | May | NEWA |
| >A> | AB | MYLAN PHARMS INC | EQ 10MG BASE | A091226 001 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 20MG BASE | A091226 002 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A091226 003 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 80MG BASE | A091226 004 | May 29, 2012 | May | NEWA |
| >A> | AB | SANDOZ INC | EQ 10MG BASE | A077575 001 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 20MG BASE | A077575 002 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A077575 003 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 80MG BASE | A077575 004 | May 29, 2012 | May | NEWA |
| >A> | AB | TEVA PHARMS | EQ 10MG BASE | A078773 001 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 20MG BASE | A078773 002 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A078773 003 | May 29, 2012 | May | NEWA |
| >A> | AB | | EQ 80MG BASE | A078773 004 | May 29, 2012 | May | NEWA |

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

| | | | | | | | |
|----|---|---------------------------------------|---------|-------------|--------------|-----|------|
| AP | + | BEDFORD | 10MG/ML | A074901 001 | Jul 18, 1997 | Feb | CTEC |
| AP | | SAGENT PHARMS | 10MG/ML | A091489 001 | Feb 17, 2012 | Feb | NEWA |
| | | ATRACURIUM BESYLATE PRESERVATIVE FREE | | | | | |
| AP | + | BEDFORD | 10MG/ML | A074900 001 | Jul 18, 1997 | Feb | CTEC |
| AP | | SAGENT PHARMS | 10MG/ML | A091488 001 | Feb 17, 2012 | Feb | NEWA |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | | | | |
|----|---|-----------------|------------------------|-------------|--------------|-----|------|
| AA | + | ROXANE | 0.025MG/5ML; 2.5MG/5ML | A087708 001 | May 03, 1982 | Apr | CRLD |
| | | LOMOTIL | | | | | |
| | | @ GD SEARLE LLC | 0.025MG/5ML; 2.5MG/5ML | N012699 001 | | Apr | DISC |

AVANAFIL

TABLET; ORAL

STENDRA

| | | | | | | | |
|--|---|-------|-------|-------------|--------------|-----|------|
| | | VIVUS | 50MG | N202276 001 | Apr 27, 2012 | Apr | NEWA |
| | | | 100MG | N202276 002 | Apr 27, 2012 | Apr | NEWA |
| | + | | 200MG | N202276 003 | Apr 27, 2012 | Apr | NEWA |

AXITINIB

TABLET; ORAL

INLYTA

| | | | | | | | |
|--|---|--------|-----|-------------|--------------|-----|------|
| | | PFIZER | 1MG | N202324 001 | Jan 27, 2012 | Jan | NEWA |
| | + | | 5MG | N202324 002 | Jan 27, 2012 | Jan | NEWA |

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------|-------|-------------|--------------|-----|------|
| >A> | AT | ALCON PHARMA | 0.05% | A202305 001 | May 31, 2012 | May | NEWA |
|-----|----|--------------|-------|-------------|--------------|-----|------|

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

| | | | | | | | |
|-----|----|-------------------|-----------------------|-------------|--------------|-----|------|
| >A> | AB | SUN PHARMA GLOBAL | EQ 0.125MG BASE/SPRAY | A090423 001 | May 23, 2012 | May | NEWA |
|-----|----|-------------------|-----------------------|-------------|--------------|-----|------|

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

>A> SPRAY, METERED; NASAL

>A> DYMISTA

| | | | | | | | |
|-----|---|-------------|---------------------------------------|-------------|--------------|-----|------|
| >A> | + | MEDA PHARMS | EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY | N202236 001 | May 01, 2012 | May | NEWA |
|-----|---|-------------|---------------------------------------|-------------|--------------|-----|------|

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

| | | | | | | | |
|--|--|-------------------|-------------------|-------------|--------------|-----|------|
| | | TAKEDA PHARMS USA | EQ 40MG MEDOXOMIL | N200796 001 | Feb 25, 2011 | Apr | CAHN |
|--|--|-------------------|-------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|-------------------|-------------|--------------|-----|------|
| | + | | EQ 80MG MEDOXOMIL | N200796 002 | Feb 25, 2011 | Apr | CAHN |
|--|---|--|-------------------|-------------|--------------|-----|------|

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

| | | | | | | | |
|--|--|-------------------|--------------------------|-------------|--------------|-----|------|
| | | TAKEDA PHARMS USA | EQ 40MG MEDOXOMIL;12.5MG | N202331 001 | Dec 20, 2011 | Apr | CAHN |
|--|--|-------------------|--------------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|------------------------|-------------|--------------|-----|------|
| | + | | EQ 40MG MEDOXOMIL;25MG | N202331 002 | Dec 20, 2011 | Apr | CAHN |
|--|---|--|------------------------|-------------|--------------|-----|------|

BACLOFEN

TABLET; ORAL

BACLOFEN

| | | | | | | | |
|----|--|-------------|------|-------------|--------------|-----|------|
| AB | | PROSAM LABS | 10MG | A077089 001 | Oct 31, 2007 | Feb | CAHN |
|----|--|-------------|------|-------------|--------------|-----|------|

| | | | | | | | |
|----|--|--|------|-------------|--------------|-----|------|
| AB | | | 20MG | A077088 001 | Oct 31, 2007 | Feb | CAHN |
|----|--|--|------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

| | | | | | | | |
|--|--|-----------|------|-------------|--------------|-----|------|
| | | @ UCB INC | 10MG | N021589 001 | Oct 30, 2003 | Jan | CAHN |
|--|--|-----------|------|-------------|--------------|-----|------|

| | | | | | | | |
|--|--|---|------|-------------|--------------|-----|------|
| | | @ | 20MG | N021589 002 | Oct 30, 2003 | Jan | CAHN |
|--|--|---|------|-------------|--------------|-----|------|

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

| | | | | | | | |
|--|---|--------------|-------|-------------|--------------|-----|------|
| | + | SALIX PHARMS | 1.1GM | N022205 001 | Feb 03, 2012 | Feb | NEWA |
|--|---|--------------|-------|-------------|--------------|-----|------|

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

| | | | | | | | |
|--|---|--------------------|-------------------|-------------|--------------|-----|------|
| | + | TEVA BRANDED PHARM | 0.08MG/ACTIVATION | N202813 001 | Mar 23, 2012 | Mar | NEWA |
|--|---|--------------------|-------------------|-------------|--------------|-----|------|

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

| | | | | | | | |
|----|--|--------------|---------------|-------------|--------------|-----|------|
| AB | | VALEANT INTL | 5%;EQ 1% BASE | N050756 001 | Dec 21, 2000 | Apr | CAHN |
|----|--|--------------|---------------|-------------|--------------|-----|------|

| | | | | | | | |
|----|---|--|---------------|-------------|--------------|-----|------|
| BT | + | | 5%;EQ 1% BASE | N050756 002 | Apr 20, 2007 | Apr | CAHN |
|----|---|--|---------------|-------------|--------------|-----|------|

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

| | | | | | | | |
|----|---|--------------|-------|-------------|--------------|-----|------|
| AB | + | VALEANT INTL | 5%;3% | N050557 001 | Oct 26, 1984 | Jan | CAHN |
|----|---|--------------|-------|-------------|--------------|-----|------|

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

| | | | | | | | | |
|----|--|-------------------|------|---------|-----|--------------|-----|------|
| AA | | EMCURE PHARMS LTD | 50MG | A202061 | 001 | Jan 27, 2012 | Jan | NEWA |
|----|--|-------------------|------|---------|-----|--------------|-----|------|

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

| | | | | | | | | |
|-----|----|----------------|--------|---------|-----|--------------|-----|------|
| >A> | AP | APP PHARMS LLC | 1MG/ML | A090233 | 001 | Jul 28, 2009 | May | CAHN |
| >D> | AP | NEXUS PHARMS | 1MG/ML | A090233 | 001 | Jul 28, 2009 | May | CAHN |

COGENTIN

| | | | | | | | | |
|----|---|------------------|--------|---------|-----|--|-----|------|
| AP | + | OAK PHARMS AKORN | 1MG/ML | N012015 | 001 | | Feb | CAHN |
|----|---|------------------|--------|---------|-----|--|-----|------|

TABLET; ORAL

BENZTROPINE MESYLATE

| | | | | | | | | |
|----|---|------------------------|-------|---------|-----|--------------|-----|------|
| | | @ LANNETT HOLDINGS INC | 0.5MG | A088877 | 001 | Apr 11, 1985 | Jan | DISC |
| | | @ | 1MG | A088894 | 001 | Apr 11, 1985 | Jan | DISC |
| | | @ | 2MG | A088895 | 001 | Apr 11, 1985 | Jan | DISC |
| AA | | PROSAM LABS | 0.5MG | A040699 | 001 | Feb 14, 2008 | Feb | CMFD |
| AA | | | 1MG | A040705 | 001 | Feb 14, 2008 | Feb | CMFD |
| AA | | | 2MG | A040706 | 001 | Feb 14, 2008 | Feb | CMFD |
| AA | + | USL PHARMA | 0.5MG | A040103 | 001 | Dec 12, 1996 | Jan | CRLD |
| AA | + | | 1MG | A040103 | 002 | Dec 12, 1996 | Jan | CRLD |
| AA | + | | 2MG | A040103 | 003 | Dec 12, 1996 | Jan | CRLD |

>D> BETAMETHASONE

>D> SYRUP; ORAL

>D> CELESTONE

| | | | | | | | | |
|-----|---|----------|-----------|---------|-----|--|-----|------|
| >D> | + | SCHERING | 0.6MG/5ML | N014215 | 002 | | May | DISC |
| >A> | | @ | 0.6MG/5ML | N014215 | 002 | | May | DISC |

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|---|----------------|---------------|---------|-----|--------------|-----|------|
| AB | + | FOUGERA PHARMS | EQ 0.05% BASE | N019137 | 001 | Jun 26, 1984 | Jan | CAHN |
|----|---|----------------|---------------|---------|-----|--------------|-----|------|

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 0.05% BASE | A076215 | 001 | Dec 09, 2003 | Jan | CAHN |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|---|----------------|---------------|---------|-----|--------------|-----|------|
| AB | + | FOUGERA PHARMS | EQ 0.05% BASE | A075276 | 001 | May 13, 2003 | Jan | CAHN |
|----|---|----------------|---------------|---------|-----|--------------|-----|------|

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 0.05% BASE | A077111 | 001 | May 21, 2007 | Jan | CAHN |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 0.05% BASE | A075373 | 001 | Jun 22, 1999 | Jan | CAHN |
|----|--|----------------|---------------|---------|-----|--------------|-----|------|

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|----------------|------------------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 0.05% BASE;1% | A075502 | 001 | Jun 05, 2001 | Jan | CAHN |
|----|--|----------------|------------------|---------|-----|--------------|-----|------|

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|----------------|------------------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 0.05% BASE;1% | A076516 | 001 | Jun 16, 2005 | Jan | CAHN |
|----|--|----------------|------------------|---------|-----|--------------|-----|------|

LOTION; TOPICAL

LOTRISONE

| | | | | | | | |
|----|---|---------------|------------------|-------------|--------------|-----|------|
| AB | + | SCHERING CORP | EQ 0.05% BASE;1% | N020010 001 | Dec 08, 2000 | Feb | CAHN |
|----|---|---------------|------------------|-------------|--------------|-----|------|

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

| | | | | | | | |
|--|---|---------|---------------|-------------|--------------|-----|------|
| | + | STIEFEL | EQ 0.12% BASE | N020934 001 | Feb 28, 1999 | Jan | CAHN |
|--|---|---------|---------------|-------------|--------------|-----|------|

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

| | | | | | | | |
|----|--|-------------|-----|-------------|--------------|-----|------|
| AB | | TEVA WOMENS | 5MG | N019982 002 | Jul 31, 1992 | Jan | CAHN |
|----|--|-------------|-----|-------------|--------------|-----|------|

| | | | | | | | |
|----|---|--|------|-------------|--------------|-----|------|
| AB | + | | 10MG | N019982 001 | Jul 31, 1992 | Jan | CAHN |
|----|---|--|------|-------------|--------------|-----|------|

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

| | | | | | | | |
|--|---|-------------------|-------|-------------|--------------|-----|------|
| | + | MERCK SHARP DOHME | 200MG | N202258 001 | May 13, 2011 | Mar | CAHN |
|--|---|-------------------|-------|-------------|--------------|-----|------|

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

| | | | | | | | |
|--|---|-------------------|------------|-------------|--------------|-----|------|
| | + | MILLENNIUM PHARMS | 3.5MG/VIAL | N021602 001 | May 13, 2003 | Jan | CDFR |
|--|---|-------------------|------------|-------------|--------------|-----|------|

BOSENTAN

TABLET; ORAL

TRACLEER

| | | | | | | | |
|-----|--|----------|--------|-------------|--------------|-----|------|
| >D> | | ACTELION | 62.5MG | N021290 001 | Nov 20, 2001 | May | CAHN |
|-----|--|----------|--------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|--|-------|-------------|--------------|-----|------|
| >D> | + | | 125MG | N021290 002 | Nov 20, 2001 | May | CAHN |
|-----|---|--|-------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|--|---------------------|--------|-------------|--------------|-----|------|
| >A> | | ACTELION PHARMS LTD | 62.5MG | N021290 001 | Nov 20, 2001 | May | CAHN |
|-----|--|---------------------|--------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|--|-------|-------------|--------------|-----|------|
| >A> | + | | 125MG | N021290 002 | Nov 20, 2001 | May | CAHN |
|-----|---|--|-------|-------------|--------------|-----|------|

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

| | | | | | | | |
|--|---|-------------|-------------------------|-------------|--------------|-----|------|
| | + | ASTRAZENECA | 0.08MG/INH;0.0045MG/INH | N021929 001 | Jul 21, 2006 | Jan | CDFR |
|--|---|-------------|-------------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|-------------------------|-------------|--------------|-----|------|
| | + | | 0.16MG/INH;0.0045MG/INH | N021929 002 | Jul 21, 2006 | Jan | CDFR |
|--|---|--|-------------------------|-------------|--------------|-----|------|

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

| | | | | | | | |
|--|--|-------------------|---------------------------|-------------|--------------|-----|------|
| | | RECKITT BENCKISER | EQ 2MG BASE;EQ 0.5MG BASE | N022410 001 | Aug 30, 2010 | Apr | CAIN |
|--|--|-------------------|---------------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|-------------------------|-------------|--------------|-----|------|
| | + | | EQ 8MG BASE;EQ 2MG BASE | N022410 002 | Aug 30, 2010 | Apr | CAIN |
|--|---|--|-------------------------|-------------|--------------|-----|------|

TABLET; SUBLINGUAL

SUBOXONE

| | | | | | | | |
|--|--|-------------------|---------------------------|-------------|--------------|-----|------|
| | | RECKITT BENCKISER | EQ 2MG BASE;EQ 0.5MG BASE | N020733 001 | Oct 08, 2002 | Apr | CPOT |
|--|--|-------------------|---------------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|-------------------------|-------------|--------------|-----|------|
| | + | | EQ 8MG BASE;EQ 2MG BASE | N020733 002 | Oct 08, 2002 | Apr | CPOT |
|--|---|--|-------------------------|-------------|--------------|-----|------|

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

| | | | | | | | |
|--|---|---------------------|-------|-------------|--------------|-----|------|
| | + | EDGEMONT PHARMS LLC | 450MG | N022497 001 | Nov 10, 2011 | Mar | CAHN |
|--|---|---------------------|-------|-------------|--------------|-----|------|

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

| | | | | | | |
|----|---------------|------|-------------|--------------|-----|------|
| | @ APOTEX | 5MG | A075521 001 | Apr 05, 2002 | Mar | DISC |
| | @ | 10MG | A075521 002 | Apr 05, 2002 | Mar | DISC |
| | @ | 15MG | A075521 003 | Apr 05, 2002 | Mar | DISC |
| | @ EGIS | 5MG | A075119 001 | Mar 14, 2002 | Mar | DISC |
| | @ | 10MG | A075119 002 | Mar 14, 2002 | Mar | DISC |
| | @ | 15MG | A075119 003 | Jan 23, 2003 | Mar | DISC |
| | @ PROSAM LABS | 5MG | A075388 001 | May 09, 2002 | Mar | DISC |
| AB | | 5MG | A075388 001 | May 09, 2002 | Feb | CMFD |
| | @ | 10MG | A075388 002 | May 09, 2002 | Mar | DISC |
| AB | | 10MG | A075388 002 | May 09, 2002 | Feb | CMFD |
| | @ | 15MG | A075388 003 | May 09, 2002 | Mar | DISC |
| AB | | 15MG | A075388 003 | May 09, 2002 | Feb | CMFD |
| AB | | 30MG | A078302 001 | Dec 17, 2007 | Feb | CMFD |

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

| | | | | | | |
|--|------------------|----|-------------|--------------|-----|------|
| | @ PERRIGO ISRAEL | 2% | A200923 001 | May 18, 2012 | Apr | NEWA |
|--|------------------|----|-------------|--------------|-----|------|

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

| | | | | | | |
|----|----------------|------------------------------------|-------------|--------------|-----|------|
| AP | + BEDFORD LABS | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | N020793 001 | Sep 21, 1999 | Jan | CAHN |
|----|----------------|------------------------------------|-------------|--------------|-----|------|

SOLUTION; ORAL

CAFCIT

| | | | | | | |
|----|----------------|------------------------------------|-------------|--------------|-----|------|
| AA | + BEDFORD LABS | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | N020793 002 | Apr 12, 2000 | Jan | CAHN |
|----|----------------|------------------------------------|-------------|--------------|-----|------|

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

| | | | | | | | |
|-----|----|--------|--------|-------------|--------------|-----|------|
| >A> | AB | TOLMAR | 0.005% | A200935 001 | May 30, 2012 | May | NEWA |
|-----|----|--------|--------|-------------|--------------|-----|------|

DOVONEX

| | | | | | | |
|-----|-------------|--------|-------------|--------------|-----|------|
| >D> | + LEO PHARM | 0.005% | N020554 001 | Jul 22, 1996 | May | CFTG |
|-----|-------------|--------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|----|-----------------|--------|-------------|--------------|-----|------|
| >A> | AB | + LEO PHARMA AS | 0.005% | N020554 001 | Jul 22, 1996 | May | CFTG |
|-----|----|-----------------|--------|-------------|--------------|-----|------|

SOLUTION; TOPICAL

CALCIPOTRIENE

| | | | | | | |
|----|----------------|--------|-------------|--------------|-----|------|
| AT | FOUGERA PHARMS | 0.005% | A078305 001 | May 06, 2008 | Jan | CAHN |
|----|----------------|--------|-------------|--------------|-----|------|

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

| | | | | | | | |
|-----|----|-------------|------------------|-------------|--------------|-----|------|
| >A> | AB | PADDOCK LLC | EQ 169MG CALCIUM | A091312 001 | Jun 01, 2012 | May | NEWA |
|-----|----|-------------|------------------|-------------|--------------|-----|------|

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

| | | | | | | |
|----|-------------------|------------------|-------------|--------------|-----|------|
| AB | SUN PHARMA GLOBAL | 25MG;200MG;100MG | A079085 001 | May 10, 2012 | Apr | NEWA |
|----|-------------------|------------------|-------------|--------------|-----|------|

| | | | | | | |
|----|--|--------------------|-------------|--------------|-----|------|
| AB | | 37.5MG;200MG;150MG | A079085 002 | May 10, 2012 | Apr | NEWA |
|----|--|--------------------|-------------|--------------|-----|------|

STALEVO 100

| | | | | | | |
|----|--------------|------------------|-------------|--------------|-----|------|
| AB | ORION PHARMA | 25MG;200MG;100MG | N021485 002 | Jun 11, 2003 | Apr | CFTG |
|----|--------------|------------------|-------------|--------------|-----|------|

TABLET; ORAL

| | | | | | | | | | |
|----|--------------|--------------------|---------|-----|--------------|-----|------|--|--|
| | STALEVO 150 | | | | | | | | |
| AB | ORION PHARMA | 37.5MG;200MG;150MG | N021485 | 003 | Jun 11, 2003 | Apr | CFTG | | |

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

| | | | | | | | | | |
|----|---------|------------|---------|-----|--------------|-----|------|--|--|
| | PARCOPA | | | | | | | | |
| AB | UCB INC | 10MG;100MG | A076699 | 001 | Aug 27, 2004 | Jan | CAHN | | |
| AB | | 25MG;100MG | A076699 | 002 | Aug 27, 2004 | Jan | CAHN | | |
| AB | + | 25MG;250MG | A076699 | 003 | Aug 27, 2004 | Jan | CAHN | | |

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

| | | | | | | | | | |
|-----|--------------------|------------|---------|-----|--------------|-----|------|--|--|
| AP | CIPLA LTD | 50MG/VIAL | A077383 | 001 | Jan 27, 2006 | Mar | CAHN | | |
| AP | | 150MG/VIAL | A077383 | 002 | Jan 27, 2006 | Mar | CAHN | | |
| AP | | 450MG/VIAL | A077383 | 003 | Jan 27, 2006 | Mar | CAHN | | |
| >A> | ONCO THERAPIES LTD | 50MG/VIAL | A091510 | 001 | May 29, 2012 | May | NEWA | | |
| >A> | | 150MG/VIAL | A091510 | 002 | May 29, 2012 | May | NEWA | | |
| >A> | | 450MG/VIAL | A091510 | 003 | May 29, 2012 | May | NEWA | | |

PARAPLATIN

@ CORDEN PHARMA

@

@

| | | | | | | | | | |
|--|--|------------|---------|-----|--------------|-----|------|--|--|
| | | 50MG/VIAL | N019880 | 001 | Mar 03, 1989 | Feb | CAHN | | |
| | | 150MG/VIAL | N019880 | 002 | Mar 03, 1989 | Feb | CAHN | | |
| | | 450MG/VIAL | N019880 | 003 | Mar 03, 1989 | Feb | CAHN | | |

INJECTABLE; IV (INFUSION)

CARBOPLATIN

| | | | | | | | | | |
|----|----------------|----------------------|---------|-----|--------------|-----|------|--|--|
| AP | ACTAVIS TOTOWA | 50MG/5ML (10MG/ML) | A078732 | 001 | Feb 06, 2012 | Jan | NEWA | | |
| AP | | 150MG/15ML (10MG/ML) | A078732 | 002 | Feb 06, 2012 | Jan | NEWA | | |
| AP | | 450MG/45ML (10MG/ML) | A078732 | 003 | Feb 06, 2012 | Jan | NEWA | | |
| AP | | 600MG/60ML (10MG/ML) | A078732 | 004 | Feb 06, 2012 | Jan | NEWA | | |
| AP | CIPLA LTD | 50MG/5ML (10MG/ML) | A077861 | 001 | Jan 18, 2007 | Mar | CAHN | | |
| AP | | 150MG/15ML (10MG/ML) | A077861 | 002 | Jan 18, 2007 | Mar | CAHN | | |
| AP | | 450MG/45ML (10MG/ML) | A077861 | 003 | Jan 18, 2007 | Mar | CAHN | | |
| AP | | 600MG/60ML (10MG/ML) | A077861 | 004 | Jan 18, 2007 | Mar | CAHN | | |

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

| | | | | | | | | | |
|----|-------------|-------|---------|-----|--------------|-----|------|--|--|
| AA | PROSAM LABS | 350MG | A040188 | 001 | Mar 07, 1997 | Feb | CAHN | | |
|----|-------------|-------|---------|-----|--------------|-----|------|--|--|

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

| | | | | | | | | | |
|--|--|---------------|---------|-----|--------------|-----|------|--|--|
| | | EQ 250MG BASE | A064156 | 001 | Aug 28, 1997 | Apr | DISC | | |
| | | EQ 500MG BASE | A064156 | 002 | Aug 28, 1997 | Apr | DISC | | |

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

| | | | | | | | | | |
|----|-----------------|-------------------|---------|-----|--------------|-----|------|--|--|
| | | EQ 125MG BASE/5ML | A064166 | 001 | Oct 02, 1997 | Apr | DISC | | |
| AB | + | EQ 125MG BASE/5ML | A064166 | 001 | Oct 02, 1997 | Feb | CTEC | | |
| | @ | EQ 187MG BASE/5ML | A064165 | 001 | Oct 02, 1997 | Apr | DISC | | |
| AB | + | EQ 187MG BASE/5ML | A064165 | 001 | Oct 02, 1997 | Feb | CTEC | | |
| | @ | EQ 250MG BASE/5ML | A064164 | 001 | Oct 02, 1997 | Apr | DISC | | |
| AB | + | EQ 250MG BASE/5ML | A064164 | 001 | Oct 02, 1997 | Feb | CTEC | | |
| | @ | EQ 375MG BASE/5ML | A064155 | 001 | Oct 02, 1997 | Apr | DISC | | |
| AB | + | EQ 375MG BASE/5ML | A064155 | 001 | Oct 02, 1997 | Feb | CTEC | | |
| AB | YUNG SHIN PHARM | EQ 125MG BASE/5ML | A065412 | 001 | Feb 17, 2012 | Feb | NEWA | | |

FOR SUSPENSION; ORAL

CEFACLOR

| | | | | | | |
|----|-----------------|-------------------|-------------|--------------|-----|------|
| AB | YUNG SHIN PHARM | EQ 187MG BASE/5ML | A065412 002 | Feb 17, 2012 | Feb | NEWA |
| AB | | EQ 250MG BASE/5ML | A065412 003 | Feb 17, 2012 | Feb | NEWA |
| AB | | EQ 375MG BASE/5ML | A065412 004 | Feb 17, 2012 | Feb | NEWA |

TABLET, CHEWABLE; ORAL

RANICLOR

| | | | | | | |
|---|------------------|---------------|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | EQ 125MG BASE | A065092 001 | Dec 22, 2003 | Apr | DISC |
| @ | | EQ 187MG BASE | A065092 002 | Dec 22, 2003 | Apr | DISC |
| @ | | EQ 250MG BASE | A065092 003 | Dec 22, 2003 | Apr | DISC |
| @ | | EQ 375MG BASE | A065092 004 | Dec 22, 2003 | Apr | DISC |

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

| | | | | | | |
|---|------------------|---------------|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | EQ 500MG BASE | A065015 001 | Jun 22, 1999 | Apr | DISC |
|---|------------------|---------------|-------------|--------------|-----|------|

TABLET; ORAL

CEFADROXIL

| | | | | | | |
|---|---------|-------------|-------------|--------------|-----|------|
| @ | RANBAXY | EQ 1GM BASE | A065018 001 | Apr 23, 1999 | Apr | DISC |
|---|---------|-------------|-------------|--------------|-----|------|

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

| | | | | | | |
|-----|---------|------------------|-------------|--------------|-----|------|
| >A> | B BRAUN | EQ 2GM BASE/VIAL | N050779 003 | Jan 13, 2012 | May | NEWA |
|-----|---------|------------------|-------------|--------------|-----|------|

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

| | | | | | | |
|---|---------------|-------|-------------|--------------|-----|------|
| | VANSEN PHARMA | 200MG | N021222 001 | Aug 29, 2001 | Mar | CAHN |
| + | | 400MG | N021222 002 | Jul 21, 2008 | Mar | CAHN |

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

| | | | | | | | |
|----|---|-------------------|------------------|-------------|--------------|-----|------|
| AP | + | SANOFI AVENTIS US | EQ 1GM BASE/VIAL | A062659 001 | Jan 13, 1987 | Mar | CRLD |
| AP | + | | EQ 2GM BASE/VIAL | A062659 002 | Jan 13, 1987 | Mar | CRLD |

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

| | | | | | | | |
|----|------------|------------------|-------------|--------------|--------------|------|------|
| AB | APOTEX INC | 125MG/5ML | A065351 001 | Feb 29, 2012 | Feb | NEWA | |
| AB | | 250MG/5ML | A065351 002 | Feb 29, 2012 | Feb | NEWA | |
| | @ | RANBAXY LABS LTD | 125MG/5ML | A065202 001 | Jun 30, 2006 | Apr | DISC |
| | @ | | 250MG/5ML | A065202 002 | Jun 30, 2006 | Apr | DISC |

TABLET; ORAL

CEFPROZIL

| | | | | | | |
|---|------------------|-------|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | 250MG | A065198 001 | Dec 13, 2006 | Apr | DISC |
| @ | | 500MG | A065198 002 | Dec 13, 2006 | Apr | DISC |

CEFZIL

| | | | | | | |
|---|---------------|-------|-------------|--------------|-----|------|
| @ | CORDEN PHARMA | 250MG | N050664 001 | Dec 23, 1991 | Feb | CAHN |
| @ | | 500MG | N050664 002 | Dec 23, 1991 | Feb | CAHN |

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

| | | | | | | | |
|----|---|--------------|------------|-------------|--------------|-----|------|
| AP | + | COVIS PHARMA | 500MG/VIAL | N050578 001 | Jul 19, 1985 | Apr | CAHN |
|----|---|--------------|------------|-------------|--------------|-----|------|

INJECTABLE; INJECTION

FORTAZ

| | | | | | | | |
|----|---|--------------|----------|-------------|--------------|-----|------|
| AP | + | COVIS PHARMA | 1GM/VIAL | N050578 002 | Jul 19, 1985 | Apr | CAHN |
| AP | + | | 2GM/VIAL | N050578 003 | Jul 19, 1985 | Apr | CAHN |
| AP | + | | 6GM/VIAL | N050578 004 | Jul 19, 1985 | Apr | CAHN |

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

| | | | | | | | |
|--|---|----------------|-----------------|-------------|--------------|-----|------|
| | | @ COVIS PHARMA | EQ 10MG BASE/ML | N050634 001 | Apr 28, 1989 | Apr | CAHN |
| | + | | EQ 20MG BASE/ML | N050634 002 | Apr 28, 1989 | Apr | CAHN |
| | + | | EQ 40MG BASE/ML | N050634 003 | Apr 28, 1989 | Apr | CAHN |

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

| | | | | | | | |
|----|---|------------|------------------|-------------|--------------|-----|------|
| AP | + | SANDOZ INC | EQ 1GM BASE/VIAL | A065204 001 | May 03, 2005 | Mar | CRLD |
| AP | + | | EQ 2GM BASE/VIAL | A065204 002 | May 03, 2005 | Mar | CRLD |

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

| | | | | | | | |
|--|--|--------------------|---------------|-------------|--------------|-----|------|
| | | @ RANBAXY LABS LTD | EQ 125MG BASE | A065043 003 | Feb 15, 2002 | Apr | DISC |
| | | @ | EQ 250MG BASE | A065043 002 | Feb 15, 2002 | Apr | DISC |
| | | @ | EQ 500MG BASE | A065043 001 | Feb 15, 2002 | Apr | DISC |

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

| | | | | | | | |
|----|---|--------------|--------------------|-------------|--------------|-----|------|
| AB | + | COVIS PHARMA | EQ 750MG BASE/VIAL | N050558 002 | Oct 19, 1983 | Apr | CAHN |
|----|---|--------------|--------------------|-------------|--------------|-----|------|

INJECTABLE; INJECTION

ZINACEF

| | | | | | | | |
|----|---|--------------|--------------------|-------------|--------------|-----|------|
| AP | + | COVIS PHARMA | EQ 1.5GM BASE/VIAL | N050558 003 | Oct 19, 1983 | Apr | CAHN |
| AP | + | | EQ 7.5GM BASE/VIAL | N050558 004 | Oct 23, 1986 | Apr | CAHN |

ZINACEF IN PLASTIC CONTAINER

| | | | | | | | |
|--|---|--------------|-----------------|-------------|--------------|-----|------|
| | + | COVIS PHARMA | EQ 15MG BASE/ML | N050643 001 | Apr 28, 1989 | Apr | CAHN |
| | + | | EQ 30MG BASE/ML | N050643 002 | Apr 28, 1989 | Apr | CAHN |

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

| | | | | | | | |
|----|--|--------|---------|-------------|--------------|-----|------|
| AA | | SILARX | 5MG/5ML | A078876 001 | May 11, 2012 | Apr | NEWA |
|----|--|--------|---------|-------------|--------------|-----|------|

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

| | | | | | | | |
|-----|---|------------------|-----|-------------|--|-----|------|
| >A> | + | ASPEN GLOBAL INC | 2MG | N010669 002 | | May | CAHN |
| >D> | + | PBS | 2MG | N010669 002 | | May | CAHN |

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

| | | | | | | | |
|-----|--|--------------|------------|-------------|--------------|-----|------|
| >A> | | NYCOMED GMBH | 0.08MG/INH | N021658 002 | Jan 10, 2008 | May | CAHN |
| >D> | | NYCOMED US | 0.08MG/INH | N021658 002 | Jan 10, 2008 | May | CAHN |

AEROSOL, METERED; NASAL

ZETONNA

| | | | | | | | |
|--|---|--------------|-------------|-------------|--------------|-----|------|
| | + | NYCOMED GMBH | 0.037MG/INH | N202129 001 | Jan 20, 2012 | Jan | NEWA |
|--|---|--------------|-------------|-------------|--------------|-----|------|

SPRAY, METERED; NASAL

OMNARIS

| | | | | | | | |
|-----|---|--------------|------------|-------------|--------------|-----|------|
| >A> | + | NYCOMED GMBH | 0.05MG/INH | N022004 001 | Oct 20, 2006 | May | CAHN |
|-----|---|--------------|------------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|------------|------------|-------------|--------------|-----|------|
| >D> | + | NYCOMED US | 0.05MG/INH | N022004 001 | Oct 20, 2006 | May | CAHN |
|-----|---|------------|------------|-------------|--------------|-----|------|

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.77% | A076435 001 | Dec 29, 2004 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

GEL; TOPICAL

CICLOPIROX

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.77% | A077896 001 | Jun 10, 2008 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

| | | | | | | | |
|----|--|-------------------|-------|-------------|--------------|-----|------|
| AB | | GLENMARK GENERICS | 0.77% | A091595 001 | Feb 29, 2012 | Feb | NEWA |
|----|--|-------------------|-------|-------------|--------------|-----|------|

SHAMPOO; TOPICAL

CICLOPIROX

| | | | | | | | |
|----|--|----------------|----|-------------|--------------|-----|------|
| AT | | FOUGERA PHARMS | 1% | A090146 001 | May 25, 2010 | Jan | CAHN |
|----|--|----------------|----|-------------|--------------|-----|------|

SOLUTION; TOPICAL

CICLOPIROX

| | | | | | | | |
|----|--|------------------|----|-------------|--------------|-----|------|
| AT | | MYLAN PHARMS INC | 8% | A078567 001 | Sep 18, 2007 | Feb | CAHN |
|----|--|------------------|----|-------------|--------------|-----|------|

SUSPENSION; TOPICAL

CICLOPIROX

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.77% | A076422 001 | Aug 06, 2004 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

| | | | | | | | |
|--|---|-----------------|----------------------|-------------|--------------|-----|------|
| | @ | TEVA PARENTERAL | 200MG/20ML (10MG/ML) | A077782 001 | Aug 28, 2006 | Mar | DISC |
|--|---|-----------------|----------------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|----------------------|-------------|--------------|-----|------|
| | @ | | 400MG/40ML (10MG/ML) | A077782 002 | Aug 28, 2006 | Jan | DISC |
|--|---|--|----------------------|-------------|--------------|-----|------|

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

| | | | | | | | |
|--|---|-------|---------------|-------------|--------------|-----|------|
| | @ | PLIVA | EQ 100MG BASE | A076426 001 | Jun 15, 2005 | Jan | DISC |
|--|---|-------|---------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|---------------|-------------|--------------|-----|------|
| | @ | | EQ 250MG BASE | A076426 002 | Jun 15, 2005 | Jan | DISC |
|--|---|--|---------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|---------------|-------------|--------------|-----|------|
| | @ | | EQ 500MG BASE | A076426 003 | Jun 15, 2005 | Jan | DISC |
|--|---|--|---------------|-------------|--------------|-----|------|

| | | | | | | | |
|--|---|--|---------------|-------------|--------------|-----|------|
| | @ | | EQ 750MG BASE | A076426 004 | Jun 15, 2005 | Jan | DISC |
|--|---|--|---------------|-------------|--------------|-----|------|

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

| | | | | | | | |
|----|--|--------------------|-------------------------|-------------|--------------|-----|------|
| AB | | DR REDDYS LABS LTD | 212.6MG;EQ 287.5MG BASE | A077701 002 | Oct 31, 2007 | Apr | NEWA |
|----|--|--------------------|-------------------------|-------------|--------------|-----|------|

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

| | | | | | | | |
|----|--|------------|----------------|-------------|--------------|-----|------|
| AP | | SANDOZ INC | EQ 2MG BASE/ML | A200159 001 | Feb 03, 2012 | Jan | NEWA |
|----|--|------------|----------------|-------------|--------------|-----|------|

CISATRACURIUM BESYLATE PRESERVATIVE FREE

| | | | | | | | |
|----|--|------------|----------------|-------------|--------------|-----|------|
| AP | | SANDOZ INC | EQ 2MG BASE/ML | A200154 001 | Feb 03, 2012 | Jan | NEWA |
|----|--|------------|----------------|-------------|--------------|-----|------|

| | | | | | | | |
|----|--|--|-----------------|-------------|--------------|-----|------|
| AP | | | EQ 10MG BASE/ML | A200154 002 | Feb 03, 2012 | Jan | NEWA |
|----|--|--|-----------------|-------------|--------------|-----|------|

NIMBEX

| | | | | | | | |
|----|---|--------|----------------|-------------|--------------|-----|------|
| AP | + | ABBOTT | EQ 2MG BASE/ML | N020551 001 | Dec 15, 1995 | Jan | CFTG |
|----|---|--------|----------------|-------------|--------------|-----|------|

NIMBEX PRESERVATIVE FREE

| | | | | | | | |
|----|---|--------|----------------|-------------|--------------|-----|------|
| AP | + | ABBOTT | EQ 2MG BASE/ML | N020551 003 | Dec 15, 1995 | Jan | CFTG |
|----|---|--------|----------------|-------------|--------------|-----|------|

INJECTABLE; INJECTION

NIMBEX PRESERVATIVE FREE

| | | | | | | | |
|----|---|--------|-----------------|-------------|--------------|-----|------|
| AP | + | ABBOTT | EQ 10MG BASE/ML | N020551 002 | Dec 15, 1995 | Jan | CFTG |
|----|---|--------|-----------------|-------------|--------------|-----|------|

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

| | | | | | | | |
|----|--|--------------------|--------|-------------|--------------|-----|------|
| AP | | ONCO THERAPIES LTD | 1MG/ML | A091062 001 | Apr 18, 2012 | Apr | NEWA |
| | | @ TEVA PARENTERAL | 1MG/ML | A074814 001 | May 16, 2000 | Mar | DISC |

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

| | | | | | | | |
|----|--|----------------|------------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 2% BASE | A065139 001 | Dec 27, 2004 | Jan | CAHN |
|----|--|----------------|------------|-------------|--------------|-----|------|

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

| | | | | | | | |
|----|--|----------------|------------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 1% BASE | A064160 001 | Jan 28, 2000 | Jan | CAHN |
|----|--|----------------|------------|-------------|--------------|-----|------|

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | |
|-----|----|----------------------|-----------------|-------------|--------------|-----|------|
| >D> | + | PHARMACIA AND UPJOHN | EQ 6MG BASE/ML | N050639 001 | Aug 30, 1989 | May | CFTG |
| >A> | AP | | EQ 6MG BASE/ML | N050639 001 | Aug 30, 1989 | May | CFTG |
| >D> | + | | EQ 12MG BASE/ML | N050639 002 | Aug 30, 1989 | May | CFTG |
| >A> | AP | | EQ 12MG BASE/ML | N050639 002 | Aug 30, 1989 | May | CFTG |
| >D> | + | | EQ 18MG BASE/ML | N050639 003 | Apr 10, 1991 | May | CFTG |
| >A> | AP | | EQ 18MG BASE/ML | N050639 003 | Apr 10, 1991 | May | CFTG |

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

| | | | | | | | |
|-----|----|------------|-----------------|-------------|--------------|-----|------|
| >A> | AP | SANDOZ INC | EQ 6MG BASE/ML | A201692 001 | May 31, 2012 | May | NEWA |
| >A> | AP | | EQ 12MG BASE/ML | A201692 002 | May 31, 2012 | May | NEWA |
| >A> | AP | | EQ 18MG BASE/ML | A201692 003 | May 31, 2012 | May | NEWA |

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

| | | | | | | | |
|----|--|----------------|------------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | EQ 1% BASE | A065067 001 | Jan 31, 2002 | Jan | CAHN |
|----|--|----------------|------------|-------------|--------------|-----|------|

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

| | | | | | | | |
|----|--|----------------|------------|-------------|--------------|-----|------|
| AT | | FOUGERA PHARMS | EQ 1% BASE | A065254 001 | Feb 14, 2006 | Jan | CAHN |
|----|--|----------------|------------|-------------|--------------|-----|------|

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

| | | | | | | | |
|-----|----|-------------|-------------|-------------|--------------|-----|------|
| >D> | BX | STIEFEL GSK | 1.2%;0.025% | N050803 001 | Jul 16, 2010 | May | CRLD |
| >A> | BX | + | 1.2%;0.025% | N050803 001 | Jul 16, 2010 | May | CRLD |

CLOBAZAM

TABLET; ORAL

ONFI

| | | | | | | | |
|--|--|--------------|------|-------------|--------------|-----|------|
| | | LUNDBECK LLC | 5MG | N202067 001 | Oct 21, 2011 | Mar | CAHN |
| | | | 10MG | N202067 002 | Oct 21, 2011 | Mar | CAHN |
| | | + | 20MG | N202067 003 | Oct 21, 2011 | Mar | CAHN |

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

| | | | | | | | |
|-----|---|----------------|-------|-------------|--------------|-----|------|
| AB2 | | FOUGERA PHARMS | 0.05% | A075430 001 | May 26, 1999 | Jan | CAHN |
| AB1 | + | FOUGERA PHARMS | 0.05% | N019322 001 | Dec 27, 1985 | Jan | CAHN |

GEL; TOPICAL

| CLOBETASOL PROPIONATE | | | | | | | | | |
|-----------------------|------------------|-------|---------|-----|--------------|-----|------|--|--|
| AB | FOUGERA PHARMS | 0.05% | A075368 | 001 | Feb 15, 2000 | Jan | CAHN | | |
| TEMOVATE | | | | | | | | | |
| AB | + FOUGERA PHARMS | 0.05% | N020337 | 001 | Apr 29, 1994 | Jan | CAHN | | |
| OINTMENT; TOPICAL | | | | | | | | | |
| CLOBETASOL PROPIONATE | | | | | | | | | |
| AB | FOUGERA PHARMS | 0.05% | A074407 | 001 | Feb 23, 1996 | Jan | CAHN | | |
| TEMOVATE | | | | | | | | | |
| AB | + FOUGERA PHARMS | 0.05% | N019323 | 001 | Dec 27, 1985 | Jan | CAHN | | |
| SOLUTION; TOPICAL | | | | | | | | | |
| CLOBETASOL PROPIONATE | | | | | | | | | |
| AT | FOUGERA PHARMS | 0.05% | A075391 | 001 | Feb 08, 1999 | Jan | CAHN | | |
| TEMOVATE | | | | | | | | | |
| AT | + FOUGERA PHARMS | 0.05% | N019966 | 001 | Feb 22, 1990 | Jan | CAHN | | |

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

| | | | | | | | | | |
|----|---------------------|------------------------|---------|-----|--------------|-----|------|--|--|
| AP | MYLAN INSTITUTIONAL | 1 MG/10 ML (0.1 MG/ML) | N020615 | 001 | Oct 02, 1996 | Feb | CAHN | | |
| AP | + | 5 MG/10 ML (0.5 MG/ML) | N020615 | 002 | Apr 27, 1999 | Feb | CAHN | | |

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

| | | | | | | | | | |
|-----|----------------|-------|---------|-----|--------------|-----|------|--|--|
| >D> | @ SHIONOGI INC | 0.2MG | N022331 | 004 | Sep 28, 2010 | May | CMFD | | |
| >A> | | 0.2MG | N022331 | 004 | Sep 28, 2010 | May | CMFD | | |

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

| AB | APOTEX INC | EQ 75MG BASE | A076274 | 001 | May 17, 2012 | Apr | NEWA | | |
|--------|----------------------|---------------|---------|-----|--------------|-----|------|--|--|
| AB | AUROBINDO PHARMA LTD | EQ 75MG BASE | A090540 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | DR REDDYS LABS INC | EQ 75MG BASE | A076273 | 001 | Jan 14, 2008 | Mar | CMFD | | |
| AB | DR REDDYS LABS LTD | EQ 300MG BASE | A091023 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | GATE PHARMS | EQ 300MG BASE | A091216 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | MYLAN PHARMS INC | EQ 75MG BASE | A077665 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | | EQ 300MG BASE | A077665 | 002 | May 17, 2012 | Apr | NEWA | | |
| AB | ROXANE | EQ 75MG BASE | A078004 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | SUN PHARMA GLOBAL | EQ 75MG BASE | A090494 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | TEVA | EQ 75MG BASE | A076999 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | TEVA PHARMS | EQ 300MG BASE | A090625 | 001 | May 17, 2012 | Apr | NEWA | | |
| AB | TORRENT PHARMS LTD | EQ 75MG BASE | A090844 | 001 | May 17, 2012 | Apr | NEWA | | |
| PLAVIX | | | | | | | | | |
| AB | SANOFI AVENTIS US | EQ 75MG BASE | N020839 | 001 | Nov 17, 1997 | Mar | CTEC | | |
| AB | + | EQ 300MG BASE | N020839 | 002 | Sep 20, 2007 | Apr | CTEC | | |

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ LUNDBECK LLC

@

@

| | | | | | | | | | |
|--|--|--------|---------|-----|--|-----|------|--|--|
| | | 3.75MG | N017105 | 001 | | Mar | CAHN | | |
| | | 7.5MG | N017105 | 002 | | Mar | CAHN | | |
| | | 15MG | N017105 | 003 | | Mar | CAHN | | |

TABLET; ORAL

TRANXENE

| | | | | | | | | | |
|----|--------------|--------|---------|-----|--|-----|------|--|--|
| AB | LUNDBECK LLC | 3.75MG | N017105 | 006 | | Mar | CAHN | | |
| AB | | 7.5MG | N017105 | 007 | | Mar | CAHN | | |
| AB | + | 15MG | N017105 | 008 | | Mar | CAHN | | |

TABLET; ORAL

TRANXENE SD

@ LUNDBECK LLC

11.25MG

N017105 005

Mar CAHN

@

22.5MG

N017105 004

Mar CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB FOUGERA PHARMS

1%

A078338 001 Sep 02, 2008 Jan CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ

12.5MG

N021590 004 May 30, 2007 Apr CAHN

25MG

N021590 001 Feb 10, 2004 Apr CAHN

@

50MG

N021590 003 Jun 03, 2005 Apr CAHN

+

100MG

N021590 002 Feb 10, 2004 Apr CAHN

150MG

N021590 005 Jul 09, 2010 Apr CAHN

200MG

N021590 006 Jul 09, 2010 Apr CAHN

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

>D>

+ DURAMED RES

309MG/COPPER

N018680 001 Nov 15, 1984 May CAHN

>A>

+ TEVA WOMENS

309MG/COPPER

N018680 001 Nov 15, 1984 May CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA + JAZZ PHARMS COMMERCL 100MG/5ML

N020479 001 Feb 29, 1996 Mar CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB PROSAM LABS

5MG

A077291 001 Feb 03, 2006 Feb CAHN

AB

10MG

A077209 001 Oct 04, 2005 Feb CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP + BAXTER HLTHCARE 500MG/VIAL

N012142 003 Apr CRLD

AP + 1GM/VIAL

N012142 004 Aug 30, 1982 Apr CRLD

AP + 2GM/VIAL

N012142 005 Aug 30, 1982 Apr CRLD

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

>D> AB1 PLIVA 25MG

A065044 002 Dec 20, 2000 May CAHN

>D> AB1 100MG

A065044 001 Dec 20, 2000 May CAHN

>A> AB1 WATSON LABS INC 25MG

A065044 002 Dec 20, 2000 May CAHN

>A> AB1 100MG

A065044 001 Dec 20, 2000 May CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP ONCO THERAPIES LTD 100MG/ML

A201784 001 Jan 30, 2012 Jan NEWA

DACTINOMYCIN

| | | | | | | |
|----|-----------------------|------------|-------------|--|-----|------|
| | INJECTABLE; INJECTION | | | | | |
| | COSMEGEN | | | | | |
| AP | + LUNDBECK LLC | 0.5MG/VIAL | N050682 001 | | Mar | CAHN |

DARUNAVIR ETHANOLATE

| | | | | | | |
|--|------------------|------------------|-------------|--------------|-----|------|
| | SUSPENSION; ORAL | | | | | |
| | PREZISTA | | | | | |
| | + JANSSEN PRODS | EQ 100MG BASE/ML | N202895 001 | Dec 16, 2011 | Feb | CAHN |
| | TABLET; ORAL | | | | | |
| | PREZISTA | | | | | |
| | JANSSEN PRODS | EQ 75MG BASE | N021976 004 | Dec 18, 2008 | Feb | CAHN |
| | | EQ 150MG BASE | N021976 005 | Dec 18, 2008 | Feb | CAHN |
| | @ | EQ 300MG BASE | N021976 001 | Jun 23, 2006 | Feb | CAHN |
| | | EQ 400MG BASE | N021976 003 | Oct 21, 2008 | Feb | CAHN |
| | + | EQ 600MG BASE | N021976 002 | Feb 25, 2008 | Feb | CAHN |

DES Loratadine

| | | | | | | |
|----|------------------|-----|-------------|--------------|-----|------|
| | TABLET; ORAL | | | | | |
| | DES Loratadine | | | | | |
| AB | BELCHER PHARMS | 5MG | A078355 001 | Apr 19, 2012 | Apr | NEWA |
| AB | MYLAN PHARMS INC | 5MG | A078351 001 | Feb 10, 2012 | Jan | NEWA |

Desmopressin Acetate

| | | | | | | |
|----|-----------------------|-------|-------------|--------------|-----|------|
| | SOLUTION; NASAL | | | | | |
| | DDAVP | | | | | |
| AB | + SANOFI AVENTIS US | 0.01% | N017922 001 | | Mar | CFTG |
| | DES MOPRESSIN ACETATE | | | | | |
| AB | SUN PHARM INDS | 0.01% | A077212 001 | Apr 12, 2012 | Mar | NEWA |

Desogestrel; Ethinyl Estradiol

| | | | | | | |
|----|-------------------|--------------------------|-------------|--------------|-----|------|
| | TABLET; ORAL-28 | | | | | |
| | VIORELE | | | | | |
| AB | GLENMARK GENERICS | .15MG,N/A; 0.02MG,0.01MG | A091346 001 | Apr 02, 2012 | Mar | NEWA |

Desonide

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| | LOTION; TOPICAL | | | | | |
| | DESONIDE | | | | | |
| AB | FOUGERA PHARMS | 0.05% | A075860 001 | Mar 19, 2002 | Jan | CAHN |
| | OINTMENT; TOPICAL | | | | | |
| | DESONIDE | | | | | |
| AB | FOUGERA PHARMS | 0.05% | A075751 001 | Mar 12, 2001 | Jan | CAHN |

Desoximetasone

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| | CREAM; TOPICAL | | | | | |
| | DES OXIMETASONE | | | | | |
| AB | FOUGERA PHARMS | 0.25% | A078369 001 | Jun 29, 2010 | Jan | CAHN |
| | TOPICORT | | | | | |
| | + TARO | 0.05% | A073210 001 | Nov 30, 1990 | Apr | CTNA |
| | + | 0.25% | A073193 001 | Nov 30, 1990 | Apr | CTNA |
| | @ TARO PHARMS NORTH | 0.25% | N017856 001 | | Apr | DISC |
| | TOPICORT LP | | | | | |
| | @ TARO PHARMS NORTH | 0.05% | N018309 001 | | Apr | DISC |

| | | | | | | | | |
|-----|---------------------------------------|---------------------|----------------------|---------|-----|--------------|-----|------|
| | GEL; TOPICAL | | | | | | | |
| | TOPICORT | | | | | | | |
| AB | + | TARO | 0.05% | A074904 | 001 | Jul 14, 1998 | Apr | CTNA |
| | | @ TARO PHARMS NORTH | 0.05% | N018586 | 001 | Mar 29, 1982 | Apr | DISC |
| | OINTMENT; TOPICAL | | | | | | | |
| | DESOXIMETASONE | | | | | | | |
| AB | + | TARO | 0.25% | A074286 | 001 | Jun 07, 1996 | Mar | CRLD |
| | TOPICORT | | | | | | | |
| | + | TARO | 0.25% | A074286 | 001 | Jun 07, 1996 | Apr | CTNA |
| | | @ TARO PHARMS NORTH | 0.25% | N018763 | 001 | Sep 30, 1983 | Mar | DISC |
| | <u>DEXAMETHASONE SODIUM PHOSPHATE</u> | | | | | | | |
| | INJECTABLE; INJECTION | | | | | | | |
| | DEXAMETHASONE SODIUM PHOSPHATE | | | | | | | |
| AP | + | APP PHARMS LLC | EQ 10MG PHOSPHATE/ML | A040572 | 001 | Apr 22, 2005 | Feb | CRLD |
| | <u>DIAZEPAM</u> | | | | | | | |
| | INJECTABLE; INJECTION | | | | | | | |
| | DIAZEPAM | | | | | | | |
| | | @ HOSPIRA | 5MG/ML | A071584 | 001 | Oct 13, 1987 | Apr | DISC |
| | <u>DIFLORASONE DIACETATE</u> | | | | | | | |
| | CREAM; TOPICAL | | | | | | | |
| | DIFLORASONE DIACETATE | | | | | | | |
| BX | + | FOUGERA PHARMS | 0.05% | A076263 | 001 | Dec 20, 2002 | Jan | CAHN |
| AB1 | + | | 0.05% | A075187 | 001 | Mar 30, 1998 | Jan | CAHN |
| | OINTMENT; TOPICAL | | | | | | | |
| | DIFLORASONE DIACETATE | | | | | | | |
| AB | | FOUGERA PHARMS | 0.05% | A075374 | 001 | Apr 27, 1999 | Jan | CAHN |
| | <u>DIFLUNISAL</u> | | | | | | | |
| | TABLET; ORAL | | | | | | | |
| | DIFLUNISAL | | | | | | | |
| AB | | EMCURE PHARMS USA | 500MG | A202845 | 001 | Mar 08, 2012 | Feb | NEWA |
| AB | + | TEVA | 500MG | A073673 | 001 | Jul 31, 1992 | Feb | CTEC |
| | <u>DILTIAZEM HYDROCHLORIDE</u> | | | | | | | |
| | INJECTABLE; INJECTION | | | | | | | |
| | DILTIAZEM HYDROCHLORIDE | | | | | | | |
| | | @ TEVA PARENTERAL | 5MG/ML | A074894 | 001 | Aug 26, 1997 | Jan | DISC |
| | <u>DIPHENHYDRAMINE HYDROCHLORIDE</u> | | | | | | | |
| | INJECTABLE; INJECTION | | | | | | | |
| | BENADRYL | | | | | | | |
| | | @ MCNEIL CONS | 50MG/ML | N006146 | 002 | | Mar | DISC |
| | BENADRYL PRESERVATIVE FREE | | | | | | | |
| | | @ MCNEIL CONS | 50MG/ML | N009486 | 001 | | Mar | DISC |
| | DIPHENHYDRAMINE HYDROCHLORIDE | | | | | | | |
| AP | + | BAXTER HLTHCARE | 50MG/ML | A080817 | 002 | | Apr | CRLD |
| | <u>DIPYRIDAMOLE</u> | | | | | | | |
| | INJECTABLE; INJECTION | | | | | | | |
| | DIPYRIDAMOLE | | | | | | | |
| | | @ TEVA PARENTERAL | 5MG/ML | A074952 | 001 | Nov 26, 1997 | Jan | DISC |

TABLET; ORALDIPYRIDAMOLE

| | | | | | | |
|----|-------------|------|-------------|--------------|-----|------|
| AB | PROSAM LABS | 25MG | A040542 001 | Apr 21, 2006 | Feb | CAHN |
| AB | | 50MG | A040542 002 | Apr 21, 2006 | Feb | CAHN |
| AB | | 75MG | A040542 003 | Apr 21, 2006 | Feb | CAHN |

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE; ORALDIVALPROEX SODIUM

| | | | | | | |
|----|--------------------|------------------------|-------------|--------------|-----|------|
| AB | DR REDDYS LABS LTD | EQ 250MG VALPROIC ACID | A090161 001 | Mar 15, 2012 | Feb | NEWA |
| AB | REDDYS | EQ 500MG VALPROIC ACID | A090070 001 | Mar 12, 2012 | Feb | NEWA |

DOCETAXELINJECTABLE; INJECTIONDOCETAXEL

| | | | | | | |
|----|---------------------|----------------------|-------------|--------------|-----|------|
| AP | ACCORD HLTHCARE | 20MG/ML (20MG/ML) | N201195 003 | Apr 20, 2012 | Apr | NEWA |
| AP | | 20MG/0.5ML (40MG/ML) | N201195 001 | Jun 08, 2011 | Jan | CTEC |
| AP | | 80MG/4ML (20MG/ML) | N201195 004 | Apr 20, 2012 | Apr | NEWA |
| AP | | 80MG/2ML (40MG/ML) | N201195 002 | Jun 08, 2011 | Jan | CTEC |
| | | 160MG/8ML (20MG/ML) | N201195 005 | Apr 20, 2012 | Apr | NEWA |
| AP | APOTEX INC | 20MG/0.5ML (40MG/ML) | N022312 001 | Jan 11, 2012 | Jan | NEWA |
| AP | | 80MG/2ML (40MG/ML) | N022312 002 | Jan 11, 2012 | Jan | NEWA |
| | <u>TAXOTERE</u> | | | | | |
| AP | + SANOFI AVENTIS US | 20MG/ML (20MG/ML) | N020449 003 | Aug 03, 2010 | Apr | CTEC |
| AP | + | 80MG/4ML (20MG/ML) | N020449 004 | Aug 02, 2010 | Apr | CTEC |

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMICCOSOPT PF

| | | | | | | |
|--|---------------------|-------------------------|-------------|--------------|-----|------|
| | + MERCK SHARP DOHME | EQ 2% BASE;EQ 0.5% BASE | N202667 001 | Feb 01, 2012 | Feb | NEWA |
|--|---------------------|-------------------------|-------------|--------------|-----|------|

DOXAZOSIN MESYLATETABLET; ORALDOXAZOSIN MESYLATE

| | | | | | | |
|--|-----------------|-------------|-------------|--------------|-----|------|
| | @ NESHER PHARMS | EQ 1MG BASE | A075609 001 | Oct 18, 2000 | Feb | DISC |
| | @ | EQ 2MG BASE | A075609 002 | Oct 18, 2000 | Feb | DISC |
| | @ | EQ 4MG BASE | A075609 003 | Oct 18, 2000 | Feb | DISC |
| | @ | EQ 8MG BASE | A075609 004 | Oct 18, 2000 | Feb | DISC |

DOXEPIN HYDROCHLORIDECREAM; TOPICALZONALON

| | | | | | | |
|--|------------------|----|-------------|--------------|-----|------|
| | + FOUGERA PHARMS | 5% | N020126 001 | Apr 01, 1994 | Jan | CAHN |
|--|------------------|----|-------------|--------------|-----|------|

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTIONDOXORUBICIN HYDROCHLORIDE

| | | | | | | |
|----|--------------------|--------|-------------|--------------|-----|------|
| AP | ONCO THERAPIES LTD | 2MG/ML | A200901 001 | Feb 14, 2012 | Jan | NEWA |
| AP | SUN PHARM INDS | 2MG/ML | A091418 001 | Feb 15, 2012 | Jan | NEWA |

INJECTABLE, LIPOSOMAL; INJECTIONDOXIL

| | | | | | | |
|--|-------------------|--------------------|-------------|--------------|-----|------|
| | + JANSSEN R AND D | 20MG/10ML (2MG/ML) | N050718 001 | Nov 17, 1995 | Jan | CAHN |
| | + | 50MG/25ML (2MG/ML) | N050718 002 | Jun 13, 2000 | Jan | CAHN |

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

| | | | | | | | |
|-----|----|------------------|---------------|-------------|--------------|-----|------|
| >A> | AB | MYLAN PHARMS INC | EQ 150MG BASE | A202778 001 | Jun 08, 2012 | May | NEWA |
| | | @ SANDOZ INC | EQ 50MG BASE | A065032 001 | Jun 30, 2000 | Mar | DISC |
| | | @ | EQ 100MG BASE | A065032 002 | Jun 30, 2000 | Mar | DISC |

TABLET; ORAL

DOXYCYCLINE

| | | | | | | | |
|--|--|--------------|---------------|-------------|--------------|-----|------|
| | | @ SANDOZ INC | EQ 50MG BASE | A065353 001 | Nov 27, 2006 | Mar | DISC |
| | | @ | EQ 75MG BASE | A065353 002 | Nov 27, 2006 | Mar | DISC |
| | | @ | EQ 100MG BASE | A065353 003 | Nov 27, 2006 | Mar | DISC |

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

| | | | | | | | |
|----|--|-------------|--------------|-------------|--------------|-----|------|
| AB | | LARKEN LABS | EQ 20MG BASE | A065287 001 | Feb 28, 2006 | Apr | CMFD |
|----|--|-------------|--------------|-------------|--------------|-----|------|

TABLET, DELAYED RELEASE; ORAL

DORYX

| | | | | | | | |
|----|---|--------------|---------------|-------------|--------------|-----|------|
| AB | + | MAYNE PHARMA | EQ 150MG BASE | N050795 003 | Jun 20, 2008 | Jan | CTEC |
|----|---|--------------|---------------|-------------|--------------|-----|------|

DOXYCYCLINE HYCLATE

| | | | | | | | |
|----|--|------------------|---------------|-------------|--------------|-----|------|
| AB | | MYLAN PHARMS INC | EQ 150MG BASE | A091052 001 | Feb 08, 2012 | Jan | NEWA |
|----|--|------------------|---------------|-------------|--------------|-----|------|

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

| | | | | | | | |
|--|--|----------------|--------------|-------------|--------------|-----|------|
| | | BAYER HLTHCARE | 0.25MG;0.5MG | N021355 001 | Feb 29, 2012 | Feb | NEWA |
|--|--|----------------|--------------|-------------|--------------|-----|------|

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

| | | | | | | | |
|----|---|----------------|----|-------------|--------------|-----|------|
| AB | + | FOUGERA PHARMS | 1% | A076075 001 | Nov 26, 2002 | Jan | CAHN |
|----|---|----------------|----|-------------|--------------|-----|------|

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

| | | | | | | | |
|--|---|---------------------|--------------------------|-------------|--------------|-----|------|
| | + | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;300MG | N202123 001 | Aug 10, 2011 | Apr | CAIN |
|--|---|---------------------|--------------------------|-------------|--------------|-----|------|

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

| | | | | | | | |
|--|---|------------|-------|-------------|--------------|-----|------|
| | @ | SANDOZ INC | 2.5MG | A075621 001 | Aug 22, 2000 | Feb | DISC |
| | @ | | 2.5MG | A075496 001 | Aug 22, 2000 | Jan | DISC |
| | @ | | 5MG | A075621 002 | Aug 22, 2000 | Feb | DISC |
| | @ | | 5MG | A075496 002 | Aug 22, 2000 | Jan | DISC |
| | @ | | 10MG | A075621 003 | Aug 22, 2000 | Feb | DISC |
| | @ | | 10MG | A075459 001 | Aug 22, 2000 | Jan | DISC |
| | @ | | 20MG | A075621 004 | Aug 22, 2000 | Feb | DISC |
| | @ | | 20MG | A075459 002 | Aug 22, 2000 | Jan | DISC |

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|--|---|------------|------------|-------------|--------------|-----|------|
| | @ | SANDOZ INC | 5MG;12.5MG | A076116 001 | Sep 19, 2001 | Mar | DISC |
| | @ | | 10MG;25MG | A076116 002 | Sep 19, 2001 | Mar | DISC |

ENTACAPONE

TABLET; ORAL

COMTAN

| | | | | | | | |
|-----|---|--------------|-------|-------------|--------------|-----|------|
| >D> | + | ORION | 200MG | N020796 001 | Oct 19, 1999 | May | CAHN |
| >A> | + | ORION PHARMA | 200MG | N020796 001 | Oct 19, 1999 | May | CAHN |

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

| | | | | | | | |
|----|--|----------|-------|-------------|--------------|-----|------|
| AT | | LUITPOLD | 0.05% | A090951 001 | Oct 31, 2011 | Mar | CAHN |
|----|--|----------|-------|-------------|--------------|-----|------|

EPINEPHRINE

INJECTABLE; IM-SC

ADRENACLICK

| | | | | | | | |
|----|---|---------------|---------------------|-------------|--------------|-----|------|
| BX | + | COREPHARMA | EQ 0.15MG /DELIVERY | N020800 003 | Nov 25, 2009 | Mar | CAHN |
| BX | + | | EQ 0.3MG /DELIVERY | N020800 004 | Nov 25, 2009 | Mar | CAHN |
| | | TWINJECT 0.15 | | | | | |
| BX | + | COREPHARMA | EQ 0.15MG /DELIVERY | N020800 002 | May 28, 2004 | Mar | CAHN |
| | | TWINJECT 0.3 | | | | | |
| BX | + | COREPHARMA | EQ 0.3MG /DELIVERY | N020800 001 | May 30, 2003 | Mar | CAHN |

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

| | | | | | | | |
|-----|----|-----------------------------------|----------------|--------------|-------------|-----|------|
| >D> | AP | SEPTODONT | 0.01MG/ML;2% | A084048 001 | | May | CRLD |
| >A> | AP | + | 0.01MG/ML;2% | A084048 001 | | May | CRLD |
| >D> | | XYLOCAINE DENTAL WITH EPINEPHRINE | | | | | |
| >D> | AP | + | DENTSPLY PHARM | 0.01MG/ML;2% | N021381 001 | May | DISC |
| >A> | | @ | 0.01MG/ML;2% | N021381 001 | | May | DISC |
| >D> | AP | + | | 0.02MG/ML;2% | N021381 002 | May | DISC |
| >A> | | @ | 0.02MG/ML;2% | N021381 002 | | May | DISC |

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

| | | | | | | | |
|----|--|----------------------|----------------------|-------------|--------------|-----|------|
| AP | | CIPLA LTD | 50MG/25ML (2MG/ML) | A065361 001 | Oct 22, 2007 | Mar | CAHN |
| AP | | | 200MG/100ML (2MG/ML) | A065361 002 | Oct 22, 2007 | Mar | CAHN |
| AP | | HISUN PHARM HANGZHOU | 50MG/25ML (2MG/ML) | A090075 001 | Mar 25, 2010 | Mar | CAHN |
| AP | | | 200MG/100ML (2MG/ML) | A090075 002 | Mar 25, 2010 | Mar | CAHN |
| AP | | ONCO THERAPIES LTD | 50MG/25ML (2MG/ML) | A091599 001 | Mar 12, 2012 | Mar | NEWA |
| AP | | | 200MG/100ML (2MG/ML) | A091599 002 | Mar 12, 2012 | Mar | NEWA |

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

| | | | | | | | |
|-----|---|---------------------|--------------------|-------------|--------------|-----|------|
| >D> | + | ACTELION | EQ 1.5MG BASE/VIAL | N022260 001 | Jun 27, 2008 | May | CAHN |
| >A> | + | ACTELION PHARMS LTD | EQ 1.5MG BASE/VIAL | N022260 001 | Jun 27, 2008 | May | CAHN |

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

| | | | | | | | |
|----|--|----------------|----|-------------|--------------|-----|------|
| AT | | FOUGERA PHARMS | 2% | A064184 001 | Sep 30, 1997 | Jan | CAHN |
|----|--|----------------|----|-------------|--------------|-----|------|

SOLUTION; TOPICAL

C-SOLVE-2

| | | | | | | | |
|----|--|----------------|----|-------------|--------------|-----|------|
| AT | | FOUGERA PHARMS | 2% | A062468 001 | Jul 03, 1985 | Jan | CMFD |
|----|--|----------------|----|-------------|--------------|-----|------|

SWAB; TOPICAL

| | | | | | | | | | |
|----|-----------------------|----|--|---------|-----|--------------|-----|------|--|
| | ERYCETE | | | | | | | | |
| | @ JOHNSON AND JOHNSON | 2% | | N050594 | 001 | Feb 15, 1985 | Apr | CAHN | |
| | ERYTHROMYCIN | | | | | | | | |
| AT | + FOUGERA PHARMS | 2% | | A065320 | 001 | Jul 25, 2006 | Jan | CAHN | |

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

| | | | | | | | | | |
|-----|------------------------|-----------------|--|---------|-----|--------------|-----|------|--|
| AA | AMNEAL PHARMS | EQ 5MG BASE/5ML | | A202227 | 001 | Mar 14, 2012 | Feb | NEWA | |
| AA | AUROBINDO PHARMA LTD | EQ 5MG BASE/5ML | | A079062 | 001 | Apr 02, 2012 | Mar | NEWA | |
| >A> | AA HETERO LABS LTD III | EQ 5MG BASE/5ML | | A202221 | 001 | Jun 12, 2012 | May | NEWA | |
| AA | TARO | EQ 5MG BASE/5ML | | A079121 | 001 | May 03, 2012 | Apr | NEWA | |
| | LEXAPRO | | | | | | | | |
| AA | + FOREST LABS | EQ 5MG BASE/5ML | | N021365 | 001 | Nov 27, 2002 | Feb | CFTG | |

TABLET; ORAL

ESCITALOPRAM OXALATE

| | | | | | | | | | |
|----|----------------------|--------------|--|---------|-----|--------------|-----|------|--|
| AB | IVAX SUB TEVA PHARMS | EQ 5MG BASE | | A076765 | 001 | Mar 14, 2012 | Feb | NEWA | |
| AB | | EQ 10MG BASE | | A076765 | 002 | Mar 14, 2012 | Feb | NEWA | |
| AB | | EQ 20MG BASE | | A076765 | 003 | Mar 14, 2012 | Feb | NEWA | |
| | LEXAPRO | | | | | | | | |
| AB | FOREST LABS | EQ 5MG BASE | | N021323 | 001 | Aug 14, 2002 | Feb | CFTG | |
| AB | | EQ 10MG BASE | | N021323 | 002 | Aug 14, 2002 | Feb | CFTG | |
| AB | + | EQ 20MG BASE | | N021323 | 003 | Aug 14, 2002 | Feb | CFTG | |

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

| | | | | | | | | | |
|-----|----------------|---------------------|--|---------|-----|--------------|-----|------|--|
| >D> | GALEN LTD | EQ 0.05MG BASE/24HR | | N021367 | 001 | Mar 20, 2003 | May | CAHN | |
| >D> | + | EQ 0.1MG BASE/24HR | | N021367 | 002 | Mar 20, 2003 | May | CAHN | |
| >A> | WARNER IRELAND | EQ 0.05MG BASE/24HR | | N021367 | 001 | Mar 20, 2003 | May | CAHN | |
| >A> | + | EQ 0.1MG BASE/24HR | | N021367 | 002 | Mar 20, 2003 | May | CAHN | |

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

| | | | | | | | | | |
|----|-----------------|-------------|--|---------|-----|--------------|-----|------|--|
| AB | TEVA PHARMS USA | 0.5MG;0.1MG | | A200747 | 001 | Mar 08, 2012 | Feb | NEWA | |
|----|-----------------|-------------|--|---------|-----|--------------|-----|------|--|

ETHINYL ESTRADIOL; LEVONORGESTREL

| | | | | | | | | | |
|-----|--------------------------------------|---|--|---------|-----|--------------|-----|------|--|
| >D> | TABLET; ORAL | | | | | | | | |
| >D> | LEVONORGESTREL AND ETHINYL ESTRADIOL | | | | | | | | |
| >D> | AB VINTAGE PHARMS | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | | A077502 | 001 | Nov 23, 2011 | May | CDFR | |
| >D> | AB WATSON LABS | 0.02MG;0.09MG | | A079218 | 001 | Jun 06, 2011 | May | CRLD | |
| >A> | + | 0.02MG;0.09MG | | A079218 | 001 | Jun 06, 2011 | May | CRLD | |
| >D> | LYBREL | | | | | | | | |
| >D> | AB + WYETH PHARMS INC | 0.02MG;0.09MG | | N021864 | 001 | May 22, 2007 | May | DISC | |
| >A> | @ | 0.02MG;0.09MG | | N021864 | 001 | May 22, 2007 | May | DISC | |
| | TABLET; ORAL-28 | | | | | | | | |
| | FALMINA | | | | | | | | |
| AB1 | NOVAST LABS LTD | 0.02MG;0.1MG | | A090721 | 001 | Mar 28, 2012 | Mar | NEWA | |
| | MARLISSA | | | | | | | | |
| AB | GLENMARK GENERICS | 0.03MG;0.15MG | | A091452 | 001 | Feb 29, 2012 | Feb | NEWA | |
| >A> | MYZILRA | | | | | | | | |
| >A> | AB VINTAGE PHARMS | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | | A077502 | 001 | Nov 23, 2011 | May | CDFR | |

ETHINYL ESTRADIOL; NORETHINDRONE

| | | | | | | | |
|----|-------------------|--|---------|-----|--------------|-----|------|
| | TABLET; ORAL-28 | | | | | | |
| | ALYACEN 1/35 | | | | | | |
| AB | GLENMARK GENERICS | 0.035MG;1MG | A091634 | 001 | Jan 19, 2012 | Jan | NEWA |
| | ALYACEN 7/7/7 | | | | | | |
| AB | GLENMARK GENERICS | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | A091636 | 001 | Jan 19, 2012 | Jan | NEWA |
| | WERA | | | | | | |
| AB | NOVAST LABS LTD | 0.035MG;0.5MG | A091204 | 001 | Mar 27, 2012 | Mar | NEWA |

ETHINYL ESTRADIOL; NORGESTIMATE

| | | | | | | | |
|-----|-----------------|------------------------------------|---|---------|-----|--------------|-----|
| | TABLET; ORAL-28 | | | | | | |
| | MONO-LINYAH | | | | | | |
| >A> | | | | | | | |
| >A> | AB | NOVAST LABS LTD | 0.035MG;0.25MG | A090523 | 001 | May 23, 2012 | May |
| | | NORGESTIMATE AND ETHINYL ESTRADIOL | | | | | |
| | AB | GLENMARK GENERICS | 0.035MG;0.25MG | A200538 | 001 | Apr 05, 2012 | Mar |
| | | NEWA | | | | | |
| >A> | | TRI-LINYAH | | | | | |
| >A> | AB | NOVAST LABS LTD | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | A090524 | 001 | May 30, 2012 | May |
| | | NEWA | | | | | |

ETHINYL ESTRADIOL; NORGESTREL

| | | | | | | | |
|----|-----------------|--------------|---------|-----|--------------|-----|------|
| | TABLET; ORAL-28 | | | | | | |
| | ELINEST | | | | | | |
| AB | NOVAST LABS LTD | 0.03MG;0.3MG | A091105 | 001 | Mar 28, 2012 | Mar | NEWA |

ETODOLAC

| | | | | | | | |
|----|--------------|-------|---------|-----|--------------|-----|------|
| | TABLET; ORAL | | | | | | |
| | ETODOLAC | | | | | | |
| AB | PROSAM LABS | 400MG | A074819 | 001 | Feb 28, 1997 | Feb | CMFD |
| AB | | 500MG | A074819 | 002 | Apr 28, 1998 | Feb | CMFD |

ETOPOSIDE

| | | | | | | | |
|----|-----------------------|----------------|---------|---------|-----|--------------|-----|
| | CAPSULE; ORAL | | | | | | |
| | VEPESID | | | | | | |
| | @ | CORDEN PHARMA | 50MG | N019557 | 001 | Dec 30, 1986 | Feb |
| | @ | | 100MG | N019557 | 002 | Dec 30, 1986 | Feb |
| | | CAHN | | | | | |
| | INJECTABLE; INJECTION | | | | | | |
| | ETOPOSIDE | | | | | | |
| AP | + | APP PHARMS LLC | 20MG/ML | A074983 | 001 | Sep 30, 1998 | Mar |
| AP | | BEDFORD | 20MG/ML | A074290 | 001 | Jul 17, 1995 | Mar |
| | | CRLD | | | | | |
| | VEPESID | | | | | | |
| | @ | CORDEN PHARMA | 20MG/ML | N018768 | 001 | Nov 10, 1983 | Feb |
| | | CAHN | | | | | |

ETRAVIRINE

| | | | | | | | |
|--|--------------|-----------------|-------|---------|-----|--------------|-----|
| | TABLET; ORAL | | | | | | |
| | INTELENCE | | | | | | |
| | | JANSSEN R AND D | 25MG | N022187 | 003 | Mar 26, 2012 | Mar |
| | | | 100MG | N022187 | 001 | Jan 18, 2008 | Feb |
| | + | | 200MG | N022187 | 002 | Dec 22, 2010 | Feb |
| | | CAHN | | | | | |

EVEROLIMUS

| | | | | | | | |
|--|--------------|----------|-------|---------|-----|--------------|-----|
| | TABLET; ORAL | | | | | | |
| | AFINITOR | | | | | | |
| | | NOVARTIS | 7.5MG | N022334 | 004 | Mar 30, 2012 | Apr |
| | | NEWA | | | | | |

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

| | | | | | | |
|---|--------|----------|-------------|--------------|-----|------|
| + | AMYLIN | 2MG/VIAL | N022200 001 | Jan 27, 2012 | Jan | NEWA |
|---|--------|----------|-------------|--------------|-----|------|

EZETIMIBE

TABLET; ORAL

ZETIA

| | | | | | | |
|---|---------------|------|-------------|--------------|-----|------|
| + | MSD INTL GMBH | 10MG | N021445 001 | Oct 25, 2002 | Feb | CAHN |
|---|---------------|------|-------------|--------------|-----|------|

| | | | | | | |
|---|---------------|------|-------------|--------------|-----|------|
| + | MSP SINGAPORE | 10MG | N021445 001 | Oct 25, 2002 | Jan | CAHN |
|---|---------------|------|-------------|--------------|-----|------|

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

| | | | | | | |
|--|----------|-----------|-------------|--------------|-----|------|
| | MSD INTL | 10MG;10MG | N021687 001 | Jul 23, 2004 | Jan | CAHN |
|--|----------|-----------|-------------|--------------|-----|------|

| | | | | | | |
|--|--|-----------|-------------|--------------|-----|------|
| | | 10MG;20MG | N021687 002 | Jul 23, 2004 | Jan | CAHN |
|--|--|-----------|-------------|--------------|-----|------|

| | | | | | | |
|--|--|-----------|-------------|--------------|-----|------|
| | | 10MG;40MG | N021687 003 | Jul 23, 2004 | Jan | CAHN |
|--|--|-----------|-------------|--------------|-----|------|

| | | | | | | |
|---|--|-----------|-------------|--------------|-----|------|
| + | | 10MG;80MG | N021687 004 | Jul 23, 2004 | Jan | CAHN |
|---|--|-----------|-------------|--------------|-----|------|

EZOGABINE

TABLET; ORAL

POTIGA

| | | | | | | |
|-----|-----------------|------|-------------|--------------|-----|------|
| >A> | GLAXOSMITHKLINE | 50MG | N022345 001 | Jun 10, 2011 | May | CAHN |
|-----|-----------------|------|-------------|--------------|-----|------|

| | | | | | | |
|-----|--|-------|-------------|--------------|-----|------|
| >A> | | 200MG | N022345 002 | Jun 10, 2011 | May | CAHN |
|-----|--|-------|-------------|--------------|-----|------|

| | | | | | | |
|-----|--|-------|-------------|--------------|-----|------|
| >A> | | 300MG | N022345 003 | Jun 10, 2011 | May | CAHN |
|-----|--|-------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|--|-------|-------------|--------------|-----|------|
| >A> | + | | 400MG | N022345 004 | Jun 10, 2011 | May | CAHN |
|-----|---|--|-------|-------------|--------------|-----|------|

| | | | | | | |
|-----|----------------|------|-------------|--------------|-----|------|
| >D> | VALEANT PHARMS | 50MG | N022345 001 | Jun 10, 2011 | May | CAHN |
|-----|----------------|------|-------------|--------------|-----|------|

| | | | | | | |
|-----|--|-------|-------------|--------------|-----|------|
| >D> | | 200MG | N022345 002 | Jun 10, 2011 | May | CAHN |
|-----|--|-------|-------------|--------------|-----|------|

| | | | | | | |
|-----|--|-------|-------------|--------------|-----|------|
| >D> | | 300MG | N022345 003 | Jun 10, 2011 | May | CAHN |
|-----|--|-------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|--|-------|-------------|--------------|-----|------|
| >D> | + | | 400MG | N022345 004 | Jun 10, 2011 | May | CAHN |
|-----|---|--|-------|-------------|--------------|-----|------|

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AB | MACLEODS PHARMS LTD | 125MG | A201022 001 | Jan 12, 2012 | Jan | NEWA |
|----|---------------------|-------|-------------|--------------|-----|------|

| | | | | | | |
|----|--|-------|-------------|--------------|-----|------|
| AB | | 250MG | A201022 002 | Jan 12, 2012 | Jan | NEWA |
|----|--|-------|-------------|--------------|-----|------|

| | | | | | | |
|----|--|-------|-------------|--------------|-----|------|
| AB | | 500MG | A201022 003 | Jan 12, 2012 | Jan | NEWA |
|----|--|-------|-------------|--------------|-----|------|

FAMOTIDINE

TABLET; ORAL

PEPCID

| | | | | | | |
|----|-----------------|------|-------------|--------------|-----|------|
| AB | MARATHON PHARMS | 20MG | N019462 001 | Oct 15, 1986 | Jan | CAHN |
|----|-----------------|------|-------------|--------------|-----|------|

| | | | | | | | |
|----|---|--|------|-------------|--------------|-----|------|
| AB | + | | 40MG | N019462 002 | Oct 15, 1986 | Jan | CAHN |
|----|---|--|------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

@ UCB INC

@

| | | | | | | |
|--|--|------|-------------|--------------|-----|------|
| | | 20MG | N021712 001 | Sep 24, 2004 | Jan | CAHN |
|--|--|------|-------------|--------------|-----|------|

| | | | | | | |
|--|--|------|-------------|--------------|-----|------|
| | | 40MG | N021712 002 | Sep 24, 2004 | Jan | CAHN |
|--|--|------|-------------|--------------|-----|------|

FEBUXOSTAT

TABLET; ORAL

ULORIC

| | | | | | | |
|--|-------------------|------|-------------|--------------|-----|------|
| | TAKEDA PHARMS USA | 40MG | N021856 001 | Feb 13, 2009 | Apr | CAHN |
|--|-------------------|------|-------------|--------------|-----|------|

| | | | | | | |
|---|--|------|-------------|--------------|-----|------|
| + | | 80MG | N021856 002 | Feb 13, 2009 | Apr | CAHN |
|---|--|------|-------------|--------------|-----|------|

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

| | | | | | | |
|----|----------------|-------|-------------|--------------|-----|------|
| AB | LUPIN ATLANTIS | 43MG | N021695 001 | Nov 30, 2004 | Feb | CFTG |
| AB | + | 130MG | N021695 003 | Nov 30, 2004 | Feb | CFTG |

FENOFIBRATE (MICRONIZED)

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| AB | DR REDDYS LABS SA | 43MG | A090859 001 | Mar 01, 2012 | Feb | NEWA |
| AB | | 130MG | A090859 002 | Mar 01, 2012 | Feb | NEWA |

TABLET; ORAL

FENOFIBRATE

| | | | | | | | | |
|-----|--------------|---|------------|-------|-------------|--------------|-----|------|
| >D> | AB | + | IMPAX LABS | 160MG | A076509 002 | Mar 26, 2008 | May | CRLD |
| >A> | AB | | | 160MG | A076509 002 | Mar 26, 2008 | May | CRLD |
| | AB | + | | 160MG | A076509 002 | Mar 26, 2008 | Mar | CRLD |
| >D> | | | @ TEVA | 54MG | A076433 001 | May 13, 2005 | May | CMFD |
| >A> | AB | | | 54MG | A076433 001 | May 13, 2005 | May | CMFD |
| | | | @ | 54MG | A076433 001 | May 13, 2005 | Mar | DISC |
| >D> | | | @ | 160MG | A076433 002 | May 13, 2005 | May | CMFD |
| >A> | AB | + | | 160MG | A076433 002 | May 13, 2005 | May | CMFD |
| | | | @ | 160MG | A076433 002 | May 13, 2005 | Mar | DISC |
| AB | VALEANT INTL | | | 48MG | A090715 001 | Apr 05, 2012 | Mar | NEWA |
| AB | | | | 145MG | A090715 002 | Apr 05, 2012 | Mar | NEWA |

FENTANYL

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

| | | | | | | | | |
|--|---|--|--|--------|-------------|--------------|-----|------|
| | | | | 0.1MG | N202788 001 | Jan 04, 2012 | Mar | CPOT |
| | | | | 0.1MCG | N202788 001 | Jan 04, 2012 | Jan | NEWA |
| | | | | 0.2MG | N202788 002 | Jan 04, 2012 | Mar | CPOT |
| | | | | 0.2MCG | N202788 002 | Jan 04, 2012 | Jan | NEWA |
| | + | | | 0.4MG | N202788 003 | Jan 04, 2012 | Mar | CPOT |
| | + | | | 0.4MCG | N202788 003 | Jan 04, 2012 | Jan | NEWA |
| | | | | 0.6MG | N202788 004 | Jan 04, 2012 | Mar | CPOT |
| | | | | 0.6MCG | N202788 004 | Jan 04, 2012 | Jan | NEWA |
| | | | | 0.8MG | N202788 005 | Jan 04, 2012 | Mar | CPOT |
| | | | | 0.8MCG | N202788 005 | Jan 04, 2012 | Jan | NEWA |

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

| | | | | | | | | |
|--|---|--|--|---------------|-------------|--------------|-----|------|
| | | | | EQ 0.1MG BASE | N022569 001 | Jun 30, 2011 | Jan | CPOT |
| | + | | | EQ 0.4MG BASE | N022569 002 | Jun 30, 2011 | Jan | CPOT |

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

| | | | | | | | | |
|----|-----------|--|--|---------------|-------------|--------------|-----|------|
| AB | PAR PHARM | | | EQ 0.2MG BASE | A077312 001 | Oct 30, 2009 | Feb | CAHN |
| AB | | | | EQ 0.4MG BASE | A077312 002 | Oct 30, 2009 | Feb | CAHN |
| AB | | | | EQ 0.6MG BASE | A077312 003 | Oct 30, 2009 | Feb | CAHN |
| AB | | | | EQ 0.8MG BASE | A077312 004 | Oct 30, 2009 | Feb | CAHN |
| AB | | | | EQ 1.2MG BASE | A077312 005 | Oct 30, 2009 | Feb | CAHN |
| AB | | | | EQ 1.6MG BASE | A077312 006 | Oct 30, 2009 | Feb | CAHN |

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

| | | | | | | |
|---|----------------------|-------------------------|-------------|--------------|-----|------|
| + | AVID RADIOPHARMS INC | 10-50ML (13.5-51CMI/ML) | N202008 003 | Apr 06, 2012 | Apr | NEWA |
| + | | 10-30ML (13.5-51MCI/ML) | N202008 002 | Apr 06, 2012 | Apr | NEWA |

SOLUTION; INTRAVENOUS

AMYVID

| | | | | | | | |
|--|---|----------------------|----------------------|-------------|--------------|-----|------|
| | + | AVID RADIOPHARMS INC | 10ML (13.5-51MCI/ML) | N202008 001 | Apr 06, 2012 | Apr | NEWA |
|--|---|----------------------|----------------------|-------------|--------------|-----|------|

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | |
|----|--|--------------------|----------------------|-------------|--------------|-----|------|
| AP | | HIKMA FARMACEUTICA | 200MG/100ML (2MG/ML) | A078764 001 | Jan 30, 2012 | Jan | NEWA |
| AP | | | 400MG/200ML (2MG/ML) | A078764 002 | Jan 30, 2012 | Jan | NEWA |

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | | | | | |
|----|--|--------------------|----------------------|-------------|--------------|-----|------|
| AP | | HIKMA FARMACEUTICA | 200MG/100ML (2MG/ML) | A078698 001 | Jan 30, 2012 | Jan | NEWA |
| AP | | | 400MG/200ML (2MG/ML) | A078698 002 | Jan 30, 2012 | Jan | NEWA |

TABLET; ORAL

FLUCONAZOLE

| | | | | | | | |
|--|---|------------------|-------|-------------|--------------|-----|------|
| | @ | PLIVA | 50MG | A076424 001 | Jul 29, 2004 | Feb | DISC |
| | @ | | 100MG | A076424 002 | Jul 29, 2004 | Feb | DISC |
| | @ | | 150MG | A076424 003 | Jul 29, 2004 | Feb | DISC |
| | @ | | 200MG | A076424 004 | Jul 29, 2004 | Feb | DISC |
| | @ | RANBAXY LABS LTD | 50MG | A076386 001 | Jul 29, 2004 | Apr | DISC |
| | @ | | 100MG | A076386 002 | Jul 29, 2004 | Apr | DISC |
| | @ | | 150MG | A076386 003 | Jul 29, 2004 | Apr | DISC |
| | @ | | 200MG | A076386 004 | Jul 29, 2004 | Apr | DISC |

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

| | | | | | | | |
|--|---|--------------|-----------|-------------|--------------|-----|------|
| | @ | GENZYME CORP | 50MG/VIAL | N020038 001 | Apr 18, 1991 | Mar | DISC |
|--|---|--------------|-----------|-------------|--------------|-----|------|

FLUDARABINE PHOSPHATE

| | | | | | | | |
|----|---|---------|-----------|-------------|--------------|-----|------|
| AP | + | HOSPIRA | 50MG/VIAL | A077790 001 | Apr 06, 2007 | Mar | CRLD |
|----|---|---------|-----------|-------------|--------------|-----|------|

TABLET; ORAL

OFORTA

| | | | | | | | |
|-----|---|-------------------|------|-------------|--------------|-----|------|
| >D> | | | | | | | |
| >D> | + | SANOFI AVENTIS US | 10MG | N022273 001 | Dec 18, 2008 | May | DISC |
| >A> | @ | | 10MG | N022273 001 | Dec 18, 2008 | May | DISC |

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

| | | | | | | | |
|--|---|-----------------|----------------------|-------------|--------------|-----|------|
| | @ | TEVA PARENTERAL | 0.5MG/5ML (0.1MG/ML) | A076589 002 | Oct 12, 2004 | Jan | DISC |
| | @ | | 1MG/10ML (0.1MG/ML) | A076589 001 | Oct 12, 2004 | Jan | DISC |

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

| | | | | | | | |
|----|--|-------------------|-------|-------------|--------------|-----|------|
| AT | | IDENTI PHARMS INC | 0.01% | A091306 001 | Oct 17, 2011 | Jan | CPOT |
|----|--|-------------------|-------|-------------|--------------|-----|------|

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

| | | | | | | | |
|-----|---|----------------------|-------|-------------|--------------|-----|------|
| >D> | @ | ACTAVIS MID ATLANTIC | 0.05% | A074204 001 | Jun 13, 1995 | May | CAHN |
| AB2 | | FOUGERA PHARMS | 0.05% | A076586 001 | Jun 23, 2004 | Jan | CAHN |
| >A> | @ | G AND W LABS INC | 0.05% | A074204 001 | Jun 13, 1995 | May | CAHN |

OINTMENT; TOPICAL

FLUOCINONIDE

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.05% | A074905 001 | Aug 26, 1997 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

FLUOROURACIL

CREAM; TOPICAL

FLUOROPLEX

| | | | | | | |
|---|-------------|----|-------------|--|-----|------|
| + | AQUA PHARMS | 1% | N016988 001 | | Jan | CAHN |
|---|-------------|----|-------------|--|-----|------|

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

| | | | | | | |
|-----|------------------|--------------|-------------|--------------|-----|------|
| AB1 | ELI LILLY AND CO | EQ 10MG BASE | N018936 006 | Dec 23, 1992 | Apr | CAHN |
| AB1 | | EQ 20MG BASE | N018936 001 | Dec 29, 1987 | Apr | CAHN |
| AB | + | EQ 40MG BASE | N018936 003 | Jun 15, 1999 | Apr | CAHN |
| | @ | EQ 60MG BASE | N018936 004 | Jun 15, 1999 | Apr | CAHN |
| | SARAFEM | | | | | |
| AB2 | ELI LILLY AND CO | EQ 10MG BASE | N018936 007 | Jul 06, 2000 | Apr | CAHN |
| AB2 | + | EQ 20MG BASE | N018936 008 | Jul 06, 2000 | Apr | CAHN |

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

| | | | | | | |
|--|---------------|-------|-------------|--|-----|------|
| | WATSON PHARMS | 0.05% | N012806 002 | | Apr | CMFD |
|--|---------------|-------|-------------|--|-----|------|

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

| | | | | | | | |
|----|---|----------------------|-------|-------------|--------------|-----|------|
| AB | + | IVAX SUB TEVA PHARMS | 125MG | A075780 001 | Sep 19, 2001 | Mar | CRLD |
| AB | | SANDOZ INC | 125MG | A075818 001 | Sep 18, 2001 | Mar | CRLD |

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

| | | | | | | | |
|----|---|------------------------|-------|-------------|--------------|-----|------|
| AB | + | FOUGERA PHARMS | 0.05% | N019958 001 | Dec 18, 1990 | Jan | CAHN |
| | | FLUTICASONE PROPIONATE | | | | | |
| AB | | FOUGERA PHARMS | 0.05% | A076451 001 | May 14, 2004 | Jan | CAHN |

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

| | | | | | | | |
|----|--|----------------|--------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.005% | A076300 001 | May 14, 2004 | Jan | CAHN |
|----|--|----------------|--------|-------------|--------------|-----|------|

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

| | | | | | | | |
|-----|----|------------------|--------------|-------------|--------------|-----|------|
| AB | | MYLAN PHARMS INC | EQ 20MG BASE | A090595 001 | Apr 11, 2012 | Mar | NEWA |
| AB | | | EQ 40MG BASE | A090595 002 | Apr 11, 2012 | Mar | NEWA |
| >A> | AB | TEVA PHARMS | EQ 20MG BASE | A078407 001 | Jun 12, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A078407 002 | Jun 12, 2012 | May | NEWA |
| | | LESCOL | | | | | |
| AB | | NOVARTIS | EQ 20MG BASE | N020261 001 | Dec 31, 1993 | Mar | CFTG |
| AB | + | | EQ 40MG BASE | N020261 002 | Dec 31, 1993 | Mar | CFTG |

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

| | | | | | | | |
|--|---|------------------|------|-------------|--------------|-----|------|
| | @ | RANBAXY LABS LTD | 10MG | A076580 001 | Apr 23, 2004 | Apr | DISC |
| | @ | | 20MG | A076580 002 | Apr 23, 2004 | Apr | DISC |
| | @ | | 40MG | A076580 003 | Apr 23, 2004 | Apr | DISC |

TABLET; ORAL

MONOPRIL

| | | | | | | |
|---|----------------------|------|-------------|--------------|-----|------|
| @ | BRISTOL MYERS SQUIBB | 10MG | N019915 002 | May 16, 1991 | Mar | DISC |
| @ | | 20MG | N019915 003 | May 16, 1991 | Mar | DISC |
| @ | | 40MG | N019915 004 | Mar 28, 1995 | Mar | DISC |

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

| | | | | | | |
|---|-----------------|-------------------------|-------------|--------------|-----|------|
| @ | TEVA PARENTERAL | EQ 50MG PHENYTOIN NA/ML | A076886 001 | Aug 06, 2007 | Mar | DISC |
|---|-----------------|-------------------------|-------------|--------------|-----|------|

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

| | | | | | | |
|----|---------------|-----------|-------------|--------------|-----|------|
| AA | AMNEAL PHARMS | 250MG/5ML | A202024 001 | Mar 23, 2012 | Mar | NEWA |
| AA | KIEL | 250MG/5ML | A076403 001 | May 01, 2012 | Apr | NEWA |

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

| | | | | | | |
|---|------------------|-------|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | 250MG | A076457 001 | Jun 27, 2003 | Apr | DISC |
| @ | | 500MG | A076457 002 | Jun 27, 2003 | Apr | DISC |

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

| | | | | | | |
|---|-------------|------------------------|-------------|--------------|-----|------|
| + | HOSPIRA INC | 200MG/5.26ML (38MG/ML) | N200795 001 | Aug 04, 2011 | Apr | CTNA |
| + | | 1GM/26.3ML (38MG/ML) | N200795 002 | Aug 04, 2011 | Apr | CTNA |
| + | | 2GM/52.6ML (38MG/ML) | N200795 003 | Aug 04, 2011 | Apr | CTNA |

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

| | | | | | | |
|---|------------------|-----|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | 1MG | A076875 001 | Oct 06, 2005 | Apr | DISC |
| @ | | 2MG | A076875 002 | Oct 06, 2005 | Apr | DISC |
| @ | | 4MG | A076875 003 | Oct 06, 2005 | Apr | DISC |
| @ | | 8MG | A076875 004 | Oct 06, 2005 | Apr | DISC |

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

| | | | | | | |
|----|---------------|-------|-------------|--------------|-----|------|
| AA | NEXGEN PHARMA | 1.5MG | A091522 001 | Mar 12, 2012 | Feb | NEWA |
|----|---------------|-------|-------------|--------------|-----|------|

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

| | | | | | | |
|----|-------------------|---|-------------|--------------|-----|------|
| AP | CIPLA LTD | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A078262 001 | Dec 31, 2007 | Mar | CAHN |
| AP | | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A078258 001 | Jun 30, 2008 | Mar | CAHN |
| AP | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A078258 002 | Jun 30, 2008 | Mar | CAHN |
| | | GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| AP | + APP PHARMS LLC | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A078096 001 | Jun 30, 2008 | Apr | CRLD |
| | @ TEVA PARENTERAL | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A077165 001 | Dec 31, 2007 | Apr | DISC |

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

| | | | | | | | | |
|----|---|---------------------|-----------|---------|-----|--------------|-----|------|
| AB | + | VALEANT PHARM NORTH | 125MG/5ML | A062483 | 001 | Jan 26, 1984 | Feb | CAHN |
|----|---|---------------------|-----------|---------|-----|--------------|-----|------|

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

| | | | | | | | | |
|----|--|----------------|-------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.05% | A077001 | 001 | Dec 16, 2004 | Jan | CAHN |
|----|--|----------------|-------|---------|-----|--------------|-----|------|

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

| | | | | | | | | |
|----|--|----------------|-------|---------|-----|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.05% | A076903 | 001 | Dec 16, 2004 | Jan | CAHN |
|----|--|----------------|-------|---------|-----|--------------|-----|------|

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|
| | @ | BAXTER HLTHCARE | 2,000 UNITS/100ML | N018814 | 002 | Jul 09, 1985 | Mar | DISC |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|
| | @ | BAXTER HLTHCARE | 4,000 UNITS/100ML | N018814 | 001 | Oct 31, 1983 | Mar | DISC |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | | |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|
| | @ | BAXTER HLTHCARE | 5,000 UNITS/100ML | N018814 | 003 | Jul 09, 1985 | Mar | DISC |
|--|---|-----------------|-------------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|--|---|--|--------------------|---------|-----|--------------|-----|------|
| | @ | | 10,000 UNITS/100ML | N018814 | 004 | Jul 02, 1987 | Mar | DISC |
|--|---|--|--------------------|---------|-----|--------------|-----|------|

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

| | | | | | | | | |
|-----|---|---------------|------------|---------|-----|--------------|-----|------|
| >D> | + | GE HEALTHCARE | 100MG/VIAL | N022555 | 001 | May 28, 2010 | May | CAHN |
|-----|---|---------------|------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|-----|---|---------------|------------|---------|-----|--------------|-----|------|
| >A> | + | PHOTOCURE ASA | 100MG/VIAL | N022555 | 001 | May 28, 2010 | May | CAHN |
|-----|---|---------------|------------|---------|-----|--------------|-----|------|

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|----|--|----------------------|--------|---------|-----|--------------|-----|------|
| AB | | LANNETT HOLDINGS INC | 12.5MG | A091662 | 001 | Jan 27, 2012 | Jan | NEWA |
|----|--|----------------------|--------|---------|-----|--------------|-----|------|

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

| | | | | | | | | |
|----|---|----------------|--------------|---------|-----|--------------|-----|------|
| AB | + | SANOFI AVENTIS | 12.5MG;150MG | N020758 | 002 | Sep 30, 1997 | Mar | CFTG |
|----|---|----------------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|----|---|--|--------------|---------|-----|--------------|-----|------|
| AB | + | | 12.5MG;300MG | N020758 | 003 | Aug 31, 1998 | Mar | CFTG |
|----|---|--|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|--|---|--|--------------|---------|-----|--------------|-----|------|
| | + | | 12.5MG;300MG | N020758 | 003 | Aug 31, 1998 | Feb | CRLD |
|--|---|--|--------------|---------|-----|--------------|-----|------|

IRBESARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|----|--|------|--------------|---------|-----|--------------|-----|------|
| AB | | TEVA | 12.5MG;150MG | A077369 | 001 | Mar 30, 2012 | Mar | NEWA |
|----|--|------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|----|--|--|--------------|---------|-----|--------------|-----|------|
| AB | | | 12.5MG;300MG | A077369 | 002 | Mar 30, 2012 | Mar | NEWA |
|----|--|--|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|--|---|--|------------|---------|-----|--------------|-----|------|
| | @ | | 25MG;300MG | A077369 | 003 | Mar 30, 2012 | Apr | DISC |
|--|---|--|------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|--|---|--|------------|---------|-----|--------------|-----|------|
| | @ | | 25MG;300MG | A077369 | 003 | Mar 30, 2012 | Mar | NEWA |
|--|---|--|------------|---------|-----|--------------|-----|------|

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|----|--|-------------|-------------|---------|-----|--------------|-----|------|
| AB | | ALEMBIC LTD | 12.5MG;50MG | A091617 | 001 | Feb 17, 2012 | Feb | NEWA |
|----|--|-------------|-------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|----|--|--|--------------|---------|-----|--------------|-----|------|
| AB | | | 12.5MG;100MG | A091617 | 002 | Feb 17, 2012 | Feb | NEWA |
|----|--|--|--------------|---------|-----|--------------|-----|------|

| | | | | | | | | |
|----|--|--|------------|---------|-----|--------------|-----|------|
| AB | | | 25MG;100MG | A091617 | 003 | Feb 17, 2012 | Feb | NEWA |
|----|--|--|------------|---------|-----|--------------|-----|------|

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

| | | | | | | |
|---|-------------|--------------------------|-------------|--------------|-----|------|
| | ASTRAZENECA | 12.5MG;EQ 25MG TARTRATE | N021956 001 | Aug 28, 2006 | Jan | CMFD |
| | | 12.5MG;EQ 50MG TARTRATE | N021956 002 | Aug 28, 2006 | Jan | CMFD |
| + | | 12.5MG;EQ 100MG TARTRATE | N021956 003 | Aug 28, 2006 | Apr | CRLD |
| | | 12.5MG;EQ 100MG TARTRATE | N021956 003 | Aug 28, 2006 | Jan | CMFD |

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|----|----------------|------------|-------------|--------------|-----|------|
| AB | MYLAN | 50MG;100MG | A076792 003 | Aug 20, 2004 | Jan | CTEC |
| AB | SUN PHARM INDS | 25MG;50MG | A090654 001 | Jan 19, 2012 | Jan | NEWA |
| AB | | 25MG;100MG | A090654 002 | Jan 19, 2012 | Jan | NEWA |
| AB | | 50MG;100MG | A090654 003 | Jan 19, 2012 | Jan | NEWA |

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|--|---------------|--------------|-------------|--------------|-----|------|
| | @ PADDOCK LLC | 12.5MG;7.5MG | A090096 001 | Sep 25, 2008 | Jan | DISC |
| | @ | 12.5MG;15MG | A090096 002 | Sep 25, 2008 | Jan | DISC |
| | @ | 25MG;15MG | A090096 003 | Sep 25, 2008 | Jan | DISC |

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

| | | | | | | |
|----|------------------|------|-------------|--------------|-----|------|
| AT | + FOUGERA PHARMS | 2.5% | A040351 001 | Jul 25, 2000 | Jan | CAHN |
|----|------------------|------|-------------|--------------|-----|------|

OINTMENT; TOPICAL

HYDROCORTISONE

| | | | | | | |
|----|------------------|----|-------------|--|-----|------|
| AT | + FOUGERA PHARMS | 1% | A080692 001 | | Jan | CAHN |
|----|------------------|----|-------------|--|-----|------|

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

| | | | | | | |
|----|----------------|--------|-------------|--|-----|------|
| AT | FOUGERA PHARMS | 1%;10% | A080505 001 | | Jan | CAHN |
|----|----------------|--------|-------------|--|-----|------|

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL

LOCOID

| | | | | | | |
|-----|--------------------|------|-------------|--------------|-----|------|
| >A> | + PRECISION DERMAT | 0.1% | N022076 001 | May 18, 2007 | May | CAHN |
|-----|--------------------|------|-------------|--------------|-----|------|

| | | | | | | |
|-----|--------------------|------|-------------|--------------|-----|------|
| >D> | + TRIAX PHARMS LLC | 0.1% | N022076 001 | May 18, 2007 | May | CAHN |
|-----|--------------------|------|-------------|--------------|-----|------|

OINTMENT; TOPICAL

LOCOID

| | | | | | | |
|-----|-----------------------|------|-------------|--------------|-----|------|
| >A> | AB + PRECISION DERMAT | 0.1% | N018652 001 | Oct 29, 1982 | May | CAHN |
|-----|-----------------------|------|-------------|--------------|-----|------|

| | | | | | | |
|-----|-----------------------|------|-------------|--------------|-----|------|
| >D> | AB + TRIAX PHARMS LLC | 0.1% | N018652 001 | Oct 29, 1982 | May | CAHN |
|-----|-----------------------|------|-------------|--------------|-----|------|

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | |
|----|--------|------|-------------|--------------|-----|------|
| AB | + TARO | 0.2% | A075042 001 | Aug 25, 1998 | Mar | CRLD |
|----|--------|------|-------------|--------------|-----|------|

WESTCORT

| | | | | | | |
|--|-----------|------|-------------|--|-----|------|
| | @ RANBAXY | 0.2% | N017950 001 | | Mar | DISC |
|--|-----------|------|-------------|--|-----|------|

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.2% | A075085 001 | Jul 31, 2001 | Jan | CAHN |
|----|----------------|------|-------------|--------------|-----|------|

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

| | | | | | | | |
|----|---|-----------|------|-------------|--|-----|------|
| AB | + | SHIRE LLC | 50MG | N011949 001 | | Jan | CAHN |
|----|---|-----------|------|-------------|--|-----|------|

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC 10MG/5ML

| | | | |
|-------------|--|-----|------|
| A086880 001 | | Feb | CAHN |
|-------------|--|-----|------|

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

| | | | | | | | |
|----|---|-------------------|---------------|-------------|--------------|-----|------|
| AB | + | HOFFMANN LA ROCHE | EQ 150MG BASE | N021455 002 | Mar 24, 2005 | Mar | CFTG |
|----|---|-------------------|---------------|-------------|--------------|-----|------|

IBANDRONATE SODIUM

| | | | | | | | |
|----|--|--------------------|---------------|-------------|--------------|-----|------|
| AB | | APOTEX INC | EQ 150MG BASE | A078948 001 | Mar 19, 2012 | Mar | NEWA |
| AB | | DR REDDYS LABS LTD | EQ 150MG BASE | A078997 001 | Apr 30, 2012 | Apr | NEWA |
| AB | | MYLAN PHARMS INC | EQ 150MG BASE | A078995 001 | Mar 19, 2012 | Mar | NEWA |
| AB | | ORCHID HLTHCARE | EQ 150MG BASE | A078998 001 | Mar 19, 2012 | Mar | NEWA |
| AB | | WATSON LABS INC | EQ 150MG BASE | A079003 001 | Mar 20, 2012 | Mar | NEWA |

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK LLC EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

| | | | |
|-------------|--------------|-----|------|
| N021903 001 | Apr 13, 2006 | Mar | CAHN |
|-------------|--------------|-----|------|

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@ TEVA PARENTERAL 5MG/VIAL

| | | | |
|-------------|--------------|-----|------|
| A065037 003 | May 01, 2002 | Mar | DISC |
|-------------|--------------|-----|------|

@ 10MG/VIAL

| | | | |
|-------------|--------------|-----|------|
| A065037 002 | May 01, 2002 | Mar | DISC |
|-------------|--------------|-----|------|

@ 20MG/VIAL

| | | | |
|-------------|--------------|-----|------|
| A065037 001 | May 01, 2002 | Mar | DISC |
|-------------|--------------|-----|------|

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

| | | | | | | | |
|----|--|-------------|------|-------------|--------------|-----|------|
| AB | | PROSAM LABS | 10MG | A040753 001 | Feb 28, 2008 | Feb | CMFD |
| AB | | | 25MG | A040752 001 | Feb 28, 2008 | Feb | CMFD |
| AB | | | 50MG | A040751 001 | Feb 28, 2008 | Feb | CMFD |

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

| | | | | | | | |
|----|--|-------------------|----|-------------|--------------|-----|------|
| AB | | APOTEX INC | 5% | A091308 001 | Apr 06, 2012 | Mar | NEWA |
| AB | | FOUGERA PHARMS | 5% | A078548 001 | Feb 25, 2010 | Jan | CAHN |
| AB | | GLENMARK GENERICS | 5% | A201994 001 | Mar 06, 2012 | Feb | NEWA |

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

| | | | | | | | |
|----|---|--------------|------------------|-------------|--------------|-----|------|
| AP | + | LUNDBECK LLC | EQ 1MG BASE/VIAL | N018878 001 | Jan 30, 1985 | Mar | CAHN |
|----|---|--------------|------------------|-------------|--------------|-----|------|

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

| | | | | | | |
|---|---------------|--------|-------------|--------------|-----|------|
| | LEO PHARMA AS | 0.015% | N202833 001 | Jan 23, 2012 | Jan | NEWA |
| + | | 0.05% | N202833 002 | Jan 23, 2012 | Jan | NEWA |

IRBESARTAN

TABLET; ORAL

AVAPRO

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| AB | SANOFI AVENTIS US | 75MG | N020757 001 | Sep 30, 1997 | Mar | CFTG |
| AB | | 150MG | N020757 002 | Sep 30, 1997 | Mar | CFTG |
| AB | + | 300MG | N020757 003 | Sep 30, 1997 | Mar | CFTG |

IRBESARTAN

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | TEVA PHARMS | 75MG | A077159 001 | Mar 30, 2012 | Mar | NEWA |
| AB | | 150MG | A077159 002 | Mar 30, 2012 | Mar | NEWA |
| AB | | 300MG | A077159 003 | Mar 30, 2012 | Mar | NEWA |

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

| | | | | | | |
|----|----------------------|----------------------|-------------|--------------|-----|------|
| AP | CIPLA LTD | 40MG/2ML (20MG/ML) | A077219 001 | Feb 20, 2008 | Mar | CAHN |
| AP | | 100MG/5ML (20MG/ML) | A077219 002 | Feb 20, 2008 | Mar | CAHN |
| AP | EMCURE PHARMS LTD | 40MG/2ML (20MG/ML) | A200771 001 | Feb 14, 2012 | Jan | NEWA |
| AP | | 100MG/5ML (20MG/ML) | A200771 002 | Feb 14, 2012 | Jan | NEWA |
| AP | HISUN PHARM HANGZHOU | 40MG/2ML (20MG/ML) | A090016 001 | Jan 28, 2009 | Mar | CAHN |
| AP | | 100MG/5ML (20MG/ML) | A090016 002 | Jan 28, 2009 | Mar | CAHN |
| | @ TEVA PARENTERAL | 500MG/25ML (20MG/ML) | A090101 001 | Nov 26, 2008 | Mar | DISC |

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

| | | | | | | |
|--|-----------------|------|-------------|--------------|-----|------|
| | @ SKYEPHARMA AG | 60MG | A075166 001 | Oct 07, 1999 | Jan | DISC |
|--|-----------------|------|-------------|--------------|-----|------|

ISOTRETINOIN

CAPSULE; ORAL

| | | | | | | |
|-----|----------------|------|-------------|--------------|-----|------|
| >A> | ABSORICA | | | | | |
| >A> | CIPHER | 10MG | N021951 001 | May 25, 2012 | May | NEWA |
| >A> | | 20MG | N021951 002 | May 25, 2012 | May | NEWA |
| >A> | | 30MG | N021951 003 | May 25, 2012 | May | NEWA |
| >A> | | 40MG | N021951 004 | May 25, 2012 | May | NEWA |
| | MYORISAN | | | | | |
| AB | DOUGLAS PHARMS | 10MG | A076485 001 | Jan 19, 2012 | Jan | NEWA |
| AB | | 20MG | A076485 002 | Jan 19, 2012 | Jan | NEWA |
| AB | | 40MG | A076485 003 | Jan 19, 2012 | Jan | NEWA |

IVACAFTOR

TABLET; ORAL

KALYDECO

| | | | | | | |
|---|---------------|-------|-------------|--------------|-----|------|
| + | VERTEX PHARMS | 150MG | N203188 001 | Jan 31, 2012 | Jan | NEWA |
|---|---------------|-------|-------------|--------------|-----|------|

IVERMECTIN

LOTION; TOPICAL

SKLICE

| | | | | | | |
|---|----------------|------|-------------|--------------|-----|------|
| + | SANOFI PASTEUR | 0.5% | N202736 001 | Feb 07, 2012 | Feb | NEWA |
|---|----------------|------|-------------|--------------|-----|------|

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

| | | | | | | |
|----|----------------|----|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 2% | A076294 001 | Apr 28, 2004 | Jan | CAHN |
|----|----------------|----|-------------|--------------|-----|------|

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

| | | | | | | |
|----|------------------|--------|-------------|--------------|-----|------|
| AP | GLAND PHARMA LTD | 5MG/ML | A090699 001 | Apr 03, 2012 | Mar | NEWA |
|----|------------------|--------|-------------|--------------|-----|------|

LACTULOSE

SOLUTION; ORAL
LACTULOSE

| | | | | | | |
|----|----------------|-----------|-------------|--------------|-----|------|
| AA | FRESENIUS KABI | 10GM/15ML | A090503 001 | Jan 25, 2012 | Jan | NEWA |
|----|----------------|-----------|-------------|--------------|-----|------|

SOLUTION; ORAL, RECTAL
LACTULOSE

| | | | | | | |
|----|----------------|-----------|-------------|--------------|-----|------|
| AA | FRESENIUS KABI | 10GM/15ML | A090502 001 | Jan 25, 2012 | Jan | NEWA |
|----|----------------|-----------|-------------|--------------|-----|------|

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

| | | | | | | |
|----|----------------------|-------------|-------------|--------------|-----|------|
| AB | AUROBINDO PHARMA LTD | 150MG;300MG | A202418 001 | May 15, 2012 | Apr | NEWA |
| AB | LUPIN LTD | 150MG;300MG | A090246 001 | May 15, 2012 | Apr | NEWA |

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

| | | | | | | |
|----|-------------------|-------|-------------|--------------|-----|------|
| AB | GLENMARK GENERICS | 25MG | A090169 001 | May 12, 2012 | Apr | NEWA |
| AB | | 100MG | A090169 002 | May 12, 2012 | Apr | NEWA |
| AB | | 150MG | A090169 003 | May 12, 2012 | Apr | NEWA |
| AB | | 200MG | A090169 004 | May 12, 2012 | Apr | NEWA |

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

| | | | | | | | |
|-----|---|--------------|---------------|-------------|--------------|-----|------|
| >D> | + | IPSEN INC | EQ 60MG BASE | N022074 001 | Aug 30, 2007 | May | CAHN |
| | | | EQ 60MG BASE | N022074 001 | Aug 30, 2007 | Apr | CAHN |
| >D> | + | | EQ 90MG BASE | N022074 002 | Aug 30, 2007 | May | CAHN |
| | | | EQ 90MG BASE | N022074 002 | Aug 30, 2007 | Apr | CAHN |
| >D> | + | | EQ 120MG BASE | N022074 003 | Aug 30, 2007 | May | CAHN |
| | | | EQ 120MG BASE | N022074 003 | Aug 30, 2007 | Apr | CAHN |
| >A> | + | IPSEN PHARMA | EQ 60MG BASE | N022074 001 | Aug 30, 2007 | May | CAHN |
| >A> | + | | EQ 90MG BASE | N022074 002 | Aug 30, 2007 | May | CAHN |
| >A> | + | | EQ 120MG BASE | N022074 003 | Aug 30, 2007 | May | CAHN |

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

| | | | | | | |
|----|-------------------|------|-------------|--------------|-----|------|
| AB | TAKEDA PHARMS USA | 15MG | N020406 001 | May 10, 1995 | Mar | CAHN |
| AB | + | 30MG | N020406 002 | May 10, 1995 | Mar | CAHN |

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

| | | | | | | |
|---|-------------|------|-------------|--------------|-----|------|
| @ | TEVA PHARMS | 15MG | A078730 001 | Oct 15, 2010 | Mar | DISC |
| @ | | 30MG | A078730 002 | Oct 15, 2010 | Mar | DISC |

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

PREVACID

| | | | | | | |
|---|-------------------|------|-------------|--------------|-----|------|
| | TAKEDA PHARMS USA | 15MG | N021428 001 | Aug 30, 2002 | Mar | CTEC |
| + | | 30MG | N021428 002 | Aug 30, 2002 | Mar | CTEC |

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

| | | | | | | |
|---|-------------|---------------|-------------|--------------|-----|------|
| | @ SHIRE LLC | EQ 250MG BASE | N021468 001 | Oct 26, 2004 | Feb | CAHN |
| | | EQ 500MG BASE | N021468 002 | Oct 26, 2004 | Feb | CAHN |
| | | EQ 750MG BASE | N021468 003 | Nov 23, 2005 | Feb | CAHN |
| + | | EQ 1GM BASE | N021468 004 | Nov 23, 2005 | Feb | CAHN |

LETROZOLE

TABLET; ORAL

LETROZOLE

| | | | | | | |
|----|------------|-------|-------------|--------------|-----|------|
| AB | APOTEX INC | 2.5MG | A091303 001 | Apr 19, 2012 | Apr | NEWA |
|----|------------|-------|-------------|--------------|-----|------|

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

| | | | | | | |
|--|-------------------|-------------------|-------------|--------------|-----|------|
| | @ TEVA PARENTERAL | EQ 50MG BASE/VIAL | A081278 001 | Sep 28, 1993 | Mar | DISC |
|--|-------------------|-------------------|-------------|--------------|-----|------|

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

| | | | | | | | |
|-----|---|------------------|--------------|-------------|--------------|-----|------|
| >A> | + | ABBOTT ENDOCRINE | 3.75MG/VIAL | N020011 001 | Oct 22, 1990 | May | CAHN |
| >A> | + | | 7.5MG/VIAL | N019732 001 | Jan 26, 1989 | May | CAHN |
| >A> | + | | 11.25MG/VIAL | N020708 001 | Mar 07, 1997 | May | CAHN |
| >D> | + | ABBOTT LABS | 3.75MG/VIAL | N020011 001 | Oct 22, 1990 | May | CAHN |
| >D> | + | | 7.5MG/VIAL | N019732 001 | Jan 26, 1989 | May | CAHN |
| >D> | + | | 11.25MG/VIAL | N020708 001 | Mar 07, 1997 | May | CAHN |

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

| | | | | | | | |
|-----|----|----------------|----------------------|-------------|--------------|-----|------|
| >A> | AP | APP PHARMS LLC | 500MG/5ML (100MG/ML) | A090813 001 | May 26, 2010 | May | CAHN |
| | AP | HOSPIRA INC | 500MG/ML (100MG/ML) | A202869 001 | Apr 06, 2012 | Mar | NEWA |
| >D> | AP | NEXUS PHARMS | 500MG/5ML (100MG/ML) | A090813 001 | May 26, 2010 | May | CAHN |
| | AP | PHARMAFORCE | 500MG/5ML (100MG/ML) | A202143 001 | Jan 31, 2012 | Jan | NEWA |

SOLUTION; ORAL

LEVETIRACETAM

| | | | | | | |
|----|-------------------|----------|-------------|--------------|-----|------|
| AA | HI-TECH PHARMACAL | 100MG/ML | A090601 001 | Feb 28, 2012 | Feb | NEWA |
| AA | VINTAGE PHARMS | 100MG/ML | A090079 001 | Apr 11, 2012 | Mar | NEWA |

TABLET; ORAL

LEVETIRACETAM

| | | | | | | |
|----|-----------------|-------|-------------|--------------|-----|------|
| AB | WATSON LABS INC | 250MG | A078797 002 | Jan 15, 2009 | Apr | NEWA |
| AB | | 500MG | A078797 003 | Jan 15, 2009 | Apr | NEWA |
| AB | | 750MG | A078797 004 | Jan 15, 2009 | Apr | NEWA |

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

| | | | | | | | |
|-----|----|--------------------|-------|-------------|--------------|-----|------|
| >A> | AB | BOCA PHARMA | 500MG | A201464 001 | May 25, 2012 | May | NEWA |
| >A> | AB | | 750MG | A201464 002 | May 25, 2012 | May | NEWA |
| >A> | AB | TORRENT PHARMS LTD | 500MG | A091338 001 | May 29, 2012 | May | NEWA |
| >A> | AB | | 750MG | A091338 002 | May 29, 2012 | May | NEWA |

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

| | | | | | | |
|----|---------------------|-------|-------------|--------------|-----|------|
| AB | CIPLA LTD | 250MG | A076890 001 | Mar 30, 2012 | Mar | NEWA |
| AB | | 500MG | A076890 002 | Mar 30, 2012 | Mar | NEWA |
| AB | | 750MG | A076890 003 | Mar 30, 2012 | Mar | NEWA |
| AB | MACLEODS PHARMS LTD | 250MG | A200839 001 | Mar 22, 2012 | Mar | NEWA |
| AB | | 500MG | A200839 002 | Mar 22, 2012 | Mar | NEWA |
| AB | | 750MG | A200839 003 | Mar 22, 2012 | Mar | NEWA |
| AB | ORCHID HLTHCARE | 250MG | A202200 001 | Jan 30, 2012 | Jan | NEWA |
| AB | | 500MG | A202200 002 | Jan 30, 2012 | Jan | NEWA |
| AB | | 750MG | A202200 003 | Jan 30, 2012 | Jan | NEWA |

LEVONORGESTREL

TABLET; ORAL

PLAN B

| | | | | | | | | |
|-----|----|---|--------------------|--------|-------------|--------------|-----|------|
| >A> | AB | + | TEVA BRANDED PHARM | 0.75MG | N021045 002 | Aug 24, 2006 | May | CAHN |
| >A> | | | @ | 0.75MG | N021045 001 | Jul 28, 1999 | May | CAHN |
| >D> | AB | + | TEVA WOMENS | 0.75MG | N021045 002 | Aug 24, 2006 | May | CAHN |
| >D> | | | @ | 0.75MG | N021045 001 | Jul 28, 1999 | May | CAHN |

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE DENTAL

| | | | | | | | | |
|-----|----|---|----------------|----|-------------|--|-----|------|
| >D> | | | | | | | | |
| >D> | AP | + | DENTSPLY PHARM | 2% | N021380 001 | | May | DISC |
| >A> | | | @ | 2% | N021380 001 | | May | DISC |

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

| | | | | | | |
|----|----------------|-----------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 2.5%;2.5% | A076453 001 | Aug 18, 2003 | Jan | CAHN |
|----|----------------|-----------|-------------|--------------|-----|------|

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

| | | | | | | |
|--|----------------------|-------------|-------------|--------------|-----|------|
| | BOEHRINGER INGELHEIM | 2.5MG;500MG | N201281 001 | Jan 30, 2012 | Jan | NEWA |
| | | 2.5MG;850MG | N201281 002 | Jan 30, 2012 | Jan | NEWA |
| | + | 2.5MG;1GM | N201281 003 | Jan 30, 2012 | Jan | NEWA |

LOMUSTINE

CAPSULE; ORAL

CEENU

| | | | | | | | | |
|-----|--|--|----------------------|-------|-------------|-------------|-----|------|
| >D> | | | | | | | | |
| >D> | | | BRISTOL MYERS SQUIBB | 10MG | N017588 001 | | May | DISC |
| >A> | | | @ | 10MG | N017588 001 | | May | DISC |
| >D> | | | | 40MG | N017588 002 | | May | DISC |
| >A> | | | @ | 40MG | N017588 002 | | May | DISC |
| >D> | | | + | 100MG | N017588 003 | | May | DISC |
| >A> | | | + | @ | 100MG | N017588 003 | May | DISC |

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

| | | | | | | |
|----|-------------------|--------|-------------|--------------|-----|------|
| AA | HI-TECH PHARMA CO | 2MG/ML | A200169 001 | Jan 30, 2012 | Jan | NEWA |
|----|-------------------|--------|-------------|--------------|-----|------|

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

| | | | | | | | |
|-----|----|---------------------|-------|-------------|--------------|-----|------|
| >A> | AB | MACLEODS PHARMS LTD | 25MG | A202230 001 | May 30, 2012 | May | NEWA |
| >A> | AB | | 50MG | A202230 002 | May 30, 2012 | May | NEWA |
| >A> | AB | | 100MG | A202230 003 | May 30, 2012 | May | NEWA |

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

| | | | | | | |
|---|----------------|-------|-------------|--------------|-----|------|
| + | DISCOVERY LABS | 8.5ML | N021746 001 | Mar 06, 2012 | Apr | NEWA |
|---|----------------|-------|-------------|--------------|-----|------|

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

| | | | | | | |
|---|---------------------|-------|-------------|--------------|-----|------|
| | SUNOVION PHARMS INC | 20MG | N200603 003 | Dec 07, 2011 | Apr | NEWA |
| + | | 40MG | N200603 001 | Oct 28, 2010 | Apr | CRLD |
| | | 80MG | N200603 002 | Oct 28, 2010 | Apr | CRLD |
| | | 120MG | N200603 004 | Apr 26, 2012 | Apr | NEWA |

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

| | | | | | | |
|--|---------|----------------------|-------------|--------------|-----|------|
| | HOSPIRA | 20GM/500ML (40MG/ML) | N020309 004 | Jan 18, 1995 | Jan | NEWA |
| | | 40GM/1000ML(40MG/ML) | N020309 005 | Jan 18, 1995 | Jan | NEWA |

MALATHION

LOTION; TOPICAL

MALATHION

| | | | | | | |
|-----|------------------|------------|-------------|--------------|-----|------|
| AT | MYLAN PHARMS INC | 0.5% | A078743 001 | Mar 06, 2009 | Feb | CAHN |
| >A> | AT | SUVEN LIFE | A091559 001 | May 23, 2012 | May | NEWA |

MANNITOL

POWDER; INHALATION

ARIDOL KIT

| | | | | | | | |
|-----|---|---------------|----------------------------|-------------|--------------|-----|------|
| >D> | + | PHARMAXIS | N/A, 5MG, 10MG, 20MG, 40MG | N022368 001 | Oct 05, 2010 | May | CAHN |
| >A> | + | PHARMAXIS LTD | N/A, 5MG, 10MG, 20MG, 40MG | N022368 001 | Oct 05, 2010 | May | CAHN |

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

| | | | | | | | |
|-----|---|-----------|--------------------|-------------|--------------|-----|------|
| >A> | + | IPSEN INC | 40MG/4ML (10MG/ML) | N021839 001 | Aug 30, 2005 | May | CAHN |
| >D> | + | TERCICA | 40MG/4ML (10MG/ML) | N021839 001 | Aug 30, 2005 | May | CAHN |

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

| | | | | | | |
|----|-----------------|--------|-------------|--------------|-----|------|
| AA | EPIC PHARMA LLC | 12.5MG | A200294 001 | Apr 13, 2012 | Mar | NEWA |
| AA | | 25MG | A200294 002 | Apr 13, 2012 | Mar | NEWA |

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

| | | | | | | |
|---|-----------------|----------|-------------|--------------|-----|------|
| @ | TEVA PARENTERAL | 150MG/ML | A076552 001 | Oct 27, 2004 | Apr | DISC |
|---|-----------------|----------|-------------|--------------|-----|------|

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

| | | | | | | | | | |
|----|---|-------------------------|------|---------|-----|--------------|-----|------|--|
| | | MEMANTINE HYDROCHLORIDE | | | | | | | |
| | | @ ORCHID HLTHCARE | 5MG | A090044 | 001 | Mar 12, 2012 | Mar | DISC | |
| AB | | | 5MG | A090044 | 001 | Mar 12, 2012 | Feb | NEWA | |
| | | @ | 10MG | A090044 | 002 | Mar 12, 2012 | Mar | DISC | |
| AB | | | 10MG | A090044 | 002 | Mar 12, 2012 | Feb | NEWA | |
| | | NAMENDA | | | | | | | |
| | | FOREST LABS | 5MG | N021487 | 001 | Oct 16, 2003 | Mar | CTEC | |
| AB | | | 5MG | N021487 | 001 | Oct 16, 2003 | Feb | CTEC | |
| | + | | 10MG | N021487 | 002 | Oct 16, 2003 | Mar | CTEC | |
| AB | + | | 10MG | N021487 | 002 | Oct 16, 2003 | Feb | CTEC | |

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

| | | | | | | | | | |
|-----|----|----------------|----|---------|-----|--------------|-----|------|--|
| >D> | | POLOCAINE | | | | | | | |
| >D> | AP | DENTSPLY PHARM | 3% | A088653 | 001 | Aug 21, 1984 | May | DISC | |
| >A> | | @ | 3% | A088653 | 001 | Aug 21, 1984 | May | DISC | |

MESALAMINE

SUPPOSITORY; RECTAL

ROWASA

| | | | | | | | | | |
|--|--|---------------|-------|---------|-----|--------------|-----|------|--|
| | | @ MEDA PHARMS | 500MG | N019919 | 001 | Dec 18, 1990 | Jan | CAHN | |
|--|--|---------------|-------|---------|-----|--------------|-----|------|--|

MESNA

INJECTABLE; INTRAVENOUS

MESNA

| | | | | | | | | | |
|----|--|---------------------|----------|---------|-----|--------------|-----|------|--|
| AP | | MYLAN INSTITUTIONAL | 100MG/ML | A076488 | 001 | Mar 08, 2012 | Feb | NEWA | |
|----|--|---------------------|----------|---------|-----|--------------|-----|------|--|

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|----|--|-----------------|-------|---------|-----|--------------|-----|------|--|
| AB | | MARKSANS PHARMA | 500MG | A090888 | 001 | Mar 12, 2012 | Feb | NEWA | |
| AB | | | 850MG | A090888 | 002 | Mar 12, 2012 | Feb | NEWA | |
| AB | | | 1GM | A090888 | 003 | Mar 12, 2012 | Feb | NEWA | |

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

| | | | | | | | | | |
|-----|--|--------------------|-------|---------|-----|--------------|-----|------|--|
| AB1 | | INVENTIA HLTHCARE | 500MG | A201991 | 001 | Jan 18, 2012 | Jan | NEWA | |
| | | @ RANBAXY LABS LTD | 500MG | A076413 | 001 | Jun 18, 2004 | Apr | DISC | |
| | | @ | 750MG | A077211 | 001 | Jun 29, 2005 | Apr | DISC | |

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

| | | | | | | | | | |
|--|---|----------------------|-------------------|---------|-----|--------------|-----|------|--|
| | | BRISTOL MYERS SQUIBB | 500MG;EQ 5MG BASE | N200678 | 001 | Nov 05, 2010 | Apr | CAHN | |
| | | | 1GM;EQ 2.5MG BASE | N200678 | 003 | Nov 05, 2010 | Apr | CAHN | |
| | + | | 1GM;EQ 5MG BASE | N200678 | 002 | Nov 05, 2010 | Apr | CAHN | |

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

| | | | | | | | | | |
|-----|---|-------------------|--------------------|---------|-----|--------------|-----|------|--|
| >D> | | MERCK | 500MG;EQ 50MG BASE | N022044 | 001 | Mar 30, 2007 | May | CAHN | |
| >D> | + | | 1GM;EQ 50MG BASE | N022044 | 002 | Mar 30, 2007 | May | CAHN | |
| >A> | | MERCK SHARP DOHME | 500MG;EQ 50MG BASE | N022044 | 001 | Mar 30, 2007 | May | CAHN | |
| >A> | + | | 1GM;EQ 50MG BASE | N022044 | 002 | Mar 30, 2007 | May | CAHN | |

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

| | | | | | | |
|---|-------------------|--------------------|-------------|--------------|-----|------|
| | MERCK SHARP DOHME | 500MG;EQ 50MG BASE | N202270 001 | Feb 02, 2012 | Feb | NEWA |
| | | 1GM;EQ 50MG BASE | N202270 002 | Feb 02, 2012 | Feb | NEWA |
| + | | 1GM;EQ 100MG BASE | N202270 003 | Feb 02, 2012 | Feb | NEWA |

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

| | | | | | | |
|----|-------------|------|-------------|--------------|-----|------|
| AB | BOCA PHARMA | 5MG | A202068 001 | Mar 07, 2012 | Feb | NEWA |
| AB | | 10MG | A202068 002 | Mar 07, 2012 | Feb | NEWA |

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

| | | | | | | |
|----|----------------|-------|-------------|--|-----|------|
| AA | SOLCO HLTHCARE | 500MG | A086989 001 | | Mar | CMFD |
| AA | | 750MG | A086988 001 | | Mar | CMFD |

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

| | | | | | | |
|----|-----------------|-------------------------------------|-------------|--------------|-----|------|
| AP | APP PHARMS LLC | EQ 1GM BASE/VIAL | A040266 001 | Feb 26, 1999 | Jan | CMFD |
| AP | PHARMACHEMIE BV | EQ 100MG BASE/4ML (EQ 25MG BASE/ML) | A200171 001 | Feb 27, 2012 | Feb | NEWA |

METHOTREXATE SODIUM

| | | | | | | | |
|----|---|---------|-------------------------------------|-------------|--------------|-----|------|
| AP | + | BEDFORD | EQ 100MG BASE/4ML (EQ 25MG BASE/ML) | A089341 001 | Sep 16, 1986 | Feb | CTEC |
|----|---|---------|-------------------------------------|-------------|--------------|-----|------|

METHOTREXATE SODIUM PRESERVATIVE FREE

| | | | | | | | |
|----|---|---------------------|--------------------------------------|-------------|--------------|-----|------|
| AP | + | MYLAN INSTITUTIONAL | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A040767 001 | Apr 30, 2007 | Feb | CAHN |
| AP | | ONCO THERAPIES LTD | EQ 50MG BASE/2ML (EQ 25MG BASE/ML) | A201529 001 | Mar 29, 2012 | Mar | NEWA |
| AP | | | EQ 100MG BASE/4ML (EQ 25MG BASE/ML) | A201529 002 | Mar 29, 2012 | Mar | NEWA |
| AP | | | EQ 200MG BASE/8ML (EQ 25MG BASE/ML) | A201529 003 | Mar 29, 2012 | Mar | NEWA |
| AP | | | EQ 250MG BASE/10ML (EQ 25MG BASE/ML) | A201529 004 | Mar 29, 2012 | Mar | NEWA |
| AP | | | EQ 1GM BASE/40ML (EQ 25MG BASE/ML) | A201530 001 | Mar 29, 2012 | Mar | NEWA |

METHYLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYLOTHIAZIDE

| | | | | | | | |
|----|---|------------------|-----|-------------|--------------|-----|------|
| AB | + | MYLAN PHARMS INC | 5MG | A087672 001 | Aug 17, 1982 | Mar | CRLD |
|----|---|------------------|-----|-------------|--------------|-----|------|

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

>D> PROGENICS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

>A> SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

SOLUTION; SUBCUTANEOUS

RELISTOR

| | | | | | | | |
|-----|---|--------------|-------------------------|-------------|--------------|-----|------|
| >D> | + | PROGENICS | 12MG/0.6ML (12MG/0.6ML) | N021964 001 | Apr 24, 2008 | May | CAHN |
| >A> | + | SALIX PHARMS | 12MG/0.6ML (12MG/0.6ML) | N021964 001 | Apr 24, 2008 | May | CAHN |

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | |
|----|--|--------------------|------|-------------|--------------|-----|------|
| AB | | SUN PHARM INDS INC | 5MG | A090710 001 | Mar 15, 2012 | Feb | NEWA |
| AB | | | 10MG | A090710 002 | Mar 15, 2012 | Feb | NEWA |
| AB | | | 20MG | A090710 003 | Mar 15, 2012 | Feb | NEWA |

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

| | | | | | | | |
|--|---|-----------------|--------------------|-------------|--------------|-----|------|
| | @ | TEVA PARENTERAL | EQ 125MG BASE/VIAL | A081266 001 | Nov 30, 1992 | Mar | DISC |
|--|---|-----------------|--------------------|-------------|--------------|-----|------|

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | |
|--|---|-----------------|----------------|-------------|--------------|-----|------|
| | @ | TEVA PARENTERAL | EQ 5MG BASE/ML | A073135 001 | Nov 27, 1991 | Jan | DISC |
|--|---|-----------------|----------------|-------------|--------------|-----|------|

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

| | | | | | | | |
|----|---|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.75% | A076408 001 | May 28, 2004 | Jan | CAHN |
| | + | NORITATE | | | | | |
| | + | VALEANT INTL | 1% | N020743 001 | Sep 26, 1997 | Apr | CAHN |

GEL; TOPICAL

METRONIDAZOLE

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.75% | A077018 001 | Jun 06, 2006 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

LOTION; TOPICAL

METRONIDAZOLE

| | | | | | | | |
|----|--|----------------|-------|-------------|--------------|-----|------|
| AB | | FOUGERA PHARMS | 0.75% | A077197 001 | May 24, 2006 | Jan | CAHN |
|----|--|----------------|-------|-------------|--------------|-----|------|

METYROSINE

CAPSULE; ORAL

DEMSEER

| | | | | | | | |
|-----|---|----------------------|-------|-------------|--|-----|------|
| >D> | + | ATON | 250MG | N017871 001 | | May | CAHN |
| >A> | + | BIOVAIL TECHNOLOGIES | 250MG | N017871 001 | | May | CAHN |

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

| | | | | | | | |
|----|--|------------------|----------------|-------------|--------------|-----|------|
| AP | | GLAND PHARMA LTD | EQ 1MG BASE/ML | A090696 001 | Feb 29, 2012 | Feb | NEWA |
| AP | | | EQ 5MG BASE/ML | A090850 001 | Jan 25, 2012 | Jan | NEWA |

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

| | | | | | | | |
|----|---|-----------|-------|-------------|--------------|-----|------|
| AB | | SHIRE LLC | 2.5MG | N019815 001 | Sep 06, 1996 | Jan | CAHN |
| AB | + | | 5MG | N019815 002 | Sep 06, 1996 | Jan | CAHN |
| AB | | | 10MG | N019815 003 | Mar 20, 2002 | Jan | CAHN |

MIFEPRISTONE

TABLET; ORAL

KORLYM

| | | | | | | | |
|--|---|----------------|-------|-------------|--------------|-----|------|
| | + | CORCEPT THERAP | 300MG | N202107 001 | Feb 17, 2012 | Feb | NEWA |
|--|---|----------------|-------|-------------|--------------|-----|------|

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

| | | | | | | | |
|-----|----|------------------|---------------|-------------|--------------|-----|------|
| >A> | AB | PRECISION DERMAT | EQ 50MG BASE | N050649 001 | May 31, 1990 | May | CAHN |
| >A> | | @ | EQ 75MG BASE | N050649 003 | Feb 12, 2001 | May | CAHN |
| >A> | AB | | EQ 100MG BASE | N050649 002 | May 31, 1990 | May | CAHN |
| >D> | AB | TRIAx PHARMS LLC | EQ 50MG BASE | N050649 001 | May 31, 1990 | May | CAHN |
| >D> | | @ | EQ 75MG BASE | N050649 003 | Feb 12, 2001 | May | CAHN |
| >D> | AB | | EQ 100MG BASE | N050649 002 | May 31, 1990 | May | CAHN |

INJECTABLE; INJECTION

MINOCIN

| | | | | | | | |
|-----|---|------------------|--------------------|-------------|--|-----|------|
| >A> | + | PRECISION DERMAT | EQ 100MG BASE/VIAL | N050444 001 | | May | CAHN |
| >D> | + | TRIAx PHARMS LLC | EQ 100MG BASE/VIAL | N050444 001 | | May | CAHN |

SUSPENSION; ORAL

MINOCIN

| | | | | | | | |
|-----|--|--------------------|------------------|-------------|--|-----|------|
| >A> | | @ PRECISION DERMAT | EQ 50MG BASE/5ML | N050445 001 | | May | CAHN |
| >D> | | @ TRIAX PHARMS | EQ 50MG BASE/5ML | N050445 001 | | May | CAHN |

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

| | | | | | | | |
|--|---|---------------|------------|-------------|--------------|-----|------|
| | + | MOBIUS THERAP | 0.2MG/VIAL | N022572 001 | Feb 07, 2012 | Feb | NEWA |
|--|---|---------------|------------|-------------|--------------|-----|------|

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|--|----|----------------|------|-------------|--------------|-----|------|
| | AB | FOUGERA PHARMS | 0.1% | A076171 001 | Apr 08, 2005 | Jan | CAHN |
|--|----|----------------|------|-------------|--------------|-----|------|

LOTION; TOPICAL

MOMETASONE FUROATE

| | | | | | | | |
|--|----|----------------|------|-------------|--------------|-----|------|
| | AB | FOUGERA PHARMS | 0.1% | A075919 001 | Nov 29, 2007 | Jan | CAHN |
|--|----|----------------|------|-------------|--------------|-----|------|

OINTMENT; TOPICAL

ELOCON

| | | | | | | | | |
|-----|----|---|-------------------|------|-------------|--------------|-----|------|
| >A> | AB | + | MERCK SHARP DOHME | 0.1% | N019543 001 | Apr 30, 1987 | May | CAHN |
| >D> | AB | + | SCHERING | 0.1% | N019543 001 | Apr 30, 1987 | May | CAHN |

MOMETASONE FUROATE

| | | | | | | | |
|--|----|----------------|------|-------------|--------------|-----|------|
| | AB | FOUGERA PHARMS | 0.1% | A077061 001 | Mar 28, 2005 | Jan | CAHN |
|--|----|----------------|------|-------------|--------------|-----|------|

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

| | | | | | | | |
|-----|---|---------------------|----------------------|-------------|--------------|-----|------|
| >D> | + | EKR THERAP | 10MG/ML (10MG/ML) | N021671 001 | May 18, 2004 | May | CAHN |
| >D> | | @ | 15MG/1.5ML (10MG/ML) | N021671 002 | May 18, 2004 | May | CAHN |
| >D> | | @ | 20MG/2ML (10MG/ML) | N021671 003 | May 18, 2004 | May | CAHN |
| >A> | | @ PACIRA PHARMS INC | 10MG/ML (10MG/ML) | N021671 001 | May 18, 2004 | May | CAHN |
| >A> | | @ | 15MG/1.5ML (10MG/ML) | N021671 002 | May 18, 2004 | May | CAHN |
| >A> | | @ | 20MG/2ML (10MG/ML) | N021671 003 | May 18, 2004 | May | CAHN |

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

| | | | | | | | |
|--|----|------------------|------|-------------|--------------|-----|------|
| | AB | RANBAXY LABS LTD | 15MG | A078761 001 | May 11, 2012 | Apr | NEWA |
| | AB | | 30MG | A078761 002 | May 11, 2012 | Apr | NEWA |

TABLET, EXTENDED RELEASE; ORALMORPHINE SULFATE

| | | | | | | |
|-----|------------------|---------------------|-------------|--------------|--------------|----------|
| AB | RANBAXY LABS LTD | 60MG | A078761 003 | May 11, 2012 | Apr | NEWA |
| AB | | 100MG | A078761 004 | May 11, 2012 | Apr | NEWA |
| AB | | 200MG | A078761 005 | May 11, 2012 | Apr | NEWA |
| >D> | ORAMORPH SR | | | | | |
| >D> | BC | XANODYNE PHARM | 15MG | N019977 004 | Nov 23, 1994 | May DISC |
| >D> | BC | | 30MG | N019977 001 | Aug 15, 1991 | May DISC |
| >D> | BC | | 60MG | N019977 002 | Aug 15, 1991 | May DISC |
| >D> | BC | + | 100MG | N019977 003 | Aug 15, 1991 | May DISC |
| >A> | @ | XANODYNE PHARMS INC | 15MG | N019977 004 | Nov 23, 1994 | May DISC |
| >A> | @ | | 30MG | N019977 001 | Aug 15, 1991 | May DISC |
| >A> | @ | | 60MG | N019977 002 | Aug 15, 1991 | May DISC |
| >A> | @ | | 100MG | N019977 003 | Aug 15, 1991 | May DISC |

MUPIROCINOINTMENT; TOPICALMUPIROCIN

| | | | | | | |
|----|----------------|----|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 2% | A065192 001 | Nov 30, 2005 | Jan | CAHN |
|----|----------------|----|-------------|--------------|-----|------|

NABUMETONETABLET; ORALNABUMETONE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | PROSAM LABS | 500MG | A079093 001 | Feb 27, 2009 | Feb | CMFD |
| AB | | 750MG | A079093 002 | Feb 27, 2009 | Feb | CMFD |

NAFTIFINE HYDROCHLORIDECREAM; TOPICALNAFTIN

| | | | | | | |
|---|-------------|----|-------------|--------------|-----|------|
| + | MERZ PHARMS | 2% | N019599 002 | Jan 13, 2012 | Jan | NEWA |
|---|-------------|----|-------------|--------------|-----|------|

NALTREXONE HYDROCHLORIDETABLET; ORALNALTREXONE HYDROCHLORIDE

| | | | | | | |
|----|-------------------|------|-------------|--------------|-----|------|
| AB | SUN PHARMA GLOBAL | 50MG | A090356 001 | Feb 24, 2012 | Feb | NEWA |
|----|-------------------|------|-------------|--------------|-----|------|

NAPROXEN SODIUMTABLET; ORALANAPROX

| | | | | | | |
|-----|----|-------------------|-------------------|---------------|-------------|-----------------------|
| >A> | AB | HOFFMANN LA ROCHE | EQ 250MG BASE | N018164 001 | | May CAHN |
| >D> | AB | ROCHE PALO | EQ 250MG BASE | N018164 001 | | May CAHN |
| | | ANAPROX DS | | | | |
| >A> | AB | + | HOFFMANN LA ROCHE | EQ 500MG BASE | N018164 003 | Sep 30, 1987 May CAHN |
| >D> | AB | + | ROCHE PALO | EQ 500MG BASE | N018164 003 | Sep 30, 1987 May CAHN |

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET; ORALTREXIMET

| | | | | | | |
|-----|---|--------------------|--------------------|-------------|--------------|----------|
| >D> | + | GLAXOSMITHKLINE | 500MG;EQ 85MG BASE | N021926 001 | Apr 15, 2008 | May CAHN |
| >A> | + | SMITHKLINE BEECHAM | 500MG;EQ 85MG BASE | N021926 001 | Apr 15, 2008 | May CAHN |

NARATRIPTAN HYDROCHLORIDETABLET; ORALNARATRIPTAN

| | | | | | | |
|-----|----|------------------|---------------|-------------|--------------|----------|
| >A> | AB | MYLAN PHARMS INC | EQ 1MG BASE | A202431 001 | May 31, 2012 | May NEWA |
| >A> | AB | | EQ 2.5MG BASE | A202431 002 | May 31, 2012 | May NEWA |

TABLET; ORAL

NARATRIPTAN

| | | | | | | | |
|----|-----------------|---------------|---------|-----|--------------|-----|------|
| AB | ORCHID HLTHCARE | EQ 1MG BASE | A091441 | 001 | Apr 30, 2012 | Apr | NEWA |
| AB | | EQ 2.5MG BASE | A091441 | 002 | Apr 30, 2012 | Apr | NEWA |

NEVIRAPINE

SUSPENSION; ORAL

| | | | | | | | |
|-----|------------|----------------------|----------|---------|-----|--------------|----------|
| >A> | NEVIRAPINE | | | | | | |
| >A> | AA | AUROBINDO | 50MG/5ML | A077702 | 001 | May 22, 2012 | May NEWA |
| | | VIRAMUNE | | | | | |
| >D> | + | BOEHRINGER INGELHEIM | 50MG/5ML | N020933 | 001 | Sep 11, 1998 | May CFTG |
| >A> | AA | + | 50MG/5ML | N020933 | 001 | Sep 11, 1998 | May CFTG |

TABLET; ORAL

| | | | | | | | |
|-----|------------|----------------------|-------|---------|-----|--------------|----------|
| >A> | NEVIRAPINE | | | | | | |
| >A> | AB | APOTEX INC | 200MG | A203021 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | AUROBINDO | 200MG | A077521 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | CIPLA | 200MG | A077956 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | HETERO LABS LTD III | 200MG | A078584 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | MICRO LABS LTD | 200MG | A203080 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | MYLAN LABS | 200MG | A078864 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | MYLAN PHARMS INC | 200MG | A202523 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | PRINSTON INC | 200MG | A078644 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | SCIEGEN PHARMS INC | 200MG | A203176 | 001 | May 22, 2012 | May NEWA |
| >A> | AB | STRIDES | 200MG | A078195 | 001 | May 22, 2012 | May NEWA |
| | | VIRAMUNE | | | | | |
| >D> | + | BOEHRINGER INGELHEIM | 200MG | N020636 | 001 | Jun 21, 1996 | May CFTG |
| >A> | AB | + | 200MG | N020636 | 001 | Jun 21, 1996 | May CFTG |

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

| | | | | | | | |
|-----|-----|---------|------|---------|-----|--------------|----------|
| >A> | AB1 | ACTAVIS | 90MG | A077899 | 003 | May 25, 2012 | May NEWA |
|-----|-----|---------|------|---------|-----|--------------|----------|

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

| | | | | | | | |
|--|---|------------------|-----------|---------|-----|--------------|----------|
| | @ | RANBAXY LABS LTD | 75MG;25MG | A076951 | 001 | Mar 30, 2005 | Apr DISC |
|--|---|------------------|-----------|---------|-----|--------------|----------|

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

| | | | | | | | |
|--|---|----------------|------|---------|-----|--------------|----------|
| | + | APTALIS PHARMA | 0.4% | N021359 | 001 | Jun 21, 2011 | Jan CAHN |
|--|---|----------------|------|---------|-----|--------------|----------|

NIZATIDINE

CAPSULE; ORAL

AXID

| | | | | | | | |
|--|---|--------------------|-------|---------|-----|--------------|----------|
| | @ | SMITHKLINE BEECHAM | 150MG | N019508 | 001 | Apr 12, 1988 | Mar DISC |
|--|---|--------------------|-------|---------|-----|--------------|----------|

| | | | | | | | |
|--|---|--|-------|---------|-----|--------------|----------|
| | @ | | 300MG | N019508 | 002 | Apr 12, 1988 | Mar DISC |
|--|---|--|-------|---------|-----|--------------|----------|

NIZATIDINE

| | | | | | | | |
|----|---|------------------|-------|---------|-----|--------------|----------|
| | @ | MYLAN PHARMS INC | 150MG | A075934 | 001 | Jul 09, 2002 | Apr DISC |
| AB | + | | 300MG | A075806 | 002 | Jul 05, 2002 | Apr CRLD |
| | @ | | 300MG | A075934 | 002 | Jul 09, 2002 | Apr DISC |

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

| | | | | | | | |
|-----|----|---------------------|----------------|-------------|--------------|-----|------|
| >A> | AP | CLARIS LIFESCIENCES | EQ 1MG BASE/ML | A040859 001 | Mar 27, 2012 | May | CAHN |
| >D> | AP | SINETICA | EQ 1MG BASE/ML | A040859 001 | Mar 27, 2012 | May | CAHN |
| | AP | | EQ 1MG BASE/ML | A040859 001 | Mar 27, 2012 | Mar | NEWA |

NYSTATIN

CREAM; TOPICAL

NYSTATIN

| | | | | | | | |
|----|--|----------------|------------------|-------------|--|-----|------|
| AT | | FOUGERA PHARMS | 100,000 UNITS/GM | A062129 001 | | Jan | CAHN |
|----|--|----------------|------------------|-------------|--|-----|------|

OINTMENT; TOPICAL

NYSTATIN

| | | | | | | | |
|----|---|----------------|------------------|-------------|--------------|-----|------|
| AT | + | FOUGERA PHARMS | 100,000 UNITS/GM | A062124 002 | Sep 23, 1982 | Jan | CAHN |
|----|---|----------------|------------------|-------------|--------------|-----|------|

OFLOXACIN

TABLET; ORAL

OFLOXACIN

| | | | | | | | |
|--|---|------------------|-------|-------------|--------------|-----|------|
| | @ | RANBAXY LABS LTD | 200MG | A076220 001 | Sep 02, 2003 | Apr | DISC |
| | @ | | 300MG | A076220 002 | Sep 02, 2003 | Apr | DISC |
| | @ | | 400MG | A076220 003 | Sep 02, 2003 | Apr | DISC |

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

| | | | | | | | |
|----|--|-------------|-----------|-------------|--------------|-----|------|
| AP | | PHARMAFORCE | 10MG/VIAL | A201741 001 | Mar 20, 2012 | Mar | NEWA |
| AP | | SANDOZ INC | 10MG/VIAL | A201588 001 | Oct 24, 2011 | Mar | CAHN |

TABLET; ORAL

OLANZAPINE

| | | | | | | | |
|----|--|----------------------|-------|-------------|--------------|-----|------|
| AB | | APOTEX INC | 2.5MG | A090798 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 5MG | A090798 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 7.5MG | A090798 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 10MG | A090798 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 15MG | A090798 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 20MG | A090798 006 | Apr 23, 2012 | Apr | NEWA |
| AB | | AUROBINDO PHARMA LTD | 2.5MG | A202050 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 5MG | A202050 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 7.5MG | A202050 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 10MG | A202050 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 15MG | A202050 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 20MG | A202050 006 | Apr 23, 2012 | Apr | NEWA |
| AB | | DR REDDYS LABS LTD | 2.5MG | A076255 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 5MG | A076255 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 7.5MG | A076255 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 10MG | A076255 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 15MG | A076133 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | MYLAN | 2.5MG | A076866 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 5MG | A076866 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 7.5MG | A076866 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 10MG | A076866 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 15MG | A076866 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 20MG | A076866 006 | Apr 23, 2012 | Apr | NEWA |
| AB | | ORCHID HLTHCARE | 2.5MG | A202287 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 5MG | A202287 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | | 7.5MG | A202287 003 | Apr 23, 2012 | Apr | NEWA |

TABLET; ORAL

OLANZAPINE

| | | | | | | |
|----|--------------------|-------|-------------|--------------|-----|------|
| AB | ORCHID HLTHCARE | 10MG | A202287 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | 15MG | A202287 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | 20MG | A202287 006 | Apr 23, 2012 | Apr | NEWA |
| AB | SUN PHARM INDS | 2.5MG | A091038 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | 5MG | A091038 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | 7.5MG | A091038 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | 10MG | A091038 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | 15MG | A091038 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | 20MG | A091038 006 | Apr 23, 2012 | Apr | NEWA |
| AB | TORRENT PHARMS LTD | 2.5MG | A091434 001 | Apr 23, 2012 | Apr | NEWA |
| AB | | 5MG | A091434 002 | Apr 23, 2012 | Apr | NEWA |
| AB | | 7.5MG | A091434 003 | Apr 23, 2012 | Apr | NEWA |
| AB | | 10MG | A091434 004 | Apr 23, 2012 | Apr | NEWA |
| AB | | 15MG | A091434 005 | Apr 23, 2012 | Apr | NEWA |
| AB | | 20MG | A091434 006 | Apr 23, 2012 | Apr | NEWA |

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | BARR LABS INC | 5MG | A077243 001 | Jan 30, 2012 | Jan | NEWA |
| AB | | 10MG | A077243 002 | Jan 30, 2012 | Jan | NEWA |
| AB | | 15MG | A077243 003 | Jan 30, 2012 | Jan | NEWA |
| AB | | 20MG | A077243 004 | Jan 30, 2012 | Jan | NEWA |
| AB | SUN PHARM INDS | 5MG | A090881 001 | Feb 28, 2012 | Feb | NEWA |
| AB | | 10MG | A090881 002 | Feb 28, 2012 | Feb | NEWA |
| AB | | 15MG | A090881 003 | Feb 28, 2012 | Feb | NEWA |
| AB | | 20MG | A090881 004 | Feb 28, 2012 | Feb | NEWA |

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

| | | | | | | |
|----|--------------------|------|-------------|--------------|-----|------|
| AB | DR REDDYS LABS LTD | 10MG | A078490 002 | Mar 16, 2009 | Apr | NEWA |
| AB | | 20MG | A078490 003 | Mar 16, 2009 | Apr | NEWA |

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

| | | | | | | |
|---|-------|----------------|-------------|--------------|-----|------|
| + | ROCHE | EQ 6MG BASE/ML | N021246 002 | Mar 21, 2011 | Jan | CRLD |
|---|-------|----------------|-------------|--------------|-----|------|

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

| | | | | | | |
|----|---------------|-------------------|-------------|--------------|-----|------|
| AP | SAGENT PHARMS | EQ 1GM BASE/VIAL | A091246 001 | Mar 30, 2012 | Mar | NEWA |
| AP | | EQ 2GM BASE/VIAL | A091246 002 | Mar 30, 2012 | Mar | NEWA |
| AP | | EQ 10GM BASE/VIAL | A091245 001 | Mar 30, 2012 | Mar | NEWA |

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

| | | | | | | |
|----|---------------|---------------------|-------------|--------------|-----|------|
| AP | + TEVA PHARMS | 50MG/10ML (5MG/ML) | N022160 001 | Aug 07, 2009 | Mar | CRLD |
| AP | + | 100MG/20ML (5MG/ML) | N022160 002 | Aug 07, 2009 | Mar | CRLD |

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

| | | | | | | |
|---|----------------|------------|-------------|--------------|-----|------|
| + | FOUGERA PHARMS | EQ 1% BASE | N019828 001 | Dec 30, 1988 | Jan | CAHN |
|---|----------------|------------|-------------|--------------|-----|------|

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

| | | | | | | | | |
|--|---|-----------------|----|---------|-----|--------------|-----|------|
| | + | ARROW INTL | 3% | N202513 | 001 | Dec 07, 2011 | Apr | CAHN |
| | + | WATSON LABS INC | 3% | N202513 | 001 | Dec 07, 2011 | Feb | CAHN |

OXYBUTYNIN CHLORIDE

TABLET; ORAL
DITROPAN

| | | | | | | | | |
|----|---|------------------|------|---------|-----|--------------|-----|------|
| | | @ JANSSEN PHARMS | 5MG | N017577 | 001 | | Mar | DISC |
| AB | + | VINTAGE PHARMS | 5MG | A075079 | 001 | Oct 31, 1997 | Mar | CRLD |
| | | MYLAN PHARMS INC | 15MG | A076644 | 002 | May 10, 2007 | Mar | NEWA |

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

| | | | | | | | | |
|----|---|------------------|---------|---------|-----|--------------|-----|------|
| | + | VISTAPHARM | 5MG/5ML | N201194 | 001 | Jan 12, 2012 | Jan | NEWA |
| AB | | MALLINCKRODT INC | 5MG | A076758 | 003 | Mar 19, 2007 | Apr | NEWA |

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

| | | | | | | | | |
|-----|----|---------------------------|------|---------|-----|--------------|-----|------|
| >D> | | OPANA ER | | | | | | |
| >D> | AB | ENDO PHARMS | 5MG | N021610 | 001 | Jun 22, 2006 | May | DISC |
| >A> | | @ | 5MG | N021610 | 001 | Jun 22, 2006 | May | DISC |
| >D> | AB | | 10MG | N021610 | 002 | Jun 22, 2006 | May | DISC |
| >A> | | @ | 10MG | N021610 | 002 | Jun 22, 2006 | May | DISC |
| >D> | AB | | 20MG | N021610 | 003 | Jun 22, 2006 | May | DISC |
| >A> | | @ | 20MG | N021610 | 003 | Jun 22, 2006 | May | DISC |
| >D> | AB | | 30MG | N021610 | 007 | Feb 29, 2008 | May | DISC |
| >A> | | @ | 30MG | N021610 | 007 | Feb 29, 2008 | May | DISC |
| >D> | AB | + | 40MG | N021610 | 004 | Jun 22, 2006 | May | DISC |
| >A> | | @ | 40MG | N021610 | 004 | Jun 22, 2006 | May | DISC |
| | | OXYMORPHONE HYDROCHLORIDE | | | | | | |
| >D> | AB | IMPAX LABS | 5MG | A079087 | 001 | Jun 14, 2010 | May | CTEC |
| >A> | | | 5MG | A079087 | 001 | Jun 14, 2010 | May | CTEC |
| >D> | AB | | 10MG | A079087 | 003 | Jun 14, 2010 | May | CTEC |
| >A> | | | 10MG | A079087 | 003 | Jun 14, 2010 | May | CTEC |
| >D> | AB | | 20MG | A079087 | 005 | Jun 14, 2010 | May | CTEC |
| >A> | | | 20MG | A079087 | 005 | Jun 14, 2010 | May | CTEC |
| >D> | AB | | 30MG | A079087 | 006 | Jul 22, 2010 | May | CTEC |
| >A> | | | 30MG | A079087 | 006 | Jul 22, 2010 | May | CTEC |
| >D> | AB | | 40MG | A079087 | 007 | Jun 14, 2010 | May | CTEC |
| >A> | | | 40MG | A079087 | 007 | Jun 14, 2010 | May | CTEC |

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN

| | | | | | | | | |
|--|---|-----------------|------------------------------------|---------|-----|--------------|-----|------|
| | @ | TEVA PARENTERAL | 10USP UNITS/ML (10USP UNITS/ML) | A077453 | 001 | Jan 24, 2008 | Jan | DISC |
| | @ | | 100USP UNITS/10ML (10USP UNITS/ML) | A077453 | 002 | Jan 24, 2008 | Mar | DISC |

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

| | | | | | | | |
|---|---------------|--------|---------|-----|--------------|-----|------|
| @ | CORDEN PHARMA | 6MG/ML | N020262 | 001 | Dec 29, 1992 | Mar | CAHN |
|---|---------------|--------|---------|-----|--------------|-----|------|

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

| | | | | | | | |
|---|----------|-----------|---------|-----|--------------|-----|------|
| @ | NOVARTIS | 30MG/VIAL | N020036 | 001 | Oct 31, 1991 | Mar | DISC |
|---|----------|-----------|---------|-----|--------------|-----|------|

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

| | | | | | | | |
|--|-------------|--|---------|-----|--------------|-----|------|
| | ABBOTT LABS | 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS | N020725 | 001 | Apr 30, 2009 | Feb | CAHN |
|--|-------------|--|---------|-----|--------------|-----|------|

| | | | | | | | |
|--|--|---|---------|-----|--------------|-----|------|
| | | 60,000USP UNITS;12,000USP UNITS;38,000USP UNITS | N020725 | 002 | Apr 30, 2009 | Feb | CAHN |
|--|--|---|---------|-----|--------------|-----|------|

| | | | | | | | |
|---|--|--|---------|-----|--------------|-----|------|
| + | | 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS | N020725 | 003 | Apr 30, 2009 | Feb | CAHN |
|---|--|--|---------|-----|--------------|-----|------|

>A> PERTZYE

| | | | | | | | |
|-----|--------------------|--|---------|-----|--------------|-----|------|
| >A> | DIGESTIVE CARE INC | 30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS | N022175 | 001 | May 17, 2012 | May | NEWA |
|-----|--------------------|--|---------|-----|--------------|-----|------|

| | | | | | | | |
|-----|---|---|---------|-----|--------------|-----|------|
| >A> | + | 60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS | N022175 | 002 | May 17, 2012 | May | NEWA |
|-----|---|---|---------|-----|--------------|-----|------|

ULTRESA

| | | | | | | | |
|--|-------------------|---|---------|-----|--------------|-----|------|
| | APTALIS PHARMA US | 27,600USP UNITS;13,800USP UNITS;27,600USP UNITS | N022222 | 001 | Mar 01, 2012 | Mar | NEWA |
|--|-------------------|---|---------|-----|--------------|-----|------|

| | | | | | | | |
|--|--|---|---------|-----|--------------|-----|------|
| | | 41,400USP UNITS;20,700USP UNITS;41,400USP UNITS | N022222 | 002 | Mar 01, 2012 | Mar | NEWA |
|--|--|---|---------|-----|--------------|-----|------|

| | | | | | | | |
|---|--|---|---------|-----|--------------|-----|------|
| + | | 46,000USP UNITS;23,000USP UNITS;46,000USP UNITS | N022222 | 003 | Mar 01, 2012 | Mar | NEWA |
|---|--|---|---------|-----|--------------|-----|------|

ZENPEP

| | | | | | | | |
|--|-------------------|--|---------|-----|--------------|-----|------|
| | APTALIS PHARMA US | 16,000USP UNITS;3,000USP UNITS;10,000USP UNITS | N022210 | 005 | Jun 15, 2011 | Apr | NEWA |
|--|-------------------|--|---------|-----|--------------|-----|------|

| | | | | | | | |
|--|--|--|---------|-----|--------------|-----|------|
| | | 109,000USP UNITS;20,000USP UNITS;68,000USP UNITS | N022210 | 004 | Aug 27, 2009 | Apr | CRLD |
|--|--|--|---------|-----|--------------|-----|------|

| | | | | | | | |
|---|--|--|---------|-----|--------------|-----|------|
| + | | 136,000USP UNITS;25,000USP UNITS;85,000USP UNITS | N022210 | 006 | Jul 13, 2011 | Apr | NEWA |
|---|--|--|---------|-----|--------------|-----|------|

TABLET; ORAL

VIOKACE

| | | | | | | | |
|--|-------------------|---|---------|-----|--------------|-----|------|
| | APTALIS PHARMA US | 39,150USP UNITS;10,440USP UNITS;39,150USP UNITS | N022542 | 001 | Mar 01, 2012 | Mar | NEWA |
|--|-------------------|---|---------|-----|--------------|-----|------|

| | | | | | | | |
|---|--|---|---------|-----|--------------|-----|------|
| + | | 78,300USP UNITS;20,880USP UNITS;78,300USP UNITS | N022542 | 002 | Mar 01, 2012 | Mar | NEWA |
|---|--|---|---------|-----|--------------|-----|------|

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

| | | | | | | | |
|----|------------|--------------|---------|-----|--------------|-----|------|
| AB | APOTEX INC | EQ 20MG BASE | A090807 | 001 | May 02, 2012 | Apr | NEWA |
|----|------------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|--------------|---------|-----|--------------|-----|------|
| AB | | EQ 40MG BASE | A090807 | 002 | May 02, 2012 | Apr | NEWA |
|----|--|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|---------------------|--------------|---------|-----|--------------|-----|------|
| AB | MACLEODS PHARMS LTD | EQ 20MG BASE | A200821 | 001 | Feb 16, 2012 | Jan | NEWA |
|----|---------------------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|--------------|---------|-----|--------------|-----|------|
| AB | | EQ 40MG BASE | A200821 | 002 | Feb 16, 2012 | Jan | NEWA |
|----|--|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|------------------|--------------|---------|-----|--------------|-----|------|
| AB | RANBAXY LABS LTD | EQ 20MG BASE | A200794 | 001 | May 02, 2012 | Apr | NEWA |
|----|------------------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|--------------|---------|-----|--------------|-----|------|
| AB | | EQ 40MG BASE | A200794 | 002 | May 02, 2012 | Apr | NEWA |
|----|--|--------------|---------|-----|--------------|-----|------|

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

| | | | | | | | |
|----|-------------------|--------------|---------|-----|--------------|-----|------|
| AB | ACTAVIS ELIZABETH | EQ 10MG BASE | A076968 | 001 | Jun 21, 2010 | Feb | CMFD |
|----|-------------------|--------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|--------------|---------|-----|--------------|-----|------|
| AB | | EQ 20MG BASE | A076968 | 002 | Jun 21, 2010 | Feb | CMFD |
|----|--|--------------|---------|-----|--------------|-----|------|

TABLET; ORALPAROXETINE HYDROCHLORIDE

| | | | | | | |
|----|-------------------|--------------|-------------|--------------|-----|------|
| AB | ACTAVIS ELIZABETH | EQ 30MG BASE | A076968 003 | Jun 21, 2010 | Feb | CMFD |
| AB | | EQ 40MG BASE | A076968 004 | Jun 21, 2010 | Feb | CMFD |

PEGAPTANIB SODIUMINJECTABLE; INTRAVITREALMACUGEN

| | | | | | | | |
|-----|---|--------------------|----------------------|-------------|--------------|-----|------|
| >D> | + | EYETECH INC | EQ 0.3MG ACID/0.09ML | N021756 001 | Dec 17, 2004 | May | CAHN |
| >A> | + | VALEANT PHARMS LLC | EQ 0.3MG ACID/0.09ML | N021756 001 | Dec 17, 2004 | May | CAHN |

PEGINESATIDE ACETATESOLUTION; INTRAVENOUS, SUBCUTANEOUSOMONTYS

| | | | | | | |
|---|---------|------------------------------------|-------------|--------------|-----|------|
| + | AFFYMAX | EQ 10MG BASE/ML (EQ 10MG BASE/ML) | N202799 007 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N202799 008 | Mar 27, 2012 | Mar | NEWA |

OMONTYS PRESERVATIVE FREE

| | | | | | | |
|---|---------|---------------------------------------|-------------|--------------|-----|------|
| + | AFFYMAX | EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | N202799 001 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | N202799 002 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N202799 003 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) | N202799 004 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) | N202799 005 | Mar 27, 2012 | Mar | NEWA |
| + | | EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) | N202799 006 | Mar 27, 2012 | Mar | NEWA |

PENTOBARBITAL SODIUMINJECTABLE; INJECTIONNEMBUTAL SODIUM

| | | | | | | |
|---|------------|---------|-------------|--|-----|------|
| + | OAK PHARMS | 50MG/ML | A083246 001 | | Feb | CAHN |
|---|------------|---------|-------------|--|-----|------|

PERINDOPRIL ERBUMINETABLET; ORALACEON

| | | | | | | |
|----|------|-----|-------------|--------------|-----|------|
| AB | XOMA | 2MG | N020184 001 | Dec 30, 1993 | Jan | CAHN |
| AB | | 4MG | N020184 002 | Dec 30, 1993 | Jan | CAHN |
| AB | + | 8MG | N020184 003 | Dec 30, 1993 | Jan | CAHN |

PERMETHRINCREAM; TOPICALELIMITE

| | | | | | | | | |
|-----|----|---|--------------------|----|-------------|--------------|-----|------|
| >D> | AB | + | ALLERGAN | 5% | N019855 001 | Aug 25, 1989 | May | CAHN |
| >A> | AB | + | RENAISSANCE PHARMA | 5% | N019855 001 | Aug 25, 1989 | May | CAHN |

PHENTERMINE HYDROCHLORIDECAPSULE; ORALPHENTERMINE HYDROCHLORIDE

| | | | | | | |
|----|---------|------|-------------|--------------|-----|------|
| AA | LANNETT | 15MG | A087022 002 | Jan 20, 2012 | Feb | NEWA |
|----|---------|------|-------------|--------------|-----|------|

TABLET; ORALPHENTERMINE HYDROCHLORIDE

| | | | | | | |
|---|------------|------|-------------|--------------|-----|------|
| @ | SANDOZ INC | 30MG | A088605 001 | Sep 28, 1987 | Feb | DISC |
|---|------------|------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORALSUPRENZA

| | | | | | | |
|--|---------------|------|-------------|--------------|-----|------|
| | CITIUS PHARMS | 30MG | N202088 002 | Jun 13, 2011 | Apr | CRLD |
|--|---------------|------|-------------|--------------|-----|------|

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

| | | | | | |
|-----------------|--------|-------------|--------------|-----|------|
| + CITIUS PHARMS | 37.5MG | N202088 003 | Mar 27, 2012 | Apr | CRLD |
| | 37.5MG | N202088 003 | Mar 27, 2012 | Mar | NEWA |

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

| | | | | | |
|------------------------|--------------|-------------|--------------|-----|------|
| + LANNETT HOLDINGS INC | EQ 15MG BASE | A040872 001 | Jul 28, 2011 | Jan | CRLD |
| + | EQ 30MG BASE | A040872 002 | Jul 28, 2011 | Jan | CRLD |

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

| | | | | | |
|----------------------|-----------|-------------|--|-----|------|
| BP + INTL MEDICATION | 1MG/0.5ML | A083722 001 | | Feb | CRLD |
|----------------------|-----------|-------------|--|-----|------|

PINDOLOL

TABLET; ORAL

PINDOLOL

| | | | | | | |
|-----|--------------------|------|-------------|--------------|-----|------|
| >D> | @ GENPHARM | 5MG | A074013 001 | Sep 24, 1992 | May | CAHN |
| >D> | @ | 10MG | A074018 001 | Sep 24, 1992 | May | CAHN |
| >A> | @ MYLAN PHARMS INC | 5MG | A074013 001 | Sep 24, 1992 | May | CAHN |
| >A> | @ | 10MG | A074018 001 | Sep 24, 1992 | May | CAHN |

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

| | | | | | |
|-------------------|--------------|-------------|--------------|-----|------|
| TAKEDA PHARMS USA | EQ 15MG BASE | N021073 001 | Jul 15, 1999 | Mar | CAHN |
| | EQ 30MG BASE | N021073 002 | Jul 15, 1999 | Mar | CAHN |
| + | EQ 45MG BASE | N021073 003 | Jul 15, 1999 | Mar | CAHN |

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

| | | | | | |
|------------------------|-------|-------------|--------------|-----|------|
| @ FUTURE PAK | 10MEQ | A070999 001 | Oct 22, 1987 | Mar | DISC |
| KAON CL-10 | | | | | |
| @ SAVAGE LABS | 10MEQ | N017046 002 | | Mar | DISC |
| KLOR-CON M20 | | | | | |
| AB + UPSHER-SMITH LABS | 20MEQ | A074726 001 | Nov 20, 1998 | Mar | CRLD |
| KLOTRIX | | | | | |
| @ APOTHECON | 10MEQ | N017850 001 | | Mar | DISC |
| POTASSIUM CHLORIDE | | | | | |
| @ NESHER PHARMS | 20MEQ | A076044 001 | Apr 05, 2002 | Mar | DISC |
| @ SCHERING | 10MEQ | N019439 002 | Jun 13, 1986 | Mar | DISC |
| @ | 20MEQ | N019439 001 | Jun 13, 1986 | Mar | DISC |

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

| | | | | | |
|----------|--------------|-------------|--------------|-----|------|
| @ NOVA K | 10MEQ/PACKET | N019647 002 | Oct 13, 1988 | Feb | CAHN |
| @ | 20MEQ/PACKET | N019647 001 | Oct 13, 1988 | Feb | CAHN |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | |
|---------------|---------|-------------|--------------|-----|------|
| AB APOTEX INC | 0.125MG | A090151 001 | Apr 30, 2012 | Apr | NEWA |
|---------------|---------|-------------|--------------|-----|------|

TABLET; ORALPRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | | |
|----|------------|--------|-------------|--------------|-----|------|
| AB | APOTEX INC | 0.25MG | A090151 002 | Apr 30, 2012 | Apr | NEWA |
| AB | | 0.5MG | A090151 003 | Apr 30, 2012 | Apr | NEWA |
| AB | | 0.75MG | A090151 006 | Apr 30, 2012 | Apr | NEWA |
| AB | | 1MG | A090151 004 | Apr 30, 2012 | Apr | NEWA |
| AB | | 1.5MG | A090151 005 | Apr 30, 2012 | Apr | NEWA |

PRAVASTATIN SODIUMTABLET; ORALPRAVASTATIN SODIUM

@ RANBAXY LABS LTD

@

@

@

| | | | | | | |
|--|--|------|-------------|--------------|-----|------|
| | | 10MG | A076445 001 | Apr 23, 2007 | Apr | DISC |
| | | 20MG | A076445 002 | Apr 23, 2007 | Apr | DISC |
| | | 40MG | A076445 003 | Apr 23, 2007 | Apr | DISC |
| | | 80MG | A076445 004 | Apr 23, 2007 | Apr | DISC |

PREDNICARBATECREAM; TOPICALPREDNICARBATE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.1% | A077287 001 | Sep 19, 2006 | Jan | CAHN |
|----|----------------|------|-------------|--------------|-----|------|

OINTMENT; TOPICALPREDNICARBATE

| | | | | | | |
|----|----------------|------|-------------|--------------|-----|------|
| AB | FOUGERA PHARMS | 0.1% | A077236 001 | Mar 09, 2007 | Jan | CAHN |
|----|----------------|------|-------------|--------------|-----|------|

PREGABALINCAPSULE; ORALLYRICA

PF PRISM

| | | | | | | |
|--|---|-------|-------------|--------------|-----|------|
| | | 25MG | N021446 001 | Dec 30, 2004 | Jan | CAHN |
| | | 50MG | N021446 002 | Dec 30, 2004 | Jan | CAHN |
| | | 75MG | N021446 003 | Dec 30, 2004 | Jan | CAHN |
| | | 100MG | N021446 004 | Dec 30, 2004 | Jan | CAHN |
| | | 150MG | N021446 005 | Dec 30, 2004 | Jan | CAHN |
| | | 200MG | N021446 006 | Dec 30, 2004 | Jan | CAHN |
| | | 225MG | N021446 007 | Dec 30, 2004 | Jan | CAHN |
| | + | 300MG | N021446 008 | Dec 30, 2004 | Jan | CAHN |

SOLUTION; ORALLYRICA

| | | | | | | | |
|--|---|----------|---------|-------------|--------------|-----|------|
| | + | PF PRISM | 20MG/ML | N022488 001 | Jan 04, 2010 | Jan | CAHN |
|--|---|----------|---------|-------------|--------------|-----|------|

PRILOCAINE HYDROCHLORIDEINJECTABLE; INJECTIONCITANEST PLAIN DENTAL

| | | | | | | |
|-----|----|---|----------------|----|-------------|----------|
| >D> | | | | | | |
| >D> | AP | + | DENTSPLY PHARM | 4% | N021382 001 | May DISC |
| >A> | | | @ | 4% | N021382 001 | May DISC |

PRILOCAINE HYDROCHLORIDE

| | | | | | | |
|-----|----|---|---------------|----|-------------|-----------------------|
| >D> | AP | | SEPTODONT INC | 4% | A079235 001 | Sep 29, 2010 May CRLD |
| >A> | | + | | 4% | A079235 001 | Sep 29, 2010 May CRLD |

PROGESTERONECAPSULE; ORALPROGESTERONE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | TEVA PHARMS | 100MG | A202121 001 | Feb 29, 2012 | Feb | NEWA |
| AB | | 200MG | A202121 002 | Feb 29, 2012 | Feb | NEWA |

PROMETRIUM

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | ABBOTT LABS | 100MG | N019781 001 | May 14, 1998 | Feb | CFTG |
| AB | + | 200MG | N019781 002 | Oct 15, 1999 | Feb | CFTG |

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

| | | | | | | |
|----|----------------------|---------------|-------------|--------------|-----|------|
| AB | ACCORD HLTHCARE INC | EQ 25MG BASE | A202152 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A202152 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A202152 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A202152 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A202152 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A202152 006 | Mar 27, 2012 | Mar | NEWA |
| AB | APOTEX INC | EQ 25MG BASE | A090960 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A090960 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A090960 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A090960 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A090960 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A090960 006 | Mar 27, 2012 | Mar | NEWA |
| AB | AUROBINDO PHARMA LTD | EQ 25MG BASE | A091388 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A091388 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A091388 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 150MG BASE | A091388 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A091388 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A091388 006 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A091388 007 | Mar 27, 2012 | Mar | NEWA |
| AB | DR REDDYS LABS LTD | EQ 25MG BASE | A077380 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A077380 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A077380 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 150MG BASE | A077380 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A077380 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A077380 006 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A077380 007 | Mar 27, 2012 | Mar | NEWA |
| AB | LUPIN LTD | EQ 25MG BASE | A201109 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A201109 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A201109 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A201109 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A201109 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A201109 006 | Mar 27, 2012 | Mar | NEWA |
| AB | MYLAN PHARMS INC | EQ 25MG BASE | A090323 001 | Mar 27, 2012 | Mar | NEWA |
| AB | ROXANE | EQ 25MG BASE | A090120 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A090749 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A090749 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A090749 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A090749 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A090749 005 | Mar 27, 2012 | Mar | NEWA |
| AB | SUN PHARMA GLOBAL | EQ 25MG BASE | A201190 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A201190 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A201190 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A201190 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A201190 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A201190 006 | Mar 27, 2012 | Mar | NEWA |
| AB | TEVA PHARMS | EQ 25MG BASE | A077745 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 50MG BASE | A077745 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 100MG BASE | A077745 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 150MG BASE | A077745 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 200MG BASE | A077745 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 300MG BASE | A077745 006 | Mar 27, 2012 | Mar | NEWA |
| AB | | EQ 400MG BASE | A077745 007 | Mar 27, 2012 | Mar | NEWA |

TABLET; ORAL

QUETIAPINE FUMARATE

| | | | | | | | |
|----|--|--------------------|---------------|-------------|--------------|-----|------|
| AB | | TORRENT PHARMS LTD | EQ 25MG BASE | A200363 001 | Mar 27, 2012 | Mar | NEWA |
| AB | | | EQ 50MG BASE | A200363 002 | Mar 27, 2012 | Mar | NEWA |
| AB | | | EQ 100MG BASE | A200363 003 | Mar 27, 2012 | Mar | NEWA |
| AB | | | EQ 200MG BASE | A200363 004 | Mar 27, 2012 | Mar | NEWA |
| AB | | | EQ 300MG BASE | A200363 005 | Mar 27, 2012 | Mar | NEWA |
| AB | | | EQ 400MG BASE | A200363 006 | Mar 27, 2012 | Mar | NEWA |

SEROQUEL

| | | | | | | | |
|----|---|-------------|---------------|-------------|--------------|-----|------|
| AB | + | ASTRAZENECA | EQ 25MG BASE | N020639 001 | Sep 26, 1997 | Mar | CFTG |
| AB | | | EQ 50MG BASE | N020639 007 | Oct 04, 2005 | Mar | CFTG |
| AB | | | EQ 100MG BASE | N020639 002 | Sep 26, 1997 | Mar | CFTG |
| AB | | | EQ 200MG BASE | N020639 003 | Sep 26, 1997 | Mar | CFTG |
| AB | + | | EQ 300MG BASE | N020639 005 | Jul 26, 2000 | Mar | CFTG |
| AB | | | EQ 400MG BASE | N020639 006 | Oct 04, 2005 | Mar | CFTG |

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

| | | | | | | | |
|--|--|--------------------|------|-------------|--------------|-----|------|
| | | @ RANBAXY LABS LTD | 5MG | A078849 001 | Mar 06, 2009 | Apr | DISC |
| | | @ | 10MG | A078849 002 | Mar 06, 2009 | Apr | DISC |

TABLET; ORAL

ALTACE

| | | | | | | | |
|--|--|---------------|--------|-------------|--------------|-----|------|
| | | @ KING PFIZER | 1.25MG | N022021 001 | Feb 27, 2007 | Jan | DISC |
| | | @ | 2.5MG | N022021 002 | Feb 27, 2007 | Jan | DISC |
| | | @ | 5MG | N022021 003 | Feb 27, 2007 | Jan | DISC |
| | | @ | 10MG | N022021 004 | Feb 27, 2007 | Jan | DISC |

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

| | | | | | | | |
|----|---|-----------------------------|--------------------|-------------|--------------|-----|------|
| AP | + | COVIS PHARMA | EQ 25MG BASE/ML | N019090 001 | Oct 19, 1984 | Mar | CAHN |
| | | ZANTAC IN PLASTIC CONTAINER | | | | | |
| | + | COVIS PHARMA | EQ 1MG BASE/ML | N019593 002 | Sep 27, 1991 | Mar | CAHN |
| | | @ | EQ 50MG BASE/100ML | N019593 001 | Dec 17, 1986 | Mar | CAHN |

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

| | | | | | | | |
|----|--|-------------|-------|-------------|--|-----|------|
| AB | | PROSAM LABS | 300MG | N050429 001 | | Feb | CMFD |
|----|--|-------------|-------|-------------|--|-----|------|

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

| | | | | | | | |
|--|---|---------------|--------------|-------------|--------------|-----|------|
| | + | JANSSEN PRODS | EQ 25MG BASE | N202022 001 | May 20, 2011 | Feb | CAHN |
|--|---|---------------|--------------|-------------|--------------|-----|------|

RISPERIDONE

TABLET; ORAL

RISPERIDONE

| | | | | | | | |
|----|--|-------------|--------|-------------|--------------|-----|------|
| AB | | PROSAM LABS | 0.25MG | A078071 001 | Jun 17, 2009 | Feb | CMFD |
| AB | | | 0.5MG | A078071 002 | Jun 17, 2009 | Feb | CMFD |
| AB | | | 1MG | A078071 003 | Jun 17, 2009 | Feb | CMFD |
| AB | | | 2MG | A078071 004 | Jun 17, 2009 | Feb | CMFD |
| AB | | | 3MG | A078071 005 | Jun 17, 2009 | Feb | CMFD |
| AB | | | 4MG | A078071 006 | Jun 17, 2009 | Feb | CMFD |

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

| | | | | | | |
|----|------|-------|-------------|--------------|-----|------|
| AB | TEVA | 0.5MG | A076908 001 | Mar 12, 2012 | Feb | NEWA |
| AB | | 1MG | A076908 002 | Mar 12, 2012 | Feb | NEWA |
| AB | | 2MG | A076908 003 | Mar 12, 2012 | Feb | NEWA |

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

| | | | | | | | |
|-----|----|--------------------|---------------|-------------|--------------|-----|------|
| >A> | AB | ALEMBIC PHARMS LTD | EQ 1.5MG BASE | A091689 001 | Jun 12, 2012 | May | NEWA |
| >A> | AB | | EQ 3MG BASE | A091689 002 | Jun 12, 2012 | May | NEWA |
| >A> | AB | | EQ 4.5MG BASE | A091689 003 | Jun 12, 2012 | May | NEWA |
| >A> | AB | | EQ 6MG BASE | A091689 004 | Jun 12, 2012 | May | NEWA |

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

| | | | | | | |
|----|--------|----------------|-------------|--------------|-----|------|
| AB | APOTEX | EQ 0.25MG BASE | A079165 001 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 0.5MG BASE | A079165 002 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 1MG BASE | A079165 003 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 2MG BASE | A079165 004 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 3MG BASE | A079165 005 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 4MG BASE | A079165 006 | Feb 07, 2012 | Jan | NEWA |
| AB | | EQ 5MG BASE | A079165 007 | Feb 07, 2012 | Jan | NEWA |

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

| | | | | | | | |
|----|---|--------------------|--------------|-------------|--------------|-----|------|
| AB | + | SMITHKLINE BEECHAM | EQ 2MG BASE | N022008 001 | Jun 13, 2008 | Apr | CFTG |
| AB | | | EQ 4MG BASE | N022008 003 | Jun 13, 2008 | Apr | CFTG |
| AB | | | EQ 6MG BASE | N022008 006 | Apr 10, 2009 | Apr | CFTG |
| AB | | | EQ 8MG BASE | N022008 004 | Jun 13, 2008 | Apr | CFTG |
| AB | | | EQ 12MG BASE | N022008 005 | Oct 31, 2008 | Apr | CFTG |

ROPINIROLE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------------|--------------|-------------|--------------|-----|------|
| AB | | ACTAVIS | EQ 2MG BASE | A090869 001 | May 17, 2012 | Apr | NEWA |
| AB | | | EQ 4MG BASE | A090869 002 | May 17, 2012 | Apr | NEWA |
| AB | | | EQ 6MG BASE | A090869 003 | May 17, 2012 | Apr | NEWA |
| AB | | | EQ 8MG BASE | A090869 004 | May 17, 2012 | Apr | NEWA |
| AB | | | EQ 12MG BASE | A090869 005 | May 17, 2012 | Apr | NEWA |
| >A> | AB | DR REDDYS LABS LTD | EQ 2MG BASE | A201576 001 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 4MG BASE | A201576 002 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 6MG BASE | A201576 003 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 8MG BASE | A201576 004 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 12MG BASE | A201576 005 | Jun 06, 2012 | May | NEWA |
| >A> | AB | SANDOZ INC | EQ 2MG BASE | A201047 001 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 4MG BASE | A201047 003 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 6MG BASE | A201047 004 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 8MG BASE | A201047 005 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 12MG BASE | A201047 006 | Jun 06, 2012 | May | NEWA |
| >A> | AB | WATSON LABS INC | EQ 2MG BASE | A200431 001 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 4MG BASE | A200431 002 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 6MG BASE | A200431 003 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 8MG BASE | A200431 004 | Jun 06, 2012 | May | NEWA |
| >A> | AB | | EQ 12MG BASE | A200431 005 | Jun 06, 2012 | May | NEWA |

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

| | | | | | | |
|---|---------|----------|-------------|--------------|-----|------|
| | UCB INC | 1MG/24HR | N021829 004 | Apr 02, 2012 | Apr | NEWA |
| | | 2MG/24HR | N021829 001 | May 09, 2007 | Apr | CMFD |
| | | 3MG/24HR | N021829 005 | Apr 02, 2012 | Apr | NEWA |
| | | 4MG/24HR | N021829 002 | May 09, 2007 | Apr | CMFD |
| | | 6MG/24HR | N021829 003 | May 09, 2007 | Apr | CMFD |
| + | | 8MG/24HR | N021829 006 | Apr 02, 2012 | Apr | NEWA |

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

| | | | | | | |
|---|--------------|----|-------------|--------------|-----|------|
| + | VALEANT INTL | 2% | N021385 001 | Dec 10, 2003 | Jan | CAHN |
|---|--------------|----|-------------|--------------|-----|------|

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

| | | | | | | |
|----|-------------|---------------|-------------|--------------|-----|------|
| AB | PROSAM LABS | EQ 25MG BASE | A078175 001 | Jul 21, 2010 | Feb | CMFD |
| AB | | EQ 50MG BASE | A078175 002 | Jul 21, 2010 | Feb | CMFD |
| AB | | EQ 100MG BASE | A078175 003 | Jul 21, 2010 | Feb | CMFD |

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

| | | | | | | |
|----|-------------|------|-------------|--------------|-----|------|
| AB | PROSAM LABS | 5MG | A078735 001 | Aug 30, 2010 | Feb | CMFD |
| AB | | 10MG | A078735 002 | Aug 30, 2010 | Feb | CMFD |
| AB | | 20MG | A078735 003 | Aug 30, 2010 | Feb | CMFD |
| AB | | 40MG | A078735 004 | Aug 30, 2010 | Feb | CMFD |
| AB | | 80MG | A078735 005 | Aug 30, 2010 | Feb | CMFD |

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

| | | | | | | |
|-----|-------------------|---------------|-------------|--------------|-----|------|
| >D> | MERCK CO INC | EQ 25MG BASE | N021995 001 | Oct 16, 2006 | May | CAHN |
| >D> | | EQ 50MG BASE | N021995 002 | Oct 16, 2006 | May | CAHN |
| >D> | + | EQ 100MG BASE | N021995 003 | Oct 16, 2006 | May | CAHN |
| >A> | MERCK SHARP DOHME | EQ 25MG BASE | N021995 001 | Oct 16, 2006 | May | CAHN |
| >A> | | EQ 50MG BASE | N021995 002 | Oct 16, 2006 | May | CAHN |
| >A> | + | EQ 100MG BASE | N021995 003 | Oct 16, 2006 | May | CAHN |

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

| | | | | | | |
|--|--------------------|--------------------|-------------|--------------|-----|------|
| | @ MALLINCKRODT INC | 460MG/GM; 420MG/GM | N018509 001 | Aug 07, 1985 | Jan | CAHN |
|--|--------------------|--------------------|-------------|--------------|-----|------|

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

| | | | | | | |
|----|---|--------|-------------|--------------|-----|------|
| AP | HIKMA (MAPLE) | 9MG/ML | A201850 001 | Jan 20, 2012 | Jan | NEWA |
| | SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | MEDEFIL | 9MG/ML | N202832 001 | Jan 06, 2012 | Jan | NEWA |

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

| | | | | | | | |
|-----|----|--------------|------------|-------------|--------------|-----|------|
| >D> | AB | GENERAMEDIX | 62.5MG/5ML | A078215 001 | Mar 31, 2011 | May | CAHN |
| >A> | AB | HIKMA PHARMS | 62.5MG/5ML | A078215 001 | Mar 31, 2011 | May | CAHN |

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

| | | | | | | | | |
|-----|----|---|---------------|--------|-------------|--|-----|------|
| >D> | AA | + | GE HEALTHCARE | 100uCi | N017630 001 | | May | DISC |
| >A> | | | @ | 100uCi | N017630 001 | | May | DISC |

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

@

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS 12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

| | | | | | | | |
|-----|---|-------------|------|-------------|--------------|-----|------|
| >A> | + | PARAPRO LLC | 0.9% | N022408 001 | Jan 18, 2011 | May | CAHN |
|-----|---|-------------|------|-------------|--------------|-----|------|

| | | | | | | | |
|-----|---|----------------|------|-------------|--------------|-----|------|
| >D> | + | PARAPRO PHARMS | 0.9% | N022408 001 | Jan 18, 2011 | May | CAHN |
|-----|---|----------------|------|-------------|--------------|-----|------|

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC 100MG

N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB FOUGERA PHARMS 10%

A077015 001 Nov 17, 2006 Jan CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+ JAZZ PHARMS COMMERCL 15%

N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY; VAGINAL

AVC

@ JAZZ PHARMS COMMERCL 1.05GM

N006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090310 001 Aug 11, 2010 Mar CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ MERCK SHARP DOHME 0.0015%

N202514 001 Feb 10, 2012 Feb NEWA

>A> TALIGLUCERASE ALFA

>A> POWDER; IV (INFUSION)

>A> ELELYSO

>A> + PFIZER 200 UNITS/VIAL

N022458 001 May 01, 2012 May NEWA

TAZAROTENE

>A> AEROSOL, FOAM; TOPICAL

>A> FABIOR

>A> + STIEFEL LABS INC 0.1%

N202428 001 May 11, 2012 May NEWA

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

>D> @ DRAXIMAGE N/A

N018035 001 May CAHN

>A> @ JUBILANT DRAXIMAGE N/A

N018035 001 May CAHN

DRAXIMAGE MDP-25

>D> + DRAXIMAGE N/A

N018035 002 Feb 27, 2004 May CAHN

>A> + JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004 May CAHN

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL

N022577 001 Jan 18, 2012 Jan NEWA

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC 150MG

N021356 002 Jan 18, 2012 Apr NEWA

200MG

N021356 003 Jan 18, 2012 Apr NEWA

250MG

N021356 004 Jan 18, 2012 Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 1MG BASE

A076021 001 Aug 22, 2002 Apr DISC

@ EQ 2MG BASE

A076021 002 Aug 22, 2002 Apr DISC

@ EQ 5MG BASE

A076021 003 Aug 22, 2002 Apr DISC

@ EQ 10MG BASE

A076021 004 Aug 22, 2002 Apr DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PARENTERAL 1MG/ML

A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

| | | | | | | | | |
|----|----------------------|------|---------|-----|--------------|-----|------|--|
| | CREAM; VAGINAL | | | | | | | |
| | TERCONAZOLE | | | | | | | |
| AB | FOUGERA PHARMS | 0.4% | A076712 | 001 | Feb 18, 2005 | Jan | CAHN | |
| | SUPPOSITORY; VAGINAL | | | | | | | |
| | TERCONAZOLE | | | | | | | |
| AB | FOUGERA PHARMS | 80MG | A076850 | 001 | Jul 12, 2006 | Jan | CAHN | |

TESAMORELIN ACETATE

| | | | | | | | | |
|-----|----------------------|-------------------|------------------|---------|-----|--------------|-----|------|
| | POWDER; SUBCUTANEOUS | | | | | | | |
| | EGRIFTA | | | | | | | |
| >A> | + | EMD SERONO | EQ 1MG BASE/VIAL | N022505 | 001 | Nov 10, 2010 | May | CAHN |
| >D> | + | THERATECHNOLOGIES | EQ 1MG BASE/VIAL | N022505 | 001 | Nov 10, 2010 | May | CAHN |

TESTOSTERONE

| | | | | | | | | |
|-----|----------------------|-----------------|------------------------|---------|-----|--------------|-----|------|
| | GEL; TRANSDERMAL | | | | | | | |
| | ANDROGEL | | | | | | | |
| | ABBOTT LABS | | 1% (25MG/2.5GM PACKET) | N021015 | 001 | Feb 28, 2000 | Feb | CPOT |
| BX | + | | 1% (50MG/5GM PACKET) | N021015 | 002 | Feb 28, 2000 | Feb | CPOT |
| | TESTIM | | | | | | | |
| BX | + | AUXILIUM PHARMS | 1% (50MG/5GM PACKET) | N021454 | 001 | Oct 31, 2002 | Feb | CPOT |
| | TESTOSTERONE | | | | | | | |
| | TEVA PHARMS | | 25MG/2.5GM PACKET | N202763 | 001 | Feb 14, 2012 | Feb | NEWA |
| | | | 50MG/5GM PACKET | N202763 | 002 | Feb 14, 2012 | Feb | NEWA |
| | PELLET; IMPLANTATION | | | | | | | |
| | TESTOPEL | | | | | | | |
| >A> | + | ACTIENT PHARMS | 75MG | A080911 | 001 | | May | CAHN |
| >D> | + | SLATE PHARMS | 75MG | A080911 | 001 | | May | CAHN |

TESTOSTERONE CYPIONATE

| | | | | | | | | |
|----|------------------------|----------|---------|-----|--------------|-----|------|--|
| | INJECTABLE; INJECTION | | | | | | | |
| | TESTOSTERONE CYPIONATE | | | | | | | |
| AO | HIKMA FARMACEUTICA | 200MG/ML | A091244 | 001 | May 01, 2012 | Apr | NEWA | |
| AO | MYLAN INSTITUTIONAL | 200MG/ML | A040652 | 001 | Dec 11, 2006 | Feb | CAHN | |

TESTOSTERONE ENANTHATE

| | | | | | | | | |
|----|------------------------|----------|---------|-----|--------------|-----|------|--|
| | INJECTABLE; INJECTION | | | | | | | |
| | TESTOSTERONE ENANTHATE | | | | | | | |
| AO | MYLAN INSTITUTIONAL | 200MG/ML | A040647 | 001 | Oct 05, 2009 | Feb | CAHN | |

TETRABENAZINE

| | | | | | | | | |
|--|----------------|--|--------|---------|-----|--------------|-----|------|
| | TABLET; ORAL | | | | | | | |
| | XENAZINE | | | | | | | |
| | VALEANT PHARMS | | 12.5MG | N021894 | 001 | Aug 15, 2008 | Apr | CAHN |
| | + | | 25MG | N021894 | 002 | Aug 15, 2008 | Apr | CAHN |

TETRAHYDROZOLINE HYDROCHLORIDE

| | | | | | | | | |
|--|-----------------|--|-------|---------|-----|--|-----|------|
| | SOLUTION; NASAL | | | | | | | |
| | TYZINE | | | | | | | |
| | FOUGERA PHARMS | | 0.05% | A086576 | 002 | | Jan | CAHN |
| | | | 0.1% | A086576 | 001 | | Jan | CAHN |
| | SPRAY; NASAL | | | | | | | |
| | TYZINE | | | | | | | |
| | FOUGERA PHARMS | | 0.1% | A086576 | 003 | | Jan | CAHN |

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

| | | | | | | | |
|-----|----|--------------|-------|-------------|--------------|-----|------|
| >D> | BC | UCB INC | 100MG | A087942 001 | Aug 22, 1983 | May | CTEC |
| >A> | | | 100MG | A087942 001 | Aug 22, 1983 | May | CTEC |
| >D> | BC | | 200MG | A087943 001 | Aug 22, 1983 | May | CTEC |
| >A> | | | 200MG | A087943 001 | Aug 22, 1983 | May | CTEC |
| >D> | BC | | 300MG | A087944 001 | Aug 22, 1983 | May | CTEC |
| >A> | | | 300MG | A087944 001 | Aug 22, 1983 | May | CTEC |
| >D> | | | 400MG | A081034 001 | Feb 28, 1992 | May | CRLD |
| >A> | + | | 400MG | A081034 001 | Feb 28, 1992 | May | CRLD |
| >D> | | THEOPHYLLINE | | | | | |
| >D> | BC | INWOOD LABS | 100MG | A040052 001 | Feb 14, 1994 | May | DISC |
| >A> | @ | | 100MG | A040052 001 | Feb 14, 1994 | May | DISC |
| >D> | | | 125MG | A040052 002 | Feb 14, 1994 | May | DISC |
| >A> | @ | | 125MG | A040052 002 | Feb 14, 1994 | May | DISC |
| >D> | BC | | 200MG | A040052 003 | Feb 14, 1994 | May | DISC |
| >A> | @ | | 200MG | A040052 003 | Feb 14, 1994 | May | DISC |
| >D> | BC | + | 300MG | A040052 004 | Feb 14, 1994 | May | DISC |
| >A> | @ | | 300MG | A040052 004 | Feb 14, 1994 | May | DISC |

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | |
|---|-----------------|-------------|-------------|--------------|-----|------|
| @ | BAXTER HLTHCARE | 4MG/ML | N018649 007 | Jul 26, 1982 | Mar | DISC |
| @ | | 40MG/100ML | N018649 001 | Jul 26, 1982 | Mar | DISC |
| @ | | 80MG/100ML | N018649 002 | Jul 26, 1982 | Mar | DISC |
| @ | | 160MG/100ML | N018649 003 | Jul 26, 1982 | Mar | DISC |
| @ | | 200MG/100ML | N018649 004 | Jul 26, 1982 | Mar | DISC |
| @ | | 320MG/100ML | N018649 006 | Nov 13, 1985 | Mar | DISC |
| @ | | 400MG/100ML | N018649 005 | Jul 26, 1982 | Mar | DISC |

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

| | | | | | | |
|---|----------|------|-------------|--------------|-----|------|
| @ | CEPHALON | 6MG | N020646 006 | Nov 29, 2005 | Jan | DISC |
| @ | | 8MG | N020646 007 | Nov 29, 2005 | Jan | DISC |
| @ | | 10MG | N020646 008 | Nov 29, 2005 | Jan | DISC |

TINIDAZOLE

TABLET; ORAL

TINDAMAX

| | | | | | | |
|----|----------------|-------|-------------|--------------|-----|------|
| AB | MISSION PHARMA | 250MG | N021618 001 | May 17, 2004 | Apr | CFTG |
| AB | + | 500MG | N021618 002 | May 17, 2004 | Apr | CFTG |
| | TINIDAZOLE | | | | | |
| AB | NOVEL LABS INC | 250MG | A202044 001 | Apr 30, 2012 | Apr | NEWA |
| AB | | 500MG | A202044 002 | Apr 30, 2012 | Apr | NEWA |
| AB | ROXANE | 250MG | A201172 001 | Apr 30, 2012 | Apr | NEWA |
| AB | | 500MG | A201172 002 | Apr 30, 2012 | Apr | NEWA |

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

| | | | | | | |
|----|------------|-------------|-------------|--------------|-----|------|
| AB | APOTEX INC | EQ 2MG BASE | A078868 001 | Feb 03, 2012 | Jan | NEWA |
| AB | | EQ 4MG BASE | A078868 002 | Feb 03, 2012 | Jan | NEWA |
| AB | | EQ 6MG BASE | A078868 003 | Feb 03, 2012 | Jan | NEWA |

CAPSULE; ORALZANAFLEX

| | | | | | | |
|----|--------|-------------|-------------|--------------|-----|------|
| AB | ACORDA | EQ 2MG BASE | N021447 001 | Aug 29, 2002 | Jan | CFTG |
| AB | | EQ 4MG BASE | N021447 002 | Aug 29, 2002 | Jan | CFTG |
| AB | + | EQ 6MG BASE | N021447 003 | Aug 29, 2002 | Jan | CFTG |

TABLET; ORALTIZANIDINE HYDROCHLORIDE

| | | | | | | |
|----|-------------|-------------|-------------|--------------|-----|------|
| AB | PROSAM LABS | EQ 2MG BASE | A076281 001 | Oct 20, 2003 | Feb | CMFD |
| AB | | EQ 4MG BASE | A076281 002 | Oct 20, 2003 | Feb | CMFD |
| AB | SANDOZ INC | EQ 2MG BASE | A076280 001 | Nov 26, 2002 | Feb | NEWA |

TOLBUTAMIDETABLET; ORALTOLBUTAMIDE

| | | | | | | |
|---|------------------|-------|-------------|--|-----|------|
| + | MYLAN PHARMS INC | 500MG | A086445 001 | | Mar | CRLD |
| | @ WATSON LABS | 500MG | A086109 001 | | Mar | DISC |
| | @ | 500MG | A087318 001 | | Mar | DISC |

TOLCAPONETABLET; ORALTASMAR

| | | | | | | | |
|-----|---|--------------------|-------|-------------|--------------|-----|------|
| >D> | + | VALEANT PHARM INTL | 100MG | N020697 001 | Jan 29, 1998 | May | CAHN |
| >D> | | @ | 200MG | N020697 002 | Jan 29, 1998 | May | CAHN |
| >A> | + | VALEANT PHARMS LLC | 100MG | N020697 001 | Jan 29, 1998 | May | CAHN |
| >A> | | @ | 200MG | N020697 002 | Jan 29, 1998 | May | CAHN |

TRAMADOL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORALRYBIX ODT

| | | | | | | |
|---|--------------|------|-------------|--------------|-----|------|
| + | SHIONOGI INC | 50MG | N021693 001 | May 05, 2005 | Mar | CTNA |
|---|--------------|------|-------------|--------------|-----|------|

TRANEXAMIC ACIDINJECTABLE; INJECTIONTRANEXAMIC ACID

| | | | | | | | |
|-----|----|----------------|----------|-------------|--------------|-----|------|
| >A> | AP | APP PHARMS LLC | 100MG/ML | A091596 001 | Mar 02, 2012 | May | CAHN |
| >D> | AP | NEXUS PHARMS | 100MG/ML | A091596 001 | Mar 02, 2012 | May | CAHN |
| | AP | | 100MG/ML | A091596 001 | Mar 02, 2012 | Feb | NEWA |

TRANLYCYPROMINE SULFATETABLET; ORALPARNATE

| | | | | | | | |
|----|---|--------------|--------------|-------------|--------------|-----|------|
| AB | + | COVIS PHARMA | EQ 10MG BASE | N012342 003 | Aug 16, 1985 | Jan | CAHN |
|----|---|--------------|--------------|-------------|--------------|-----|------|

TRETINOINCREAM; TOPICALRENOVA

| | | | | | | | |
|-----|---|--------------|-------|-------------|--------------|-----|------|
| | + | VALEANT INTL | 0.02% | N021108 001 | Aug 31, 2000 | Jan | CAHN |
| AB2 | + | | 0.05% | N019963 001 | Dec 29, 1995 | Jan | CAHN |

RETIN-A

| | | | | | | | |
|-----|---|--------------|--------|-------------|--------------|-----|------|
| AB | + | VALEANT INTL | 0.025% | N019049 001 | Sep 16, 1988 | Jan | CAHN |
| AB1 | + | | 0.05% | N017522 001 | | Jan | CAHN |
| AB | + | | 0.1% | N017340 001 | | Jan | CAHN |

TRETINOIN

| | | | | | | | |
|-----|-----|------------------|---------|-------------|--------------|-----|------|
| >A> | AB | PRECISION DERMAT | 0.025% | A075264 001 | Dec 24, 1998 | May | CAHN |
| >A> | | + | 0.0375% | A090098 001 | Mar 22, 2010 | May | CAHN |
| >A> | AB1 | | 0.05% | A075265 001 | Dec 24, 1998 | May | CAHN |

CREAM; TOPICAL

TRETINOIN

| | | | | | | | |
|-----|-----|------------------|---------|-------------|--------------|-----|------|
| >A> | AB | PRECISION DERMAT | 0.1% | A075213 001 | Dec 24, 1998 | May | CAHN |
| >D> | AB2 | SPEAR PHARMS | 0.05% | A076498 001 | Sep 15, 2005 | May | CAHN |
| >A> | AB2 | SUNEVA MEDCL | 0.05% | A076498 001 | Sep 15, 2005 | May | CAHN |
| >D> | AB | TRIAx PHARMS LLC | 0.025% | A075264 001 | Dec 24, 1998 | May | CAHN |
| >D> | + | | 0.0375% | A090098 001 | Mar 22, 2010 | May | CAHN |
| >D> | AB1 | | 0.05% | A075265 001 | Dec 24, 1998 | May | CAHN |
| >D> | AB | | 0.1% | A075213 001 | Dec 24, 1998 | May | CAHN |

GEL; TOPICAL

RETIN-A

| | | | | | | | |
|--|----|----------------|--------|-------------|--|-----|------|
| | AB | + VALEANT INTL | 0.01% | N017955 001 | | Jan | CAHN |
| | AB | + | 0.025% | N017579 002 | | Jan | CAHN |

TRETINOIN

| | | | | | | | |
|-----|----|------------------|--------|-------------|--------------|-----|------|
| >A> | AB | PRECISION DERMAT | 0.01% | A075589 001 | Jun 11, 2002 | May | CAHN |
| >A> | AB | | 0.025% | A075529 001 | Feb 22, 2000 | May | CAHN |
| >D> | AB | TRIAx PHARMS LLC | 0.01% | A075589 001 | Jun 11, 2002 | May | CAHN |
| >D> | AB | | 0.025% | A075529 001 | Feb 22, 2000 | May | CAHN |

SOLUTION; TOPICAL

RETIN-A

| | | | | | | | |
|----|---|--------------|-------|-------------|--|-----|------|
| AT | + | VALEANT INTL | 0.05% | N016921 001 | | Jan | CAHN |
|----|---|--------------|-------|-------------|--|-----|------|

SWAB; TOPICAL

RETIN-A

| | | | | | | | |
|--|---|--------------|-------|-------------|--|-----|------|
| | @ | VALEANT INTL | 0.05% | N016921 002 | | Jan | CAHN |
|--|---|--------------|-------|-------------|--|-----|------|

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

| | | | | | | | |
|-----|---|----------|-----------|-------------|--------------|-----|------|
| >D> | | AZMACORT | | | | | |
| >D> | + | ABBOTT | 0.1MG/INH | N018117 001 | Apr 23, 1982 | May | DISC |
| >A> | @ | | 0.1MG/INH | N018117 001 | Apr 23, 1982 | May | DISC |

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | |
|----|---|----------------|--------|-------------|--|-----|------|
| AT | | FOUGERA PHARMS | 0.025% | A085692 001 | | Jan | CAHN |
| AT | | | 0.1% | A085692 003 | | Jan | CAHN |
| AT | + | | 0.5% | A085692 002 | | Jan | CAHN |

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | |
|----|--|----------------|--------|-------------|--------------|-----|------|
| AT | | FOUGERA PHARMS | 0.025% | A040467 001 | Apr 21, 2003 | Jan | CAHN |
| AT | | | 0.1% | A040467 002 | Apr 21, 2003 | Jan | CAHN |

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | |
|----|--|----------------|--------|-------------|--|-----|------|
| AT | | FOUGERA PHARMS | 0.025% | A085691 001 | | Jan | CAHN |
| AT | | | 0.1% | A085691 003 | | Jan | CAHN |
| AT | | | 0.5% | A085691 002 | | Jan | CAHN |

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

| | | | | | | | |
|----|--|-------------|---------------|-------------|--------------|-----|------|
| AB | | TEVA PHARMS | 0.055MG/SPRAY | A078104 001 | Jul 30, 2009 | Mar | CAHN |
|----|--|-------------|---------------|-------------|--------------|-----|------|

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

| | | | | | | | |
|----|--|--------------------|---------------|-------------|--------------|-----|------|
| AB | | JUBILANT ORGANOSYS | EQ 500MG BASE | A201506 001 | Apr 03, 2012 | Mar | NEWA |
| AB | | | EQ 1GM BASE | A201506 002 | Apr 03, 2012 | Mar | NEWA |

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

| | | | | | | | |
|-----|---|-------------------|---------|-------------|--------------|-----|------|
| >A> | + | HOFFMANN LA ROCHE | 50MG/ML | N022257 001 | Aug 28, 2009 | May | CAHN |
| >D> | + | ROCHE PALO | 50MG/ML | N022257 001 | Aug 28, 2009 | May | CAHN |

TABLET; ORAL

VALCYTE

| | | | | | | | |
|-----|---|-------------------|---------------|-------------|--------------|-----|------|
| >A> | + | HOFFMANN LA ROCHE | EQ 450MG BASE | N021304 001 | Mar 29, 2001 | May | CAHN |
| >D> | + | ROCHE PALO | EQ 450MG BASE | N021304 001 | Mar 29, 2001 | May | CAHN |

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

| | | | | | | | |
|----|---|------------|---------------|-------------|--------------|-----|------|
| AB | | VIROPHARMA | EQ 125MG BASE | N050606 001 | Apr 15, 1986 | Mar | CFTG |
| AB | + | | EQ 250MG BASE | N050606 002 | Apr 15, 1986 | Mar | CFTG |

VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|----|--|---------------------|---------------|-------------|--------------|-----|------|
| AB | | AKORN | EQ 125MG BASE | A065478 001 | Apr 09, 2012 | Mar | NEWA |
| AB | | | EQ 250MG BASE | A065478 002 | Apr 09, 2012 | Mar | NEWA |
| AB | | STRIDES ARCOLAB LTD | EQ 125MG BASE | A065490 001 | Apr 09, 2012 | Mar | NEWA |
| AB | | | EQ 250MG BASE | A065490 002 | Apr 09, 2012 | Mar | NEWA |
| AB | | WATSON LABS | EQ 125MG BASE | A065510 001 | Apr 09, 2012 | Mar | NEWA |
| AB | | | EQ 250MG BASE | A065510 002 | Apr 09, 2012 | Mar | NEWA |

VANDETANIB

TABLET; ORAL

CAPRELSA

| | | | | | | | |
|--|---|----------------|-------|-------------|--------------|-----|------|
| | | IPR PHARMS INC | 100MG | N022405 001 | Apr 06, 2011 | Feb | CTNA |
| | + | | 300MG | N022405 002 | Apr 06, 2011 | Feb | CTNA |

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

| | | | | | | | |
|----|---|----------------|-------|-------------|--------------|-----|------|
| AB | | BAYER HLTHCARE | 2.5MG | N021400 003 | Aug 19, 2003 | Apr | CFTG |
| AB | | | 5MG | N021400 001 | Aug 19, 2003 | Apr | CFTG |
| AB | | | 10MG | N021400 002 | Aug 19, 2003 | Apr | CFTG |
| AB | + | | 20MG | N021400 004 | Aug 19, 2003 | Apr | CFTG |

VARDENAFIL HYDROCHLORIDE

| | | | | | | | |
|----|--|-------------|-------|-------------|--------------|-----|------|
| AB | | TEVA PHARMS | 2.5MG | A091347 001 | May 03, 2012 | Apr | NEWA |
| AB | | | 5MG | A091347 002 | May 03, 2012 | Apr | NEWA |
| AB | | | 10MG | A091347 003 | May 03, 2012 | Apr | NEWA |
| AB | | | 20MG | A091347 004 | May 03, 2012 | Apr | NEWA |

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

| | | | | | | | |
|----|--|---------------|----------------|-------------|--------------|-----|------|
| AB | | ANCHEN PHARMS | EQ 37.5MG BASE | A078087 001 | Mar 16, 2012 | Mar | NEWA |
| AB | | | EQ 75MG BASE | A078087 002 | Mar 16, 2012 | Mar | NEWA |
| AB | | | EQ 150MG BASE | A078087 003 | Mar 16, 2012 | Mar | NEWA |

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

| | | | | | | | |
|----|---|--------|-------|-------------|--------------|-----|------|
| AB | + | PFIZER | 120MG | N019152 003 | Mar 06, 1991 | Feb | CTNA |
| AB | + | | 180MG | N019152 002 | Dec 15, 1989 | Feb | CTNA |
| AB | + | | 240MG | N019152 001 | Dec 16, 1986 | Feb | CTNA |

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | APOTEX CORP | 120MG | A200878 001 | Apr 20, 2012 | Apr | NEWA |
| AB | | 180MG | A200878 002 | Apr 20, 2012 | Apr | NEWA |
| AB | | 240MG | A200878 003 | Apr 20, 2012 | Apr | NEWA |

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

| | | | | | | |
|---|--------------|--------------|-------------|--------------|-----|------|
| + | LUNDBECK LLC | 500MG/PACKET | N022006 001 | Aug 21, 2009 | Apr | CAHN |
|---|--------------|--------------|-------------|--------------|-----|------|

TABLET; ORAL

SABRIL

| | | | | | | |
|---|--------------|-------|-------------|--------------|-----|------|
| + | LUNDBECK LLC | 500MG | N020427 001 | Aug 21, 2009 | Apr | CAHN |
|---|--------------|-------|-------------|--------------|-----|------|

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VLIBRYD

| | | | | | | |
|---|-----------------|------|-------------|--------------|-----|------|
| + | FOREST LABS INC | 10MG | N022567 001 | Jan 21, 2011 | Apr | CRLD |
| | | 40MG | N022567 003 | Jan 21, 2011 | Apr | CRLD |

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

| | | | | | | |
|---|-----------|-------|-------------|--------------|-----|------|
| + | GENENTECH | 150MG | N203388 001 | Jan 30, 2012 | Jan | NEWA |
|---|-----------|-------|-------------|--------------|-----|------|

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

| | | | | | | | |
|-----|----|--------------|------------|-------------|--------------|-----|------|
| >D> | + | PFIZER | 200MG/VIAL | N021267 001 | May 24, 2002 | May | CFTG |
| >A> | AP | + | 200MG/VIAL | N021267 001 | May 24, 2002 | May | CFTG |
| >A> | | VORICONAZOLE | | | | | |
| >A> | AP | SANDOZ INC | 200MG/VIAL | A090862 001 | May 30, 2012 | May | NEWA |

TABLET; ORAL

VORICONAZOLE

| | | | | | | |
|----|-------------|-------|-------------|--------------|-----|------|
| AB | TEVA PHARMS | 50MG | A091658 001 | Apr 06, 2012 | Mar | NEWA |
| AB | | 200MG | A091658 002 | Apr 06, 2012 | Mar | NEWA |

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

| | | | | | | |
|---|----------------------|------------------------|-------------|--------------|-----|------|
| @ | JAZZ PHARMS COMMERCL | 200MCG/2ML (100MCG/ML) | N021060 003 | Dec 28, 2004 | Mar | CAHN |
|---|----------------------|------------------------|-------------|--------------|-----|------|

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

| | | | | | | |
|---|----------------------|------------------------|-------------|--------------|-----|------|
| + | JAZZ PHARMS COMMERCL | 100MCG/1ML (100MCG/ML) | N021060 002 | Dec 28, 2004 | Mar | CAHN |
| + | | 500MCG/20ML (25MCG/ML) | N021060 001 | Dec 28, 2004 | Mar | CAHN |
| + | | 500MCG/5ML (100MCG/ML) | N021060 004 | Dec 28, 2004 | Mar | CAHN |

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

| | | | | | | |
|---|------------------|-------|-------------|--------------|-----|------|
| @ | RANBAXY LABS LTD | 300MG | A077327 001 | Sep 19, 2005 | Apr | DISC |
|---|------------------|-------|-------------|--------------|-----|------|

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

| | | | | | | | |
|----|---|--------|--------------|-------------|--------------|-----|------|
| AB | + | PFIZER | EQ 20MG BASE | N020825 001 | Feb 05, 2001 | Feb | CFTG |
| AB | | | EQ 40MG BASE | N020825 002 | Feb 05, 2001 | Feb | CFTG |
| AB | | | EQ 60MG BASE | N020825 003 | Feb 05, 2001 | Feb | CFTG |
| AB | | | EQ 80MG BASE | N020825 004 | Feb 05, 2001 | Feb | CFTG |

ZIPRASIDONE HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------------|--------------|-------------|--------------|-----|------|
| AB | | APOTEX CORP | EQ 20MG BASE | A077561 001 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 40MG BASE | A077561 002 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 60MG BASE | A077561 003 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 80MG BASE | A077561 004 | Mar 02, 2012 | Feb | NEWA |
| AB | | DR REDDYS LABS INC | EQ 20MG BASE | A077565 001 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 40MG BASE | A077565 002 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 60MG BASE | A077565 003 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 80MG BASE | A077565 004 | Mar 02, 2012 | Feb | NEWA |
| AB | | LUPIN PHARMS | EQ 20MG BASE | A077560 001 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 40MG BASE | A077560 002 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 60MG BASE | A077560 003 | Mar 02, 2012 | Feb | NEWA |
| AB | | | EQ 80MG BASE | A077560 004 | Mar 02, 2012 | Feb | NEWA |
| >A> | AB | SANDOZ INC | EQ 20MG BASE | A077562 001 | Jun 01, 2012 | May | NEWA |
| >A> | AB | | EQ 40MG BASE | A077562 002 | Jun 01, 2012 | May | NEWA |
| >A> | AB | | EQ 60MG BASE | A077562 003 | Jun 01, 2012 | May | NEWA |
| >A> | AB | | EQ 80MG BASE | A077562 004 | Jun 01, 2012 | May | NEWA |

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS 800MG;10MG;165MG N020958 001 Oct 16, 2000 Mar CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCUB MAXI SWABSTICK

+ PROF DSPLS 3.15%;70% (5.1ML) N021524 003 Jun 03, 2005 Mar CAHN

CHLORASCUB SWAB

+ PROF DSPLS 3.15%;70% (1ML) N021524 001 Jun 03, 2005 Mar CAHN

CHLORASCUB SWABSTICK

+ PROF DSPLS 3.15%;70% (1.6ML) N021524 002 Jun 03, 2005 Mar CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

>A> TRIS PHARMA INC EQ 30MG HBR/5ML A091135 001 May 25, 2012 May NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A200888 001 Mar 05, 2012 Feb NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS 10MG

N020801 001 Sep 24, 1998 Mar CAHN

+ 20MG N020801 002 Dec 17, 2007 Mar CAHN

TABLET; ORAL

PEPCID AC

MCNEIL CONS 10MG

N020325 001 Apr 28, 1995 Mar CAHN

+ 20MG N020325 002 Sep 23, 2003 Mar CAHN

PEPCID AC (GELTAB)

MCNEIL CONS 10MG

N020902 001 Aug 05, 1999 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS 30MG

A091567 002 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 30MG

A079112 002 Feb 08, 2012 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS 30MG

A091567 001 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 30MG

A079112 001 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS 60MG

A091567 004 Feb 06, 2012 Jan NEWA

180MG

A091567 006 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD 60MG

A079112 004 Feb 08, 2012 Jan NEWA

180MG

A079112 006 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS 60MG

A091567 003 Feb 06, 2012 Jan NEWA

180MG

A091567 005 Feb 06, 2012 Jan NEWA

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE HIVES

| | | | | | |
|---------------|-------|-------------|--------------|-----|------|
| WOCKHARDT LTD | 60MG | A079112 003 | Feb 08, 2012 | Jan | NEWA |
| | 180MG | A079112 005 | Feb 08, 2012 | Jan | NEWA |

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

| | | | | | |
|---------------|---------------------------------------|-------------|--------------|-----|------|
| ACCUCAPS INDS | EQ 200MG FREE ACID AND POTASSIUM SALT | A077338 001 | Jul 10, 2009 | Jan | CAHN |
|---------------|---------------------------------------|-------------|--------------|-----|------|

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

| | | | | | |
|--------------------|------|-------------|--------------|-----|------|
| DR REDDYS LABS LTD | 15MG | A202194 001 | May 18, 2012 | Apr | NEWA |
| PERRIGO R AND D | 15MG | A202319 001 | May 18, 2012 | Apr | NEWA |
| WOCKHARDT LTD | 15MG | A202727 001 | May 18, 2012 | Apr | NEWA |
| PREVACID 24 HR | | | | | |
| + NOVARTIS | 15MG | N022327 001 | May 18, 2009 | Apr | CFTG |

LEVONORGESTREL

TABLET; ORAL

PLAN B

| | | | | | | |
|-----|----------------------|--------|-------------|--------------|-----|------|
| >A> | + TEVA BRANDED PHARM | 0.75MG | N021045 002 | Aug 24, 2006 | May | CAHN |
| >D> | + TEVA WOMENS | 0.75MG | N021045 002 | Aug 24, 2006 | May | CAHN |

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

| | | | | | |
|-------|-----------|-------------|--------------|-----|------|
| AVEVA | 7MG/24HR | A074612 002 | Jul 28, 2003 | Apr | NEWA |
| | 14MG/24HR | A074612 003 | Oct 20, 1997 | Apr | NEWA |

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | |
|-----|--------------|---------------|-------------|--------------|-----|------|
| >A> | APOTEX INC | EQ 150MG BASE | A200172 001 | May 31, 2012 | May | NEWA |
| | SHASUN CHEMS | EQ 75MG BASE | A201745 001 | Feb 29, 2012 | Feb | NEWA |

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2012

NO MAY 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------|--------------|-------------------------|----------------------|-----------------------------|
| <u>ACETYLCYSTEINE - ACETADOTE</u> | | | | | | |
| N021539 001 | 8148356 | May 21, 2026 | DP | | | |
| <u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u> | | | | | | |
| N022320 001 | 8105618 | Dec 23, 2022 | U-1078 | | | |
| | 8129362 | Jul 18, 2027 | U-1078 | | | |
| <u>ALBUTEROL SULFATE - PROAIR HFA</u> | | | | | | |
| N021457 001 | 6446627 | Dec 18, 2017 | DP | | | |
| | 8132712 | Sep 07, 2028 | DP | | | |
| <u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u> | | | | | | |
| N022217 001 | >A> 8168616 | Jul 05, 2025 | DP | | | |
| <u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u> | | | | | | |
| N022217 002 | >A> 8168616 | Jul 05, 2025 | DP | | | |
| <u>ALVIMOPAN - ENTEREG</u> | | | | | | |
| N021775 001 | 8112290 | Jul 31, 2030 | U-1225 | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u> | | | | | | |
| N022314 001 | 8101599 | May 16, 2023 | DP | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u> | | | | | | |
| N022314 002 | 8101599 | May 16, 2023 | DP | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u> | | | | | | |
| N022314 003 | 8101599 | May 16, 2023 | DP | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u> | | | | | | |
| N022314 004 | 8101599 | May 16, 2023 | DP | | | |
| <u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u> | | | | | | |
| N022314 005 | 8101599 | May 16, 2023 | DP | | | |
| <u>ARFORMOTEROL TARTRATE - BROVANA</u> | | | | | | |
| N021912 001 | 6589508 | Apr 03, 2013 | U-793 | | | |
| | >A> 6667344 | Jun 22, 2021 | DP | | | |
| | >A> 6814953 | Jun 22, 2021 | U-793 | | | |
| | 8110706 | Nov 09, 2021 | DP | | | |
| <u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u> | | | | | | |
| A091211 001 | | | | | PC | Mar 13, 2012 |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N202276 001 | >A> 6656935 | Sep 13, 2020 | DS DP U-155 | | NCE | Apr 27, 2017 |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N202276 002 | >A> 6656935 | Sep 13, 2020 | DS DP U-155 | | NCE | Apr 27, 2017 |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N202276 003 | >A> 6656935 | Sep 13, 2020 | DS DP U-155 | | NCE | Apr 27, 2017 |
| <u>AXITINIB - INLYTA</u> | | | | | | |
| N202324 001 | 6534524 | Jun 30, 2020 | DS DP | | NCE | Jan 27, 2017 |
| | 7141581 | Jun 30, 2020 | U-1220 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>AXITINIB - INLYTA</u> | | | | | | |
| N202324 002 | 6534524 | Jun 30, 2020 | DS DP | | NCE | Jan 27, 2017 |
| | 7141581 | Jun 30, 2020 | U-1220 | | | |
| <u>AZELASTINE HYDROCHLORIDE; FLUTICASON PROPRIONATE - DYMISTA</u> | | | | | | |
| N202236 001 | >A> 8168620 | Feb 24, 2026 | DP | | >A> NC | May 01, 2015 |
| <u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u> | | | | | | |
| N202331 001 | 5583141 | Dec 10, 2013 | DS DP U-3 | | | |
| | 5736555 | Jun 25, 2012 | DS DP U-3 | | | |
| | 7157584 | May 22, 2025 | DS | | | |
| | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| <u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u> | | | | | | |
| N202331 002 | 5583141 | Dec 10, 2013 | DS DP U-3 | | | |
| | 5736555 | Jun 25, 2012 | DS DP U-3 | | | |
| | 7157584 | May 22, 2025 | DS | | | |
| | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| <u>BALSALAZIDE DISODIUM - GIAZO</u> | | | | | | |
| N022205 001 | 6197341 | Mar 13, 2018 | DP U-1229 | | NDF | Feb 03, 2015 |
| | 7452872 | Aug 24, 2026 | U-1229 | | | |
| | 7625884 | Aug 24, 2026 | U-1229 | | | |
| <u>BECLOMETHASONE DIPROPIONATE - QNASL</u> | | | | | | |
| N202813 001 | 5605674 | Feb 25, 2014 | DP | | NP | Mar 23, 2015 |
| | 5683677 | Nov 04, 2014 | DP | | | |
| | 5776432 | Jul 07, 2015 | DP | | | |
| | 7780038 | Jan 24, 2027 | DP | | | |
| <u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u> | | | | | | |
| N022249 001 | | | | | >A> NCE | Mar 20, 2013 |
| | | | | | >A> ODE | Mar 20, 2015 |
| | | | | | >A> PED | Sep 20, 2015 |
| | | | | | >A> PED | Sep 20, 2013 |
| <u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u> | | | | | | |
| N022249 002 | | | | | >A> NCE | Mar 20, 2013 |
| | | | | | >A> ODE | Mar 20, 2015 |
| | | | | | >A> PED | Sep 20, 2015 |
| | | | | | >A> PED | Sep 20, 2013 |
| <u>BIMATOPROST - LATISSE</u> | | | | | | |
| N022369 001 | 8101161 | May 25, 2024 | U-1218 | | | |
| | 8101161 | May 25, 2024 | U-1217 | | | |
| <u>BIVALIRUDIN - ANGIOMAX</u> | | | | | | |
| N020873 001 | 5196404 | Dec 15, 2014 | DS DP U-1232 | | | |
| | 5196404 | Dec 15, 2014 | DS DP U-1040 | | | |
| | 5196404*PED | Jun 15, 2015 | | | | |
| <u>BOCEPREVIR - VICTRELIS</u> | | | | | | |
| N202258 001 | 8119602 | Mar 17, 2027 | U-1233 | | | |
| | RE43298 | Feb 22, 2022 | DS DP U-1128 | | | |
| <u>BORTEZOMIB - VELCADE</u> | | | | | | |
| N021602 001 | | | | | NR | Jan 23, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u> | | | | | | |
| N021398 001 | 8133890 | Apr 19, 2022 | U-1235 | | | |
| <u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u> | | | | | | |
| N021929 001 | 8143239 | Jan 29, 2023 | DP U-1073 | | | |
| <u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u> | | | | | | |
| N021929 002 | 8143239 | Jan 29, 2023 | DP U-1073 | | | |
| <u>BUPIVACAINE - EXPAREL</u> | | | | | | |
| N022496 001 | 6132766 | Nov 16, 2013 | DP | | | |
| <u>BUPIVACAINE - EXPAREL</u> | | | | | | |
| N022496 002 | 6132766 | Nov 16, 2013 | DP | | | |
| <u>CARVEDILOL PHOSPHATE - COREG CR</u> | | | | | | |
| N022012 001 | 6022562 | Oct 17, 2015 | DP | Y | | |
| | 8101209 | Sep 11, 2025 | DP | | | |
| | 8101209*PED | Mar 11, 2026 | | | | |
| <u>CARVEDILOL PHOSPHATE - COREG CR</u> | | | | | | |
| N022012 002 | 6022562 | Oct 17, 2015 | DP | Y | | |
| | 8101209 | Sep 11, 2025 | DP | | | |
| | 8101209*PED | Mar 11, 2026 | | | | |
| <u>CARVEDILOL PHOSPHATE - COREG CR</u> | | | | | | |
| N022012 003 | 6022562 | Oct 17, 2015 | DP | Y | | |
| | 8101209 | Sep 11, 2025 | DP | | | |
| | 8101209*PED | Mar 11, 2026 | | | | |
| <u>CARVEDILOL PHOSPHATE - COREG CR</u> | | | | | | |
| N022012 004 | 6022562 | Oct 17, 2015 | DP | Y | | |
| | 8101209 | Sep 11, 2025 | DP | | | |
| | 8101209*PED | Mar 11, 2026 | | | | |
| <u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u> | | | | | | |
| N021669 001 | >A> 7717889 | Feb 27, 2025 | DP U-1022 | | | |
| <u>CICLESONIDE - ZETONNA</u> | | | | | | |
| N020129 001 | 5482934 | Oct 24, 2017 | DS DP U-1002 | | NP | Jan 20, 2015 |
| | 5605674 | Feb 25, 2014 | DP | | | |
| | 5683677 | Nov 04, 2014 | DP | | | |
| | 5775321 | Jul 07, 2015 | DP | | | |
| | 6006745 | Dec 28, 2016 | DP | | | |
| | 6036942 | Apr 30, 2013 | DP | | | |
| | 6120752 | May 13, 2018 | DP | | | |
| | 6264923 | May 13, 2018 | DP | | | |
| <u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u> | | | | | | |
| N022156 001 | 5856346 | Jan 05, 2021 | DS DP U-893 | | | |
| <u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u> | | | | | | |
| N022156 002 | 5856346 | Jan 05, 2021 | DS DP U-893 | | | |
| <u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u> | | | | | | |
| A077665 002 | | | | | >A> PC | Nov 13, 2012 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u> | | | | | | |
| A091023 | 001 | | | | >A> PC | Nov 13, 2012 |
| <u>COLCHICINE - COLCRYS</u> | | | | | | |
| N022352 | 001 | 7964648 | Oct 06, 2028 | U-1161 | | |
| | | 8097655 | Oct 06, 2028 | U-1020 | | |
| <u>DAPTOMYCIN - CUBICIN</u> | | | | | | |
| N021572 | 002 | 8129342 | Nov 28, 2020 | DS DP | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 | 001 | 5843946*PED | Jun 01, 2016 | | | |
| | | 6037157 | Jun 26, 2016 | U-935 | | |
| | | 6037157 | Jun 26, 2016 | U-1209 | | |
| | | 6037157*PED | Dec 26, 2016 | | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-935 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-903 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-744 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-1209 | | |
| | | 6335460*PED | Feb 25, 2013 | | | |
| | | 6703403 | Jun 26, 2016 | U-935 | | |
| | | 6703403 | Jun 26, 2016 | U-1209 | | |
| | | 6703403*PED | Dec 26, 2016 | | | |
| | | 7470506 | Jun 23, 2019 | U-935 | | |
| | | 7470506 | Jun 23, 2019 | U-1209 | | |
| | | 7470506*PED | Dec 23, 2019 | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 | 002 | 5843946*PED | Jun 01, 2016 | | | |
| | | 6037157 | Jun 26, 2016 | U-935 | | |
| | | 6037157 | Jun 26, 2016 | U-1209 | | |
| | | 6037157*PED | Dec 26, 2016 | | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-935 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-903 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-744 | | |
| | | 6335460 | Aug 25, 2012 | DS DP U-1209 | | |
| | | 6335460*PED | Feb 25, 2013 | | | |
| | | 6703403 | Jun 26, 2016 | U-935 | | |
| | | 6703403 | Jun 26, 2016 | U-1209 | | |
| | | 6703403*PED | Dec 26, 2016 | | | |
| | | 7470506 | Jun 23, 2019 | U-935 | | |
| | | 7470506 | Jun 23, 2019 | U-1209 | | |
| | | 7470506*PED | Dec 23, 2019 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 003 | 5843946*PED | Jun 01, 2016 | | | | |
| | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6037157 | Jun 26, 2016 | U-1209 | | | |
| | 6037157*PED | Dec 26, 2016 | | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-935 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-903 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-744 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-1209 | | | |
| | 6335460*PED | Feb 25, 2013 | | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-1209 | | | |
| | 6703403*PED | Dec 26, 2016 | | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506*PED | Dec 23, 2019 | | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 004 | 5843946*PED | Jun 01, 2016 | | | | |
| | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6037157 | Jun 26, 2016 | U-1209 | | | |
| | 6037157*PED | Dec 26, 2016 | | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-935 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-903 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-744 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-1209 | | | |
| | 6335460*PED | Feb 25, 2013 | | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-1209 | | | |
| | 6703403*PED | Dec 26, 2016 | | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506*PED | Dec 23, 2019 | | | | |
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N021976 005 | 5843946*PED | Jun 01, 2016 | | | | |
| | 6037157 | Jun 26, 2016 | U-935 | | | |
| | 6037157 | Jun 26, 2016 | U-1209 | | | |
| | 6037157*PED | Dec 26, 2016 | | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-935 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-903 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-744 | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-1209 | | | |
| | 6335460*PED | Feb 25, 2013 | | | | |
| | 6703403 | Jun 26, 2016 | U-935 | | | |
| | 6703403 | Jun 26, 2016 | U-1209 | | | |
| | 6703403*PED | Dec 26, 2016 | | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506*PED | Dec 23, 2019 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>DARUNAVIR ETHANOLATE - PREZISTA</u> | | | | | | |
| N202895 001 | 5843946 | Dec 01, 2015 | DP U-1209 | | | |
| | 5843946*PED | Jun 01, 2016 | | | | |
| | 6037157 | Jun 26, 2016 | U-1209 | | | |
| | 6037157*PED | Dec 26, 2016 | | | | |
| | 6248775 | Aug 13, 2014 | DS | | | |
| | 6248775*PED | Feb 13, 2015 | | | | |
| | 6335460 | Aug 25, 2012 | DS DP U-1209 | | | |
| | 6335460*PED | Feb 25, 2013 | | | | |
| | 6703403 | Jun 26, 2016 | U-1209 | | | |
| | 6703403*PED | Dec 26, 2016 | | | | |
| | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506*PED | Dec 23, 2019 | | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 7700645*PED | Jun 26, 2027 | | | | |
| | RE42889 | Oct 19, 2016 | DP | | | |
| | RE42889*PED | Apr 19, 2017 | | | | |
| <u>DEGARELIX ACETATE - FIRMAGON</u> | | | | | | |
| N022201 001 | 5925730 | May 18, 2021 | DS DP U-943 | | | |
| <u>DEGARELIX ACETATE - FIRMAGON</u> | | | | | | |
| N022201 002 | 5925730 | May 18, 2021 | DS DP U-943 | | | |
| <u>DEXAMETHASONE - OZURDEX</u> | | | | | | |
| N022315 001 | 8088407 | Oct 20, 2020 | DP U-1205 | | | |
| <u>DEXLANSOPRAZOLE - DEXILANT</u> | | | | | | |
| N022287 001 | 8105626 | Sep 27, 2026 | DP | | | |
| | 8105626*PED | Mar 27, 2027 | | | | |
| | >A> 8173158 | Mar 17, 2030 | U-951 | | | |
| | >A> 8173158 | Mar 17, 2030 | U-950 | | | |
| | >A> 8173158 | Mar 17, 2030 | U-949 | | | |
| | >A> 8173158*PED | Sep 17, 2030 | | | | |
| <u>DEXLANSOPRAZOLE - DEXILANT</u> | | | | | | |
| N022287 002 | 8105626 | Sep 27, 2026 | DP | | | |
| | 8105626*PED | Mar 27, 2027 | | | | |
| | >A> 8173158 | Mar 17, 2030 | U-951 | | | |
| | >A> 8173158 | Mar 17, 2030 | U-950 | | | |
| | >A> 8173158 | Mar 17, 2030 | U-949 | | | |
| | >A> 8173158*PED | Sep 17, 2030 | | | | |
| <u>DICLOFENAC POTASSIUM - CAMBIA</u> | | | | | | |
| N022165 001 | 8097651 | Jun 16, 2026 | DS DP U-436 | | | |
| <u>DICLOFENAC POTASSIUM - ZIPSOR</u> | | | | | | |
| N022202 001 | 8110606 | Feb 24, 2029 | U-980 | | | |
| <u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u> | | | | | | |
| N022252 001 | 8153616 | Jan 30, 2028 | U-1240 | | I-648 | Mar 14, 2015 |
| <u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u> | | | | | | |
| N202667 001 | | | | | NP | Feb 01, 2015 |
| <u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u> | | | | | | |
| N021355 001 | | | | | NS | Mar 01, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u> | | | | | | |
| N202123 | 001 | | | | NCE | May 20, 2016 |
| <u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u> | | | | | | |
| A202012 | 001 | | | | PC | Jun 17, 2012 |
| <u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u> | | | | | | |
| A202012 | 002 | | | | PC | Jun 17, 2012 |
| <u>ERIBULIN MESYLATE - HALAVEN</u> | | | | | | |
| N201532 | 001 | 8097648 | Jan 22, 2021 | U-1096 | | |
| <u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u> | | | | | | |
| A076765 | 001 | | | | PC | Sep 10, 2012 |
| <u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u> | | | | | | |
| A076765 | 002 | | | | PC | Sep 10, 2012 |
| <u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u> | | | | | | |
| A076765 | 003 | | | | PC | Sep 10, 2012 |
| <u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u> | | | | | | |
| N021957 | 001 | 5877192 | May 27, 2014 | U-773 | | |
| | | 5877192 | May 27, 2014 | U-729 | | |
| | | 5877192 | May 27, 2014 | U-1207 | | |
| | | 5877192*PED | Nov 27, 2014 | | | |
| <u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u> | | | | | | |
| N021957 | 002 | 5877192 | May 27, 2014 | U-773 | | |
| | | 5877192 | May 27, 2014 | U-729 | | |
| | | 5877192 | May 27, 2014 | U-1207 | | |
| | | 5877192*PED | Nov 27, 2014 | | | |
| <u>ETRAVIRINE - INTELENCE</u> | | | | | | |
| N022187 | 001 | 6878717 | Nov 05, 2019 | U-256 | NPP | Mar 26, 2015 |
| | | 6878717 | Nov 05, 2019 | U-1237 | | |
| | | 6878717 | Nov 05, 2019 | U-1016 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-256 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1016 | | |
| <u>ETRAVIRINE - INTELENCE</u> | | | | | | |
| N022187 | 002 | 6878717 | Nov 05, 2019 | U-256 | NPP | Mar 26, 2015 |
| | | 6878717 | Nov 05, 2019 | U-1237 | | |
| | | 6878717 | Nov 05, 2019 | U-1016 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-256 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1016 | | |
| <u>ETRAVIRINE - INTELENCE</u> | | | | | | |
| N022187 | 003 | 6878717 | Nov 05, 2019 | U-256 | NPP | Mar 26, 2015 |
| | | 6878717 | Nov 05, 2019 | U-1237 | NCE | Jan 18, 2013 |
| | | 6878717 | Nov 05, 2019 | U-1016 | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | |
| | | 7887845 | Mar 25, 2019 | DP | | |
| | | 8003789 | Nov 01, 2019 | DS DP | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N022334 | 001 | | | | I-650 >A> ODE | Apr 26, 2015 Apr 26, 2019 |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N022334 | 002 | | | | I-650 >A> ODE | Apr 26, 2015 Apr 26, 2019 |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N022334 | 003 | >A> 6004973 | Jul 12, 2016 | DP | I-650 | Apr 26, 2015 |
| | | >A> 7297703 | Dec 06, 2019 | DP | >A> ODE | Apr 26, 2019 |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N022334 | 004 | 5665772 | Sep 09, 2019 | DS DP | I-650 | Apr 26, 2015 |
| | | 6004973 | Jul 12, 2016 | DP | I-638 | May 05, 2014 |
| | | 7297703 | Dec 06, 2019 | DP | I-630 | Oct 29, 2013 |
| | | | | | NCE | Mar 30, 2014 |
| | | | | | >A> ODE | Apr 26, 2019 |
| | | | | | ODE | May 05, 2018 |
| | | | | | ODE | Oct 29, 2017 |
| <u>EXENATIDE SYNTHETIC - BYDUREON</u> | | | | | | |
| N022200 | 001 | 5424286 | Dec 01, 2016 | U-1108 | NP | Jan 27, 2015 |
| | | 6479065 | Aug 10, 2020 | DP | | |
| | | 6495164 | May 25, 2020 | DP | | |
| | | 6667061 | May 25, 2020 | DP | | |
| | | 6824822 | Oct 09, 2022 | DP | | |
| | | 6858576 | Jan 06, 2017 | U-656 | | |
| | | 6872700 | Jan 14, 2020 | U-654 | | |
| | | 6956026 | Jan 07, 2018 | U-687 | | |
| | | 7223440 | Aug 31, 2021 | DP | | |
| | | 7456254 | Jun 30, 2025 | DP U-1223 | | |
| | | 7563871 | Apr 15, 2024 | DP | | |
| | | 7612176 | Apr 13, 2025 | DP U-1223 | | |
| | | 7741269 | Jan 07, 2018 | U-1224 | | |
| <u>EXENATIDE SYNTHETIC - BYETTA</u> | | | | | | |
| N021773 | 001 | | | | M-113 | Oct 19, 2014 |
| | | | | | M-111 | Oct 19, 2014 |
| <u>EXENATIDE SYNTHETIC - BYETTA</u> | | | | | | |
| N021773 | 002 | | | | M-113 | Oct 19, 2014 |
| | | | | | M-111 | Oct 19, 2014 |
| <u>EZETIMIBE - ZETIA</u> | | | | | | |
| N021445 | 001 | | | | M-109 | Jan 24, 2015 |
| <u>EZETIMIBE; SIMVASTATIN - VYTORIN</u> | | | | | | |
| N021687 | 001 | | | | M-109 | Jan 24, 2015 |
| <u>EZETIMIBE; SIMVASTATIN - VYTORIN</u> | | | | | | |
| N021687 | 002 | | | | M-109 | Jan 24, 2015 |
| <u>EZETIMIBE; SIMVASTATIN - VYTORIN</u> | | | | | | |
| N021687 | 003 | | | | M-109 | Jan 24, 2015 |
| <u>EZETIMIBE; SIMVASTATIN - VYTORIN</u> | | | | | | |
| N021687 | 004 | | | | M-109 | Jan 24, 2015 |
| <u>FAMCICLOVIR - FAMVIR</u> | | | | | | |
| N020363 | 001 | | | | M-112 | Feb 09, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|-----------------------------------|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>FAMCICLOVIR - FAMVIR</u> | | | | | | |
| N020363 | 002 | | | | M-112 | Feb 09, 2015 |
| <u>FAMCICLOVIR - FAMVIR</u> | | | | | | |
| N020363 | 003 | | | | M-112 | Feb 09, 2015 |
| <u>FENOFIBRATE - FENOGLIDE</u> | | | | | | |
| N022118 | 001 | 8124125 | Oct 01, 2024 | DP U-1234 | | |
| <u>FENOFIBRATE - FENOGLIDE</u> | | | | | | |
| N022118 | 002 | 8124125 | Oct 01, 2024 | DP U-1234 | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N202788 | 001 | | | | NP | Jan 04, 2015 |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N202788 | 002 | | | | NP | Jan 04, 2015 |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N202788 | 003 | | | | NP | Jan 04, 2015 |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N202788 | 004 | | | | NP | Jan 04, 2015 |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N202788 | 005 | | | | NP | Jan 04, 2015 |
| <u>FENTANYL CITRATE - FENTORA</u> | | | | | | |
| N021947 | 001 | 8092832 | Dec 30, 2024 | DP | | |
| <u>FENTANYL CITRATE - FENTORA</u> | | | | | | |
| N021947 | 002 | 8092832 | Dec 30, 2024 | DP | | |
| | | 8119158 | Dec 30, 2024 | DP | | |
| <u>FENTANYL CITRATE - FENTORA</u> | | | | | | |
| N021947 | 003 | 8092832 | Dec 30, 2024 | DP | | |
| | | 8119158 | Dec 30, 2024 | DP | | |
| <u>FENTANYL CITRATE - FENTORA</u> | | | | | | |
| N021947 | 004 | 8092832 | Dec 30, 2024 | DP | | |
| | | 8119158 | Dec 30, 2024 | DP | | |
| <u>FENTANYL CITRATE - FENTORA</u> | | | | | | |
| N021947 | 005 | 8092832 | Dec 30, 2024 | DP | | |
| | | 8119158 | Dec 30, 2024 | DP | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 | 001 | >A> 7579019 | Jan 22, 2020 | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 | 002 | >A> 7579019 | Jan 22, 2020 | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 | 003 | >A> 7579019 | Jan 22, 2020 | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 | 004 | >A> 7579019 | Jan 22, 2020 | U-767 | | |
| <u>FENTANYL CITRATE - ONSOLIS</u> | | | | | | |
| N022266 | 005 | >A> 7579019 | Jan 22, 2020 | U-767 | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>FESOTERODINE FUMARATE - TOVIAZ</u> | | | | | | |
| N022030 001 | 8088398 | Jun 07, 2027 | DP U-913 | | | |
| <u>FESOTERODINE FUMARATE - TOVIAZ</u> | | | | | | |
| N022030 002 | 8088398 | Jun 07, 2027 | DP U-913 | | | |
| <u>FINGOLIMOD - GILENYA</u> | | | | | | |
| N022527 001 | 6004565 | Sep 23, 2017 | U-1086 | | | |
| <u>FLORBETAPIR F-18 - AMYVID</u> | | | | | | |
| N202008 001 | 7687052 | Apr 30, 2027 | DS DP | | NCE | Apr 06, 2017 |
| <u>FLORBETAPIR F-18 - AMYVID</u> | | | | | | |
| N202008 002 | 7687052 | Apr 30, 2027 | DS DP | | NCE | Apr 06, 2017 |
| <u>FLORBETAPIR F-18 - AMYVID</u> | | | | | | |
| N202008 003 | 7687052 | Apr 30, 2027 | DS DP | | NCE | Apr 06, 2017 |
| <u>FLUNISOLIDE - AEROSPAN HFA</u> | | | | | | |
| N021247 001 | 5776433 | Jul 07, 2015 | DP | | | |
| | 5980867 | Jul 06, 2018 | DP | | | |
| <u>FOSAMPRENAVIR CALCIUM - LEXIVA</u> | | | | | | |
| N021548 001 | | | | | NPP PED | Apr 27, 2015 Oct 27, 2015 |
| <u>FOSAMPRENAVIR CALCIUM - LEXIVA</u> | | | | | | |
| N022116 001 | | | | | NPP PED | Apr 27, 2015 Oct 27, 2015 |
| <u>FOSAPREPITANT DIMEGLUMINE - EMEND</u> | | | | | | |
| N022023 002 | >A> 5512570 | Mar 04, 2014 | U-850 | | | |
| | >A> 5538982 | Jul 23, 2013 | U-850 | | | |
| | >A> 5716942 | Feb 10, 2015 | U-850 | | | |
| | >A> 7214692 | Sep 18, 2012 | U-850 | | | |
| <u>FOSPROPOFOL DISODIUM - LUSEDRA</u> | | | | | | |
| N022244 001 | 6204257 | Jul 01, 2022 | DS DP U-945 | | | |
| <u>GABAPENTIN ENACARBIL - HORIZANT</u> | | | | | | |
| N022399 001 | 8114909 | Apr 11, 2026 | U-1231 | | | |
| <u>GABAPENTIN ENACARBIL - HORIZANT</u> | | | | | | |
| N022399 002 | 8114909 | Apr 11, 2026 | U-1231 | | | |
| <u>GADOFOSVESET TRISODIUM - ABLAVAR</u> | | | | | | |
| N021711 001 | 6676929 | May 04, 2020 | DP | | | |
| <u>GADOFOSVESET TRISODIUM - ABLAVAR</u> | | | | | | |
| N021711 002 | 6676929 | May 04, 2020 | DP | | | |
| <u>GADOXETATE DISODIUM - EOVIIST</u> | | | | | | |
| N022090 001 | >A> 5798092 | Aug 25, 2015 | DS DP | | | |
| | 6039931 | Nov 13, 2021 | U-1239 | | | |
| <u>GLYCOPYRROLATE - CUVPOSA</u> | | | | | | |
| N022571 001 | | | | | ODE | Jul 28, 2017 |
| <u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u> | | | | | | |
| A077369 001 | | | | | PC | Sep 26, 2012 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u> | | | | | | |
| A077369 | 002 | | | | PC | Sep 26, 2012 |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N021588 | 001 | | | | ODE | Dec 19, 2015 |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N021588 | 002 | | | | ODE | Dec 19, 2015 |
| <u>INGENOL MEBUTATE - PICATO</u> | | | | | | |
| N202833 | 001 | 6432452 | Aug 19, 2018 | DS U-68 | NCE | Jan 23, 2017 |
| | | 6844013 | Aug 19, 2018 | DS DP U-1221 | | |
| | | 7410656 | Aug 19, 2018 | DS U-1222 | | |
| <u>INGENOL MEBUTATE - PICATO</u> | | | | | | |
| N202833 | 002 | 6432452 | Aug 19, 2018 | DS U-68 | NCE | Jan 23, 2017 |
| | | 6844013 | Aug 19, 2018 | DS DP U-1221 | | |
| | | 7410656 | Aug 19, 2018 | DS U-1222 | | |
| <u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u> | | | | | | |
| N021536 | 001 | | | | M-115 | Apr 06, 2015 |
| <u>IOFLUPANE I-123 - DATSCAN</u> | | | | | | |
| N022454 | 001 | 5310912 | Feb 25, 2013 | DS | | |
| <u>IRBESARTAN - IRBESARTAN</u> | | | | | | |
| A077159 | 001 | | | | PC | Sep 26, 2012 |
| <u>IRBESARTAN - IRBESARTAN</u> | | | | | | |
| A077159 | 002 | | | | PC | Sep 26, 2012 |
| <u>IRBESARTAN - IRBESARTAN</u> | | | | | | |
| A077159 | 003 | | | | PC | Sep 26, 2012 |
| <u>ISOTRETINOIN - ABSORICA</u> | | | | | | |
| N021951 | 001 | >A> 7435427 | Sep 21, 2021 | DP | >A> NP | May 25, 2015 |
| <u>ISOTRETINOIN - ABSORICA</u> | | | | | | |
| N021951 | 002 | >A> 7435427 | Sep 21, 2021 | DP | >A> NP | May 25, 2015 |
| <u>ISOTRETINOIN - ABSORICA</u> | | | | | | |
| N021951 | 003 | >A> 7435427 | Sep 21, 2021 | DP | >A> NP | May 25, 2015 |
| <u>ISOTRETINOIN - ABSORICA</u> | | | | | | |
| N021951 | 004 | >A> 7435427 | Sep 21, 2021 | DP | >A> NP | May 25, 2015 |
| <u>IVACAFTOR - KALYDECO</u> | | | | | | |
| N203188 | 001 | 7495103 | May 20, 2027 | DS DP | NCE ODE | Jan 31, 2017 Jan 31, 2019 |
| <u>IVERMECTIN - SKLICE</u> | | | | | | |
| N202736 | 001 | 6103248 | May 22, 2018 | DP | NP | Feb 07, 2015 |
| <u>IXABEPILONE - IXEMPRA KIT</u> | | | | | | |
| N022065 | 001 | RE41911 | Sep 28, 2020 | DS DP U-961 | | |
| | | RE41911*PED | Mar 28, 2021 | | | |
| <u>IXABEPILONE - IXEMPRA KIT</u> | | | | | | |
| N022065 | 002 | RE41911 | Sep 28, 2020 | DS DP U-961 | | |
| | | RE41911*PED | Mar 28, 2021 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>KETOCONAZOLE - EXTINA</u> | | | | | | |
| N021738 001 | 8026238 | Oct 19, 2018 | DP U-1213 | | | |
| <u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u> | | | | | | |
| A079081 001 | | | | | PC | May 15, 2012 |
| <u>LENALIDOMIDE - REVLIMID</u> | | | | | | |
| N021880 001 | 5635517 | Oct 04, 2019 | DS U-1211 | | | |
| | 6045501 | Aug 28, 2018 | U-1210 | | | |
| | 6281230 | Jul 24, 2016 | U-1212 | | | |
| | 6315720 | Oct 23, 2020 | U-1210 | | | |
| | 6555554 | Jul 24, 2016 | DP U-1211 | | | |
| | 6561976 | Aug 28, 2018 | U-1210 | | | |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| <u>LENALIDOMIDE - REVLIMID</u> | | | | | | |
| N021880 002 | 5635517 | Oct 04, 2019 | DS U-1211 | | | |
| | 6045501 | Aug 28, 2018 | U-1210 | | | |
| | 6281230 | Jul 24, 2016 | U-1212 | | | |
| | 6315720 | Oct 23, 2020 | U-1210 | | | |
| | 6555554 | Jul 24, 2016 | DP U-1211 | | | |
| | 6561976 | Aug 28, 2018 | U-1210 | | | |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| <u>LENALIDOMIDE - REVLIMID</u> | | | | | | |
| N021880 003 | 5635517 | Oct 04, 2019 | DS U-1211 | | | |
| | 6045501 | Aug 28, 2018 | U-1210 | | | |
| | 6281230 | Jul 24, 2016 | U-1212 | | | |
| | 6315720 | Oct 23, 2020 | U-1210 | | | |
| | 6555554 | Jul 24, 2016 | DP U-1211 | | | |
| | 6561976 | Aug 28, 2018 | U-1210 | | | |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LINALIDOMIDE - REVLIMID</u> | | | | | | |
| N021880 004 | 5635517 | Oct 04, 2019 | DS U-1211 | | | |
| | 6045501 | Aug 28, 2018 | U-1210 | | | |
| | 6281230 | Jul 24, 2016 | U-1212 | | | |
| | 6315720 | Oct 23, 2020 | U-1210 | | | |
| | 6555554 | Jul 24, 2016 | DP U-1211 | | | |
| | 6561976 | Aug 28, 2018 | U-1210 | | | |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| <u>LINALIDOMIDE - REVLIMID</u> | | | | | | |
| N021880 005 | 5635517 | Oct 04, 2019 | DS U-1211 | | | |
| | 6045501 | Aug 28, 2018 | U-1210 | | | |
| | 6281230 | Jul 24, 2016 | U-1212 | | | |
| | 6315720 | Oct 23, 2020 | U-1210 | | | |
| | 6555554 | Jul 24, 2016 | DP U-1211 | | | |
| | 6561976 | Aug 28, 2018 | U-1210 | | | |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7119106 | Jul 24, 2016 | DP | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| <u>LINAGLIPTIN - TRADJENTA</u> | | | | | | |
| N201280 001 | 8119648 | Aug 12, 2023 | U-774 | | | |
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N201281 001 | 6303661 | Apr 24, 2017 | U-802 | | NCE | May 02, 2016 |
| | 6890898 | Feb 02, 2019 | U-1039 | | NC | Jan 30, 2015 |
| | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | 7407955 | Aug 12, 2023 | DS DP | | | |
| | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | 8119648 | Aug 12, 2023 | U-802 | | | |
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N201281 002 | 6303661 | Apr 24, 2017 | U-802 | | NCE | May 02, 2016 |
| | 6890898 | Feb 02, 2019 | U-1039 | | NC | Jan 30, 2015 |
| | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | 7407955 | Aug 12, 2023 | DS DP | | | |
| | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | 8119648 | Aug 12, 2023 | U-802 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N201281 003 | 6303661 | Apr 24, 2017 | U-802 | | NCE | May 02, 2016 |
| | 6890898 | Feb 02, 2019 | U-1039 | | NC | Jan 30, 2015 |
| | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | 7407955 | Aug 12, 2023 | DS DP | | | |
| | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | 8119648 | Aug 12, 2023 | U-802 | | | |
| <u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u> | | | | | | |
| N022341 001 | 8114833 | Aug 13, 2025 | DP | | M-115 | Apr 06, 2015 |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 001 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 002 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 003 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 004 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7674774 | Mar 18, 2023 | DP U-842 | | | |
| | 7678771 | Mar 25, 2023 | DP U-842 | | | |
| | 7687467 | Apr 08, 2023 | DP U-842 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 005 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| <u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u> | | | | | | |
| N021977 006 | 7662788 | Feb 24, 2023 | U-727 | | I-645 | Jan 31, 2015 |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| <u>LUBIPROSTONE - AMITIZA</u> | | | | | | |
| N021908 001 | 8097649 | Oct 16, 2020 | DP | | | |
| | 8097653 | Nov 14, 2022 | U-1214 | | | |
| | 8114890 | Sep 05, 2020 | DP | | | |
| <u>LUBIPROSTONE - AMITIZA</u> | | | | | | |
| N021908 002 | 8097649 | Oct 16, 2020 | DP | | | |
| | 8114890 | Sep 05, 2020 | DP | | | |
| <u>LUCINACTANT - SURFAXIN</u> | | | | | | |
| N021746 001 | 5407914 | Nov 17, 2012 | DS DP U-1242 | | | |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N200603 001 | | | | | D-134 | Apr 26, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N200603 | 002 | | | | D-134 | Apr 26, 2015 |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N200603 | 003 | | | | D-134 NCE | Apr 26, 2015 Oct 28, 2015 |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N200603 | 004 | | | | D-134 NCE | Apr 26, 2015 Oct 28, 2015 |
| <u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u> | | | | | | |
| N021842 | 001 | | | | >A> M-116 | May 17, 2015 |
| <u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u> | | | | | | |
| N021842 | 002 | | | | >A> M-116 | May 17, 2015 |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N202270 | 001 | 6303661 | Apr 24, 2017 | U-1227 | | |
| | | 6340475 | Sep 19, 2016 | DP | | |
| | | 6635280 | Sep 19, 2016 | DP | | |
| | | 6699871 | Jul 26, 2022 | DS DP | U-1227 | |
| | | 6890898 | Feb 02, 2019 | | U-1228 | |
| | | 7078381 | Feb 02, 2019 | | U-1227 | |
| | | 7125873 | Jul 26, 2022 | DP | U-1227 | |
| | | 7326708 | Apr 11, 2026 | DS DP | U-1227 | |
| | | 7459428 | Feb 02, 2019 | | U-1227 | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N202270 | 002 | 6303661 | Apr 24, 2017 | U-1227 | | |
| | | 6340475 | Sep 19, 2016 | DP | | |
| | | 6635280 | Sep 19, 2016 | DP | | |
| | | 6699871 | Jul 26, 2022 | DS DP | U-1227 | |
| | | 6890898 | Feb 02, 2019 | | U-1228 | |
| | | 7078381 | Feb 02, 2019 | | U-1227 | |
| | | 7125873 | Jul 26, 2022 | DP | U-1227 | |
| | | 7326708 | Apr 11, 2026 | DS DP | U-1227 | |
| | | 7459428 | Feb 02, 2019 | | U-1227 | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N202270 | 003 | 6303661 | Apr 24, 2017 | U-1227 | | |
| | | 6340475 | Sep 19, 2016 | DP | | |
| | | 6635280 | Sep 19, 2016 | DP | | |
| | | 6699871 | Jul 26, 2022 | DS DP | U-1227 | |
| | | 6890898 | Feb 02, 2019 | | U-1228 | |
| | | 7078381 | Feb 02, 2019 | | U-1227 | |
| | | 7125873 | Jul 26, 2022 | DP | U-1227 | |
| | | 7326708 | Apr 11, 2026 | DS DP | U-1227 | |
| | | 7459428 | Feb 02, 2019 | | U-1227 | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u> | | | | | | |
| N021121 | 001 | 8163798 | Jul 31, 2017 | DP | | |
| | | 8163798*PED | Jan 31, 2018 | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u> | | | | | | |
| N021121 | 002 | 8163798 | Jul 31, 2017 | DP | | |
| | | 8163798*PED | Jan 31, 2018 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u> | | | | | | |
| N021121 003 | 8163798 | Jul 31, 2017 | DP | | | |
| | 8163798*PED | Jan 31, 2018 | | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u> | | | | | | |
| N021121 004 | 8163798 | Jul 31, 2017 | DP | | | |
| | 8163798*PED | Jan 31, 2018 | | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u> | | | | | | |
| A078458 001 | | | | | PC | Jul 01, 2012 |
| <u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u> | | | | | | |
| A078458 002 | | | | | PC | Jul 01, 2012 |
| <u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u> | | | | | | |
| A078458 003 | | | | | PC | Jul 01, 2012 |
| <u>MICONAZOLE - ORAVIG</u> | | | | | | |
| N022404 001 | 7651698 | Sep 11, 2022 | U-1051 | | | |
| <u>MIFEPRISTONE - KORLYM</u> | | | | | | |
| N202107 001 | | | | | NP | Feb 17, 2015 |
| <u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u> | | | | | | |
| N050781 001 | >A> 6682348 | Mar 29, 2022 | DP | | | |
| <u>MITOMYCIN - MITOSOL</u> | | | | | | |
| N022572 001 | 7806265 | Feb 01, 2029 | DP | | ODE | Feb 07, 2019 |
| <u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u> | | | | | | |
| N021067 001 | >A> 8173172 | Mar 17, 2018 | DP | | | |
| | >A> 8173172*PED | Sep 17, 2018 | | | | |
| <u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u> | | | | | | |
| N021067 002 | >A> 8173172 | Mar 17, 2018 | DP | | | |
| | >A> 8173172*PED | Sep 17, 2018 | | | | |
| <u>MONTELUKAST SODIUM - SINGULAIR</u> | | | | | | |
| N020829 002 | | | | | NPP | Mar 26, 2015 |
| <u>MONTELUKAST SODIUM - SINGULAIR</u> | | | | | | |
| N020830 001 | | | | | NPP | Mar 26, 2015 |
| <u>MONTELUKAST SODIUM - SINGULAIR</u> | | | | | | |
| N020830 002 | | | | | NPP | Mar 26, 2015 |
| <u>MONTELUKAST SODIUM - SINGULAIR</u> | | | | | | |
| N021409 001 | | | | | NPP | Mar 26, 2015 |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 001 | 8158156 | Jun 19, 2027 | U-1241 | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 002 | 8158156 | Jun 19, 2027 | U-1241 | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 003 | 8158156 | Jun 19, 2027 | U-1241 | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 004 | 8158156 | Jun 19, 2027 | U-1241 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 005 | 8158156 | Jun 19, 2027 | U-1241 | | | |
| <u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u> | | | | | | |
| N022321 006 | 8158156 | Jun 19, 2027 | U-1241 | | | |
| <u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u> | | | | | | |
| N019599 002 | | | | | NS | Jan 13, 2015 |
| <u>NICOTINE - NICODERM CQ</u> | | | | | | |
| N020165 004 | 8075911 | May 22, 2021 | DP | | | |
| <u>NICOTINE - NICODERM CQ</u> | | | | | | |
| N020165 005 | 8075911 | May 22, 2021 | DP | | | |
| <u>NICOTINE - NICODERM CQ</u> | | | | | | |
| N020165 006 | 8075911 | May 22, 2021 | DP | | | |
| <u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u> | | | | | | |
| N022068 001 | 8163904 | Aug 23, 2028 | DS DP | | | |
| <u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u> | | | | | | |
| N022068 002 | 8163904 | Aug 23, 2028 | DS DP | | | |
| <u>NITRIC OXIDE - INOMAX</u> | | | | | | |
| N020845 002 | 5558083 | Nov 22, 2013 | DP U-1226 | | | |
| | 5558083*PED | May 22, 2014 | | | | |
| | 5732693 | Dec 13, 2016 | DP U-1230 | | | |
| | 5732693*PED | Jun 13, 2017 | | | | |
| | 5752504 | Dec 13, 2016 | DP U-1230 | | | |
| | 5752504*PED | Jun 13, 2017 | | | | |
| <u>NITRIC OXIDE - INOMAX</u> | | | | | | |
| N020845 003 | 5558083 | Nov 22, 2013 | DP U-1226 | | | |
| | 5558083*PED | May 22, 2014 | | | | |
| | 5732693 | Dec 13, 2016 | DP U-1230 | | | |
| | 5732693*PED | Jun 13, 2017 | | | | |
| | 5752504 | Dec 13, 2016 | DP U-1230 | | | |
| | 5752504*PED | Jun 13, 2017 | | | | |
| <u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u> | | | | | | |
| N018705 002 | 7872049 | Mar 14, 2028 | DP U-39 | | | |
| <u>OXCARBAZEPINE - TRILEPTAL</u> | | | | | | |
| N021285 001 | 8119148 | Dec 19, 2020 | DP U-724 | | | |
| | 8119148*PED | Jun 19, 2021 | | | | |
| <u>OXYBUTYNIN - ANTUROL</u> | | | | | | |
| N202513 001 | 7029694 | Apr 26, 2020 | DP U-318 | | | |
| | 7179483 | Apr 26, 2020 | U-318 | | | |
| | 7198801 | Jun 25, 2022 | DP | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 001 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 002 | 8114383 | Oct 10, 2024 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 003 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 004 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u> | | | | | | |
| N022272 005 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 001 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 002 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 003 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 004 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 005 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 006 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u> | | | | | | |
| N201655 007 | 7851482 | Jul 10, 2029 | DS | | | |
| | 8114383 | Aug 08, 2024 | DP | | | |
| | >A> 8192722 | Sep 15, 2025 | DP | | | |
| <u>PACLITAXEL - ABRAXANE</u> | | | | | | |
| N021660 001 | 8138229 | Dec 09, 2023 | DP U-1092 | | | |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u> | | | | | | |
| N022175 001 | | | | | >A> NCE | May 17, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u> | | | | | | |
| N022175 002 | | | | | >A> NCE | May 17, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u> | | | | | | |
| N022222 001 | | | | | NCE | Mar 01, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u> | | | | | | |
| N022222 002 | | | | | NCE | Mar 01, 2017 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|------------------------|-----------------------------------|
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u> | | | | | | |
| N022222 003 | | | | | NCE | Mar 01, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u> | | | | | | |
| N022542 001 | | | | | NCE | Mar 01, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u> | | | | | | |
| N022542 002 | | | | | NCE | Mar 01, 2017 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 005 | | | | | NCE | Aug 27, 2014 |
| <u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u> | | | | | | |
| N022210 006 | | | | | NCE | Aug 27, 2014 |
| <u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u> | | | | | | |
| N022465 001 | 8114885 | Dec 19, 2021 | DS DP | | I-649 ODE | Apr 26, 2015 Apr 26, 2019 |
| <u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u> | | | | | | |
| N022465 002 | 8114885 | Dec 19, 2021 | DS DP | | I-649 ODE | Apr 26, 2015 Apr 26, 2019 |
| <u>PEGINESATIDE ACETATE - OMONTYS</u> | | | | | | |
| N202799 007 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS</u> | | | | | | |
| N202799 008 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 001 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 002 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 003 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 004 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 005 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u> | | | | | | |
| N202799 006 | 7084245 | May 12, 2024 | DS DP U-1238 | | NCE | Mar 27, 2017 |
| | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | 7528104 | May 12, 2024 | DS DP | | | |
| | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | 7919118 | May 12, 2024 | DS DP | | | |
| | 7919461 | Jun 02, 2026 | U-1238 | | | |
| <u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u> | | | | | | |
| N202088 003 | >A> 6149938 | Jul 23, 2018 | DP U-1243 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u> | | | | | | |
| N050684 001 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u> | | | | | | |
| N050684 002 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u> | | | | | | |
| N050684 003 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u> | | | | | | |
| N050684 004 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u> | | | | | | |
| N050750 001 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u> | | | | | | |
| N050750 002 | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| <u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u> | | | | | | |
| N050750 003 | 8133883 | Apr 14, 2023 | DP U-282 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>PREDNISOLONE ACETATE - FLO-PRED</u> | | | | | | |
| N022067 001 | 7799331 | Oct 11, 2028 | DP U-139 | | | |
| | 7799331 | Oct 11, 2028 | DP U-1068 | | | |
| <u>PREDNISOLONE ACETATE - FLO-PRED</u> | | | | | | |
| N022067 002 | 7799331 | Oct 11, 2028 | DP U-139 | | | |
| | 7799331 | Oct 11, 2028 | DP U-1068 | | | |
| <u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u> | | | | | | |
| N021438 001 | >A> 6500454 | Oct 04, 2021 | DP | | | |
| <u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u> | | | | | | |
| N021438 002 | >A> 6500454 | Oct 04, 2021 | DP | | | |
| <u>RALTEGRAVIR POTASSIUM - ISENTRESS</u> | | | | | | |
| N022145 001 | | | | | M-114 | Mar 28, 2015 |
| <u>RALTEGRAVIR POTASSIUM - ISENTRESS</u> | | | | | | |
| N203045 001 | 7169780 | Oct 03, 2023 | DS DP | | M-114 | Mar 28, 2015 |
| | 7217713 | Oct 21, 2022 | U-257 | | | |
| | 7435734 | Oct 21, 2022 | U-257 | | | |
| | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| <u>RALTEGRAVIR POTASSIUM - ISENTRESS</u> | | | | | | |
| N203045 002 | 7169780 | Oct 03, 2023 | DS DP | | M-114 | Mar 28, 2015 |
| | 7217713 | Oct 21, 2022 | U-257 | | | |
| | 7435734 | Oct 21, 2022 | U-257 | | | |
| | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| <u>REGADENOSON - LEXISCAN</u> | | | | | | |
| N022161 001 | 8106029 | Jun 22, 2019 | U-1042 | | | |
| | 8106183 | Feb 02, 2027 | DS | | | |
| | 8133879 | Jun 22, 2019 | DP | | | |
| <u>RIFAXIMIN - XIFAXAN</u> | | | | | | |
| N021361 001 | 8158644 | Jun 19, 2024 | DP | | | |
| | 8158781 | Jun 19, 2024 | DS | | | |
| <u>RIFAXIMIN - XIFAXAN</u> | | | | | | |
| N022554 001 | 8158644 | Jun 19, 2024 | DP | | | |
| | 8158781 | Jun 19, 2024 | DS | | | |
| <u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u> | | | | | | |
| N202022 001 | 8080551 | Apr 11, 2023 | DS DP | | | |
| | 8101629 | Aug 09, 2022 | DP | | | |
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 001 | | | | | I-647 | Apr 02, 2015 |
| | | | | | I-646 | Apr 02, 2015 |
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 002 | | | | | I-647 | Apr 02, 2015 |
| | | | | | I-646 | Apr 02, 2015 |
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 003 | | | | | I-647 | Apr 02, 2015 |
| | | | | | I-646 | Apr 02, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 004 | 6699498 | Nov 27, 2020 | DP | | I-647 | Apr 02, 2015 |
| | 6884434 | Mar 30, 2021 | DP | | I-646 | Apr 02, 2015 |
| | 7413747 | Mar 18, 2019 | DP | | | |
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 005 | 6699498 | Nov 27, 2020 | DP | | I-647 | Apr 02, 2015 |
| | 6884434 | Mar 30, 2021 | DP | | I-646 | Apr 02, 2015 |
| | 7413747 | Mar 18, 2019 | DP | | | |
| <u>ROTIGOTINE - NEUPRO</u> | | | | | | |
| N021829 006 | 6699498 | Nov 27, 2020 | DP | | I-647 | Apr 02, 2015 |
| | 6884434 | Mar 30, 2021 | DP | | I-646 | Apr 02, 2015 |
| | 7413747 | Mar 18, 2019 | DP | | | |
| <u>SILDENAFIL CITRATE - REVATIO</u> | | | | | | |
| N021845 001 | 5250534 | Mar 27, 2012 | DS DP | | I-598 | May 07, 2012 |
| | 5250534*PED | Sep 27, 2012 | | | PED | Nov 07, 2012 |
| <u>SILDENAFIL CITRATE - REVATIO</u> | | | | | | |
| N022473 001 | 5250534 | Mar 27, 2012 | DS DP | | NDF | Nov 20, 2012 |
| | 5250534*PED | Sep 27, 2012 | | | PED | May 20, 2013 |
| <u>SILDENAFIL CITRATE - VIAGRA</u> | | | | | | |
| N020895 001 | 5250534 | Mar 27, 2012 | | | | |
| | 5250534*PED | Sep 27, 2012 | | | | |
| | 6469012 | Oct 22, 2019 | | U-155 | | |
| | 6469012*PED | Apr 22, 2020 | | | | |
| <u>SILDENAFIL CITRATE - VIAGRA</u> | | | | | | |
| N020895 002 | 5250534 | Mar 27, 2012 | | | | |
| | 5250534*PED | Sep 27, 2012 | | | | |
| | 6469012 | Oct 22, 2019 | | U-155 | | |
| | 6469012*PED | Apr 22, 2020 | | | | |
| <u>SILDENAFIL CITRATE - VIAGRA</u> | | | | | | |
| N020895 003 | 5250534 | Mar 27, 2012 | | | | |
| | 5250534*PED | Sep 27, 2012 | | | | |
| | 6469012 | Oct 22, 2019 | | U-155 | | |
| | 6469012*PED | Apr 22, 2020 | | | | |
| <u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u> | | | | | | |
| N202343 001 | >A> 8168637 | Jun 26, 2022 | DP | U-1188 | | |
| <u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u> | | | | | | |
| N202343 002 | >A> 8168637 | Jun 26, 2022 | DP | U-1188 | | |
| <u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u> | | | | | | |
| N202343 003 | >A> 8168637 | Jun 26, 2022 | DP | U-1188 | | |
| <u>SODIUM NITRITE - SODIUM NITRITE</u> | | | | | | |
| N203922 001 | | | | | ODE | Jan 14, 2018 |
| <u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u> | | | | | | |
| N203923 001 | | | | | ODE | Jan 14, 2018 |
| <u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u> | | | | | | |
| N022239 001 | 8118771 | Aug 10, 2023 | DP | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>T AFLUPROST - ZIOPTAN</u> | | | | | | |
| N202514 001 | 5886035 | Dec 18, 2017 | DS DP U-778 | | NCE | Feb 10, 2017 |
| <u>T ALIGLUCERASE ALFA - ELELYSO</u> | | | | | | |
| N022458 001 | | | | | >A> NCE | May 01, 2017 |
| <u>T APENTADOL HYDROCHLORIDE - NUCYNTA ER</u> | | | | | | |
| N200533 001 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>T APENTADOL HYDROCHLORIDE - NUCYNTA ER</u> | | | | | | |
| N200533 002 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>T APENTADOL HYDROCHLORIDE - NUCYNTA ER</u> | | | | | | |
| N200533 003 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>T APENTADOL HYDROCHLORIDE - NUCYNTA ER</u> | | | | | | |
| N200533 004 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>T APENTADOL HYDROCHLORIDE - NUCYNTA ER</u> | | | | | | |
| N200533 005 | 8114383 | Oct 10, 2024 | DP | | | |
| <u>T AZAROTENE - FABIOR</u> | | | | | | |
| N202428 001 | | | | | >A> NDF | May 11, 2015 |
| <u>T ELAVANCIN HYDROCHLORIDE - VIBATIV</u> | | | | | | |
| N022110 001 | 8101575 | May 01, 2021 | DP | | | |
| | 8158580 | May 01, 2021 | DP | | | |
| <u>T ELAVANCIN HYDROCHLORIDE - VIBATIV</u> | | | | | | |
| N022110 002 | 8101575 | May 01, 2021 | DP | | | |
| | 8158580 | May 01, 2021 | DP | | | |
| <u>T ELBIVUDINE - TYZEKA</u> | | | | | | |
| N022154 001 | 7858594 | Sep 11, 2023 | DS DP U-999 | | | |
| <u>T EMSIROLIMUS - TORISEL</u> | | | | | | |
| N022088 001 | 5362718 | Apr 18, 2014 | DS DP | | M-92 | Jul 09, 2013 |
| | 5362718*PED | Oct 18, 2014 | | | M-91 | Apr 26, 2013 |
| | 8026276 | Jan 20, 2026 | DP | | ODE | May 30, 2014 |
| | 8026276*PED | Jul 20, 2026 | | | PED | Nov 30, 2014 |
| | | | | | PED | Jan 09, 2014 |
| | | | | | PED | Oct 26, 2013 |
| <u>T ENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N021356 001 | | | | | NPP | Jan 18, 2015 |
| | | | | | PED | Jul 18, 2015 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------|--------------|-------------------------|----------------------|-----------------------------|
| <u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N021356 002 | 5922695 | Jul 25, 2017 | DS U-250 | | M-95 | Oct 01, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-256 | | NPP | Jan 18, 2015 |
| | 5922695 | Jul 25, 2017 | DS U-999 | | NPP | Mar 24, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | ODE | Mar 24, 2017 |
| | 5922695*PED | Jan 25, 2018 | | | PED | Sep 24, 2017 |
| | 5935946 | Jul 25, 2017 | DS DP U-999 | | PED | Jul 18, 2015 |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | PED | Apr 01, 2014 |
| | 5935946 | Jul 25, 2017 | DS DP U-250 | | PED | Sep 24, 2013 |
| | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | U-248 | | |
| | 6043230 | Jul 25, 2017 | | U-250 | | |
| | 6043230 | Jul 25, 2017 | | U-256 | | |
| | 6043230 | Jul 25, 2017 | | U-999 | | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| <u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N021356 003 | 5922695 | Jul 25, 2017 | DS U-250 | | M-95 | Oct 01, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-256 | | NPP | Jan 18, 2015 |
| | 5922695 | Jul 25, 2017 | DS U-999 | | NPP | Mar 24, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | ODE | Mar 24, 2017 |
| | 5922695*PED | Jan 25, 2018 | | | PED | Sep 24, 2017 |
| | 5935946 | Jul 25, 2017 | DS DP U-999 | | PED | Jul 18, 2015 |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | PED | Apr 01, 2014 |
| | 5935946 | Jul 25, 2017 | DS DP U-250 | | PED | Sep 24, 2013 |
| | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | U-248 | | |
| | 6043230 | Jul 25, 2017 | | U-250 | | |
| | 6043230 | Jul 25, 2017 | | U-256 | | |
| | 6043230 | Jul 25, 2017 | | U-999 | | |
| | 6043230*PED | Jan 25, 2018 | | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------|--------------|-------------------------|----------------------|-----------------------------|
| <u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N021356 004 | 5922695 | Jul 25, 2017 | DS U-250 | | M-95 | Oct 01, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-256 | | NPP | Jan 18, 2015 |
| | 5922695 | Jul 25, 2017 | DS U-999 | | NPP | Mar 24, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | ODE | Mar 24, 2017 |
| | 5922695*PED | Jan 25, 2018 | | | PED | Sep 24, 2017 |
| | 5935946 | Jul 25, 2017 | DS DP U-999 | | PED | Jul 18, 2015 |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | PED | Apr 01, 2014 |
| | 5935946 | Jul 25, 2017 | DS DP U-250 | | PED | Sep 24, 2013 |
| | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-250 | | | |
| | 6043230 | Jul 25, 2017 | U-256 | | | |
| | 6043230 | Jul 25, 2017 | U-999 | | | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| <u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u> | | | | | | |
| N022577 001 | 5922695 | Jul 25, 2017 | DS U-250 | | M-95 | Oct 01, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-256 | | NPP | Mar 24, 2013 |
| | 5922695 | Jul 25, 2017 | DS U-999 | | NDF | Jan 18, 2015 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | ODE | Mar 24, 2017 |
| | 5922695*PED | Jan 25, 2018 | | | PED | Sep 24, 2017 |
| | 5935946 | Jul 25, 2017 | DP U-999 | Y | PED | Jul 18, 2015 |
| | 5935946 | Jul 25, 2017 | DP U-248 | Y | PED | Apr 01, 2014 |
| | 5935946 | Jul 25, 2017 | DP U-250 | Y | | |
| | 5935946 | Jul 25, 2017 | DP U-256 | Y | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-250 | | | |
| | 6043230 | Jul 25, 2017 | U-256 | | | |
| | 6043230 | Jul 25, 2017 | U-999 | | | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| <u>TESTOSTERONE - TESTIM</u> | | | | | | |
| N021454 001 | 8178518 | Apr 21, 2023 | DP | | | |
| <u>TESTOSTERONE - TESTOSTERONE</u> | | | | | | |
| N202763 001 | | | | | NP | Feb 14, 2015 |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 001 | 8143283 | Mar 01, 2013 | U-1236 | | | |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 002 | 8143283 | Mar 01, 2013 | U-1236 | | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 003 | 8143283 | Mar 01, 2013 | U-1236 | | | |
| <u>THALIDOMIDE - THALOMID</u> | | | | | | |
| N020785 004 | 8143283 | Mar 01, 2013 | U-1236 | | | |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020505 001 | | | | | NPP | Jul 15, 2014 |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020505 002 | | | | | NPP | Jul 15, 2014 |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020505 004 | | | | | NPP | Jul 15, 2014 |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020505 005 | | | | | NPP | Jul 15, 2014 |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020844 001 | | | | | NPP | Jul 15, 2014 |
| <u>TOPIRAMATE - TOPAMAX</u> | | | | | | |
| N020844 002 | | | | | NPP | Jul 15, 2014 |
| <u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u> | | | | | | |
| N020981 001 | 8158645 | Dec 10, 2024 | DP | | | |
| <u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u> | | | | | | |
| N020981 002 | 8158645 | Dec 10, 2024 | DP | | | |
| <u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u> | | | | | | |
| A091607 001 | | | | | PC | Jun 27, 2012 |
| <u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u> | | | | | | |
| A091607 002 | | | | | PC | Jun 27, 2012 |
| <u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u> | | | | | | |
| A091607 003 | | | | | PC | Jun 27, 2012 |
| <u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u> | | | | | | |
| N022411 001 | 8133893 | Mar 13, 2029 | DS DP | | | |
| <u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u> | | | | | | |
| N022411 002 | 8133893 | Mar 13, 2029 | DS DP | | | |
| <u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u> | | | | | | |
| N022048 001 | 8128960 | Dec 17, 2029 | DP | | | |
| <u>VEMURAFENIB - ZELBORAF</u> | | | | | | |
| N202429 001 | 8143271 | Jun 21, 2026 | DS DP | | | |
| <u>VISMODEGIB - ERIVEDGE</u> | | | | | | |
| N203388 001 | | | | | NCE | Jan 30, 2017 |
| <u>VORINOSTAT - ZOLINZA</u> | | | | | | |
| N021991 001 | 8093295 | May 16, 2026 | DP | | | |
| | 8101663 | Mar 04, 2023 | U-892 | | | |
| <u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u> | | | | | | |
| A077560 001 | | | | | >A> PC | Aug 29, 2012 |

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 5 - May 2012

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u> | | | | | | |
| A077560 | 002 | | | | >A> PC | Aug 29, 2012 |
| <u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u> | | | | | | |
| A077560 | 003 | | | | >A> PC | Aug 29, 2012 |
| <u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u> | | | | | | |
| A077560 | 004 | | | | >A> PC | Aug 29, 2012 |

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>